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ABSTRACT
Heart failure (HF) is a growing public health problem. In developed countries, the 
number of hospital admissions due to HF has increased. This trend has been 
attributed to the ageing of our population and an increased number of people at risk 
for HF as a result of more efficacious treatment for systemic hypertension and acute 
myocardial infarction. The syndrome of HF is associated with substantial mortality 
and morbidity rates, and consumes a significant proportion of the health care budget 
in most developed countries. In 1993-94, the health care costs attributed to HF in 
Australia were estimated to be over AUD$400 million. A significant proportion of 
this cost was due to hospitalisations. HF, under the umbrella of “cardiovascular 
disease”, has been nominated as a National Health Priority Area. Despite this fact, 
there are no population-based data regarding the prevalence of HF in Australia. Such 
descriptive epidemiological data are important for guiding health policy and 
monitoring trends of the impact of disease over time. This latter function can be used 
to assess the impact of primary preventive and illness care interventions at the 
population level.
Initial HF treatment studies have focused on patients with impaired left ventricular 
(LV) systolic function, as documented by a reduced LV ejection fraction (EF). These 
studies have confirmed the efficacy of medical therapy for symptomatic HF with 
reduced EF (HF-rEF) that results in the improvement of patient symptoms, quality of 
life and survival. In the last decade, there has been an increasing awareness regarding 
HF associated with LV diastolic dysfunction (DD). This awareness has been 
generated by the observation that approximately half the patients presenting with HF
xviii
to hospitals have “normal” EF (HF-NEF). Doppler echocardiography has provided a 
non-invasive means of evaluating diastolic function. At the time this research was 
proposed, there was no information on the burden of DD in the community from 
population-based studies using comprehensive echo-Doppler methods.
Recent echocardiographic surveys have confirmed that approximately half of the 
cases in the community with reduced EF are asymptomatic of the disease. 
Randomised controlled trials have shown that medical treatment for individuals with 
reduced EF in the preclinical phase of disease is also beneficial. However, there is a 
lack of readily available, inexpensive methods for identifying cases of preclinical LV 
dysfunction in the community. Previous studies have suggested that circulating 
biomarkers may play an important role as a marker for LV dysfunction in high-risk 
patients, but evidence from the general community was limited.
The thesis reviews the epidemiology of HF in the community. The changing 
epidemiology of HF and LV dysfunction in the era of non-invasive cardiac imaging 
is also reviewed, with much of the evidence arising during the period of this thesis 
(Chapter 1). This is followed by a review of the current Doppler echocardiographic 
methods for the assessment of diastolic function in Chapter 2. Evidence to support 
the use of non-imaging methods for the detection of LV function (circulating 
biomarkers and measurement of arterial stiffness) is presented. The third chapter 
details study methodologies, including issues relating to recruitment of a population- 
based cohort of over 1300 randomly selected Canberra residents of age 60-86 years; 
echocardiographic evaluation of cardiac function; and the assessment of circulating 
biomarkers, specifically the aminoterminal component of pro-B-type natriuretic
xix
peptide (NT-proBNP), a protein secreted principally by the cardiac ventricles in 
response to elevated cardiac pressures and wall tension; and measurement of wave 
reflection-dependent (pulse pressure) and independent [carotid-femoral pulse wave 
velocity (PWV)] indexes of aortic stiffness by applanation tonometry.
The first Australian data on the prevalence of HF and LV systolic dysfunction 
(EF<50%) in the community are presented in Chapter 4. Of the 1275 participants 
who completed all study measurements, 72 (5.6%) subjects had clinical HF that had 
been previously diagnosed and confirmed by our assessment. A further 0.6% had 
evidence of structural heart disease and symptoms/signs of cardiac insufficiency 
without a previous diagnosis of clinical HF (i.e. undiagnosed clinical HF). Thus, 
overall the prevalence of clinical HF in the sample was 6.3%. Clinical HF increased 
in prevalence with advancing age (4-fold increase in prevalence from 60-64 to 80-86 
years). Of the 75 subjects with LV systolic dysfunction, 44 (59%) were in the 
preclinical stage of disease. Based on these data, it is likely that diagnosed HF cases 
represent the “tip of the iceberg” for the national burden of HF and LV systolic 
dysfunction. Clinically identifiable HF cases can remain undiagnosed, and the 
majority of subjects with LV systolic dysfunction are preclinical.
One of the first estimates of the burden of DD in the community is presented in 
Chapter 5. The prevalence of any DD in our population-based sample was 35.6% and 
moderate-severe DD was 7.5%. Of those with moderate-severe DD, 84.7% had an 
EF>50% and 77.2% were preclinical. Predictors of DD included increasing age; 
reduced EF; obesity; history of hypertension, diabetes and myocardial infarction. 
Moderate-severe DD with normal EF, although predominantly preclinical, was
independently associated with increased LV mass, left atrial (LA) volume, 
circulating NT-proBNP levels, and decreased quality of life. Extrapolating this data, 
it is likely that DD is common in the community and frequently unaccompanied by 
overt HF. Despite the lack of symptoms, advanced DD with normal EF is associated 
with reduced quality of life and structural abnormalities that reflect increased 
cardiovascular risk.
In Chapter 6, the utility of NT-proBNP to detect systolic and diastolic LV 
dysfunction in older adults was determined. Predictors of NT-proBNP included age, 
female gender, body mass index, and cardiorenal parameters (DD severity; LV mass 
and volume; right ventricular overload; decreasing EF and creatinine clearance). The 
performance of NT-proBNP to detect any degree of LV dysfunction, including mild 
DD, was poor (AUC 0.56-0.66). In contrast, the performance of NT-proBNP for the 
detection of EF<40% and moderate-severe DD was strong with AUC>0.90 
regardless of age and gender. The ability of NT-proBNP to detect EF<40% and/or 
moderate-severe DD was optimised by using age/gender-specific limits (men 60-74, 
20pmol/L; women 60-74, 30pmol/L; >75 years, 45pmol/L). Of “false positive” tests, 
88% (126/143) were explained after considering cardiorenal determinants of 
NT-proBNP levels. Based on these results, we concluded that NT-proBNP represents 
a suboptimal marker of mild LV dysfunction, but performs strongly as a marker of 
EF<40% and/or moderate-severe DD in the community.
In chapter 7, the performances of indexes of aortic stiffness to detect preclinical DD 
were evaluated in a nested case-control study, using a stratified subsample of 233 
participants of the study population with EF>45% and without overt HF. Brachial
xxi
pulse pressure, central pulse pressure, and PWV progressively increased according to 
the severity of DD, independent of age and sex. The overall performance of PWV 
was superior to brachial pulse pressure [area under receiver operating characteristic 
curve (AUC): 0.70 versus 0.59, respectively; P = 0.0051 and central pulse pressure 
(AUC: 0.70 versus 0.56, respectively; P = 0.001) for the detection of any DD. PWV 
appeared to be superior to central and brachial pulse pressure for the detection of DD 
in older adults with “preserved” EF.
Finally, a brief outline of future directions for this cohort study is provided.
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PREFACE - INTRODUCTION AND AIMS OF THIS THESIS
Heart failure (HF) is a growing public health problem. In developed countries, the 
number of hospital admissions due to HF has increased. This trend has been 
attributed to the ageing of our population and an increased number of people at risk 
for HF as a result of more efficacious treatment for systemic hypertension and acute 
myocardial infarction. The syndrome of HF is associated with substantial mortality 
and morbidity rates, and consumes a significant proportion of the health care budget 
in most developed countries. In 1993-94, the health care costs attributed to HF were 
estimated to be over AUD$400 million. A significant proportion of this cost was due 
to hospitalisations. HF. under the umbrella of ‘cardiovascular disease’, has been 
nominated as a National Health Priority Area. Despite this fact, there are no 
population-based data regarding the prevalence of HF in Australia. Such data are 
important for guiding health policy and monitoring trends of the impact of disease 
over time. In particular, the latter function can be used to assess the impact of 
primary preventive and illness care interventions at the population level. Therefore, 
the initial set of aims related to the thesis was to determine:
• What is the prevalence of HF and left ventricular (LV) systolic dysfunction in 
Australia? (addressed in chapter 4)
• What are the clinical characteristics of subjects with HF and LV systolic 
dysfunction? (addressed in chapter 4)
Initial HF treatment studies have focused on patients with impaired LV systolic 
function. These studies have confirmed the efficacy of medical therapy for 
symptomatic LV dysfunction that results in the improvement of patient symptoms,
1
quality of life and survival. In the last decade, there has been an increasing awareness 
regarding HF associated with LV diastolic dysfunction (DD). This awareness has 
been generated by the observation that approximately half the patients presenting 
with HF to hospitals have preserved LV systolic function. Doppler echocardiography 
has provided a non-invasive means of evaluating diastolic function. At the time this 
research was proposed, there was no information on the burden of DD in the 
community from population-based studies using comprehensive echo-Doppler 
methods. Thus, the next set of aims related to this thesis addressed the following 
questions:
• What is the prevalence of DD in the community? (addressed in chapter 5)
• What are the clinical characteristics of subjects with DD? (addressed in 
chapter 5)
Recent echocardiographic surveys have confirmed that approximately half of the 
cases in the community with LV systolic dysfunction are asymptomatic of the 
disease. Randomised controlled trials have shown that medical treatment for 
individuals with LV systolic dysfunction in the preclinical phase of disease is also 
beneficial. However, there is a lack of readily available, inexpensive methods for 
identifying cases of preclinical LV dysfunction in the community. Previous studies 
have suggested that circulating biomarkers may play an important role as a marker 
for LV dysfunction in high-risk patients, but evidence from the general community 
was limited at the time that the Canberra Heart Study was being designed. The final 
set of aims relating to this thesis addressed the general question:
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• What non-imaging diagnostic methods could be used to detect LV 
dysfunction?
We specifically assessed the performances of circulating levels of aminoterminal 
pro-B-type natriuretic peptide (NT-proBNP), a protein secreted principally by the 
cardiac ventricles in response to elevated cardiac filling pressures and wall tension 
(addressed in chapter 6); and measurement of indexes of aortic stiffness by 
applanation tonometry (addressed in chapter 7).
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Chapter 1: EPIDEMIOLOGY 
OF CHRONIC HEART 
FAILURE AND LEFT 
VENTRICULAR 
DYSFUNCTION
1.1 ABSTRACT
Heart failure (HF) is a growing public health problem. The syndrome of HF is 
associated with substantial mortality and morbidity rates, and consumes a significant 
proportion of the health care budget in most developed countries. In this chapter, the 
burden of HF in the community is examined; the pathophysiology of hypertensive 
heart disease and diastolic dysfunction (DD) is outlined; and the changing 
epidemiology of HF and left ventricular (LV) dysfunction in the era of non-invasive 
cardiac imaging is reviewed.
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1.2 INTRODUCTION
Heart failure (HF) is a serious medical condition, with a poor prognosis. The 
prevalence and incidence of HF in the community has risen to “epidemic” 
proportions, and evidence suggests that the public health burden of HF will continue 
to grow.1 In this chapter, I will outline how our understanding of basic fundamental 
concepts relating to the definition and mechanisms of HF have been guided by 
findings from epidemiological studies and facilitated by evolving medical 
technologies, particularly with the development and availability of non-invasive 
cardiac imaging such as echocardiography. Specifically, I will examine the burden 
of HF in the community; outline the pathophysiology of hypertensive heart disease 
and diastolic dysfunction (DD); and review the changing epidemiology of HF and 
left ventricular (LV) dysfunction in the era of non-invasive cardiac imaging
1.3 DEFINITION OF HEART FAILURE
Attempts to define HF have resulted in controversy, due to the complexity of the 
syndrome. HF is not a disease but rather a constellation of symptoms and signs 
caused by a blend of structural and functional changes to the heart, with 
haemodynamic and neurohumoral responses associated with these changes. Despite 
many efforts, there is no single definition for HF that has received universal 
acceptance. Table 1-1 lists selected definitions that have been proposed over the last 
75 years. The definition for HF has evolved in parallel with advances in the 
understanding of syndrome pathophysiology.
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Table 1-1 Definitions of heart failure
Thomas Lewis 1933 A condition in which the heart fails to discharge its contents
adequately2
T. Harrison 1936 A syndrome characterised by dyspnoea, rales at the lung bases,
venous distension, engorgement of the viscera, and accumulation of 
fluid in the subcutaneous tissue and body cavities2
Paul Wood 1950 A state in which the heart fails to maintain an adequate circulation
for the needs of the whole body despite a satisfactory filling 
pressure2
Eugene Braunwald 1980 A pathophysiological state in which an abnormality of cardiac
function is responsible for the failure of the heart to pump blood at 
a rate commensurate with the requirements of the metabolising 
tissues2
P Poole-Wilson 1985 A clinical syndrome caused by an abnormality of the heart and
recognised by a characteristic pattern of haemodynamic, renal, 
neural and hormonal responses2
Milton Packer 1992 A complex clinical syndrome characterised by abnormalities of left
ventricular function and neurohumoral regulation, which are 
accompanied by effort intolerance, fluid retention and reduced 
longevity2
ESC Task Force 1995 Symptoms of heart failure, objective evidence of cardiac
dysfunction and response to treatment directed towards heart 
failure3
ACC/AHA Task 2001 A complex clinical syndrome that can result from any structural or 
Force functional cardiac disorder that impairs the ability of the ventricle to
fill with or eject blood4
Several conceptual models have been developed to illustrate the mechanisms of HF 
and to rationalise the opportunities for intervention, including screening and
8
prevention of the syndrome. Prior to 1980, HF was defined within the framework of 
a haemodynamic model, in which impaired myocyte contractility was considered to 
be the basis of HF. In this model, a decrease in cardiac performance results in 
symptoms on exertion initially but as cardiac haemodynamics worsen, the symptoms 
may appear at rest. The model remains useful for patients with advanced, 
decompensated HF but has been largely abandoned in favour of the neurohormonal 
model, in which structural changes to the heart are associated with activation of the 
sympathoadrenal (SAS) and renin-angiotensin-aldosterone (RAAS) systems, 
resulting in progressive cardiac remodelling. In the neurohormonal model, 
impairment of cardiac performance is a secondary phenomenon. The advantages of 
this model are that it allows classification of the syndrome at earlier stages of the 
disease process and also identifies a wider scope for pharmacological intervention.
1.4 DIAGNOSIS OF HEART FAILURE
1.4.1 Clinical guidelines for the identification of heart failure cases
A number of clinical guidelines for the diagnosis and management of HF have been
c n
published. “ The high frequency of updates is testimony to the large volume of 
research directed to this important field of medicine. There is consensus that a 
clinical diagnosis of HF is based on a complete history and examination followed by 
diagnostic testing, initially using readily available radiology and biochemistry 
assessments and subsequently with cardiac imaging (most often echocardiography) 
(Figure 1-1).
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Suspected CHF
Shortness of breath 
Fatigue 
Oedema
Clinical history 
Physical examination 
Initial investigations
Symptoms of CHF
Dyspnoea
Orthopnoea
PND
Fatigue
Oedema
Palprtatms/syncope
Past cardiovascular 
disease
Angina/Mi
Hypertension
Diabetes
Murmur/vahAjIar disease 
Cardiomyopathy 
AkxhcMobacco use 
Medications
Pulse rate and rhythm 
Blood pressure 
Etevated JVP 
Cardomegaly 
Cardiac mirmurs 
Lung creprtatons 
Hepatomegaly 
Oedema
Electrocardiogram 
Chest x-ray
Other blood tests; full blood 
count, electrolytes, renal 
functor., fever function, 
thyroid function 
Consider BNP or 
N-terminal proBNP test
c Clinical diagnosis of CHF J
Echocardiogram
T
Structural diagnosis
E.g. myopathic, valvular
Pathophysiological diagnosis
Systdc dysfunction (LVEF <40%) 
Dsastolc dysfunction (LVEF >40%)
Consider specialist referral 
■for further investigation
Figure 1-1 Algorithm suggested by the National Heart Foundation of Australia 
for the diagnosis of heart failure.
BNP = B-type natriuretic peptide; JVP = jugular venous pressure; LVEF = left- 
ventricular ejection fraction; MI = myocardial infarction; PND = paroxysmal 
nocturnal dyspnoea. From the 2006 Guidelines 7
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1.4.2 Identification of heart failure cases in epidemiological studies
In addition to challenges in defining the syndrome of HF, accurate identification of 
HF cases has been limited by the absence of a gold standard diagnostic test for HF. 
The following methods have been used by epidemiological studies to assess the 
presence and severity of HF: questionnaires; physical examination; chest 
radiography; electrocardiogram; measures of ventricular performance; exercise 
testing; and biochemical detection.
All of the methods have limitations when used independently due to poor diagnostic 
performance, especially for individuals with mild HF. This is particularly the case 
when assessing an older population, in which the prevalence of co-morbid illnesses 
that cause symptoms and signs similar to HF is high.
The diagnostic value of symptoms, signs and chest X-ray findings for the detection 
of left ventricular systolic dysfunction (<40% on left ventriculography) was assessed 
in 1306 patients with coronary disease (mean age 51 years, 84 % male) undergoing 
cardiac catheterisation (Table 1-2).14 Unfortunately, the symptoms associated with 
the syndrome of HF are not organ specific and accurate detection of signs requires 
considerable clinical skills and these facts were reflected in the results of the study.
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Table 1-2 Diagnostic performance of symptoms, signs and chest X-ray for LV 
systolic failure.
Sensitivity
(%)
Specificity
(%)
+ve Predictive 
Value
(%)
Symptoms
Shortness of breath 66 52 23
Orthopnoea 21 81 2
Nocturnal dyspnoea 33 76 26
Oedema by history 23 80 22
Physical examination
Tachycardia (>100/min) 7 99 6
Rales 13 91 27
Oedema on examination 10 93 3
Ventricular gallop sound (S3) 31 95 61
Neck vein distension 10 97 2
Chest X-ray
Cardiomegaly 62 6 32
Prior to the 1990’s, epidemiological studies employed either self-report or clinical 
scores, based on symptoms and signs to assess the presence of HF. The validity of 
the Framingham clinical scoring system was evaluated in a sample of 407 patients 
referred for assessment of left ventricular function. Both the sensitivity and 
specificity of the Framingham score to detect an LV ejection fraction (EF) <40% 
determined by the reference standard, radionuclide ventriculography, were 63%.15 
Since LV diastolic function was not assessed, true cases of HF (with “normal” EF) 
may not have been identified by the reference standard, resulting in underestimation 
of the sensitivity of the Framingham score.
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Mosterd applied six HF scores to a small sub-sample of participants of the Rotterdam
Q
study, a population-based prevalence study of LV dysfunction. Three of the scores 
were from epidemiological surveys of HF (Table 1-3), and three were derived for use 
in clinical trials (Walma, Boston, Gheorgiade scores). The reference standard was the 
cardiologist’s classification (no, possible or definite HF) based on his own medical 
history, physical examination and echocardiographic data.
Unfortunately, due to the small number of participants (5 persons with definite HF, 
17 cases with possible or definite HF), the 95 % confidence intervals were wide, 
limiting meaningful comparisons. The areas under the receiver operating 
characteristic curve (AUC) for possible and definite HF were similar for all the HF 
scores compared. The AUC for definite HF was a mean of 82% and for possible and 
definite HF was 94%.
The accuracy of clinical assessment by general practitioners has been evaluated by a 
number of studies.17'20 The most rigorous of these studies was a Finnish study of 
patients referred by their primary care physicians with a suspected diagnosis of HF.17 
The authors excluded patients with acute pulmonary oedema caused by acute 
myocardial ischaemia, and milder cases of HF were probably under-represented by 
non-referral, due to the insensitivity of clinical signs and the lack of symptoms on 
exertion. Using a modified Boston HF score and a physician’s clinical diagnosis as 
the reference standard, patients were classified as having definite, possible or 
unlikely HF. The possibility of misclassification was minimised by subjecting 
patients to non-invasive tests of cardiac function, using M-Mode echocardiography
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Table 1-3 Clinical criteria for heart failure in epidemiological studies
F r a m in g h a m 9 N H A N E S 10 M e n  B o rn  in
1 9 1 3 11
History
P a ro x y sm a l n o c tu rn a l d y sp n o e a V y
O rth o p n o e a y
D y sp n o ea  o n  ex e rtio n y y
D y sp n o e a  (W H O l -4) y
N ig h t co u g h V
M y o c a rd ia l in fa rc tio n /a n g in a y
W e ig h t lo ss y
S w o llen  leg s a t en d  o f  th e  d ay y
Physical examination
N eck  v e in  d is te n s io n V y
In c rea sed  ju g u la r  v en o u s  p re ssu re y
V en tr ic u la r  g a llo p  so u n d  (S 3 ) y y
R ales V y y
O ed e m a y y
H e p a to m e g a ly V y
H ep a to ju g u la r  re flu x V
C irc u la tio n  tim e  > =  25 seco n d s V
Chest X-ray
C a rd io m eg a ly V
A cu te  p u lm o n a ry  o ed e m a y
P leu ra l e ffu s io n y y
In te rs titia l o ed e m a y
A lv e o la r  c h a n g e s y
R e d is tr ib u tio n y
Electrocardiogram
T a c h y c a rd ia V y
A tria l F ib rilla tio n y
Pulmonary Function
V ita l C a p a c ity y
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and exercise testing with respiratory gas exchange analysis, and patients were 
reviewed clinically 6 months after their initial assessment. Up to half of HF 
diagnoses made by general practitioners were incorrect. Chronic obstructive 
pulmonary disease, angina pectoris and obesity were the most common reasons for 
an incorrect diagnosis.
Following guidelines set by the European Society of Cardiology, the diagnosis of 
HF in epidemiologic studies has included an objective measure of left ventricular 
function, usually by echocardiography. Over the last 5-10 years, investigators have 
attempted to reduce the effects of misclassification by conducting epidemiologic 
studies with outcomes that are defined according to left ventricular (LV) structure 
and function. The changing epidemiology of HF in the era of cardiac imaging will be 
discussed in section 1.7 of the thesis.
1.4.3 Sources of data for epidemiological studies
HF surveys have not always sampled from true population bases. Other sources of 
data include general practice surveys; surveillance of prescriptions for HF 
medications, especially diuretics; national death statistics; and hospital separation 
data. Studies that have used these alternate sources of data produce results that are 
subjected to error from selection and measurement bias, limiting the internal and 
external validity of their results.
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1.5 EPIDEMIOLOGY OF HEART FAILURE
1.5.1 Prevalence
The burden of HF in the community is considerable with a prevalence o f 1-2% in the 
adult population. However, HF is particularly prevalent in older persons with 
approximately 6-10% of people over the age of 65 years afflicted with the 
condition.13"22 Unfortunately, the prevalence o f HF in the community is increasing,23 
and secular trends in population demographics and cardiovascular risk factors w ill 
continue to have a major influence on the prevalence o f HF (Figure 1-2). It is 
projected that the global population of persons of age 60 years and over w ill reach 2 
billion in 2050 (more that triple the number in 2000).24 In the developed world, the 
fastest growing age group is the very old (age 80+). In addition, we are now 
experiencing the adverse effects of contemporary lifestyle on population health. 
Societal reductions in physical activity levels and increasing tendency to consume 
food that is high in energy and fat has resulted in increased global rates of obesity"' 
and diabetes. By 2015, 2.3 billion people around the world w ill be overweight and 
more than 700 million w ill be obese according to the World Health Organization.23 
These factors, accompanied by recent trends in an improved survival of patients with 
hypertensive diseases, coronary artery disease (CAD), and HF itself, together with an 
increased likelihood of correct identification o f HF cases by healthcare providers, are 
all important factors that may add to the burden of the syndrome and contribute to 
the observed HF ‘epidemic’ ." On the contrary, a factor that is likely to reduce the 
incidence of heart failure in the community includes the decreased incidence of 
myocardial infarction."
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%of population of age 65 years and over
■ Persons with HF (millions)
1960 1980 2000 2020 2040
Figure 1-2 Ageing population and the increasing prevalence of heart failure.
With the ageing demographic, heart failure cases in the community have steadily 
increased in the past and are projected to increase exponentially in the future. 
Adapted from Braunwald et al. 26
1.5.2 Incidence
Incident HF rates increase exponentially with age for both genders, and are 
approximately two times higher in men than women for each age category (Figure 
1-3).28 However, few studies have examined trends in HF incidence in the 
community." ' Data from the Framingham Study, which do not rely on diagnostic 
codes to identify HF cases and use consistent HF diagnostic criteria over the years,
17
are best suited for the examination of trends in the incidence of HF.
55-59 60-64 65-697 0-74 75-798 0-84 85-89 >90
(a) age category (years)
55-59 60-64 65-69 70-74 75-79 80-84 85-89 >90
(b) age category (years)
Figure 1-3 Age-specific incidence rates of heart failure.
(a) Age-specific male incidence rates (/1000 man years) and 95% confidence band.
(b) Age-specific female incidence rates (/1000 woman years) and 95% confidence
28band. The Rotterdam Study. Adapted from Bleumink et al. ~
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Despite the commonly-referenced assertion that HF is one of the “cardiovascular 
epidemics” to emerge in the 21st century,26 studies have shown that the age-adjusted 
incidence of HF has remained stable over the past 20 years and thus is not a true 
epidemic. ’ Indeed, the Framingham Study has shown a decline in the incidence
9 Qrate of HF, albeit only in women;
1.5.3 Lifetime risk
The concept of lifetime risk provides a useful framework to demonstrate the absolute 
cumulative risk of an individual developing a given disease during his or her 
remaining lifetime, and accounts for the risk of developing the disease of interest and 
the risk of competing causes of death. Perhaps the most robust data on HF risk 
originate from the Framingham Heart Study,32 although other studies have also 
provided estimates. Among subjects from Framingham who were free of HF at 
baseline, lifetime risk of developing HF was approximately 20%. Risk varied little 
with age but increased according to blood pressure (BP) levels at baseline and was 
halved in those who developed HF without an antecedent myocardial infarction 
(Table 1-4).32
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Table 1-4 Remaining lifetime risk for HF and for HF in absence of antecedent 
MI in men and women at selected index ages
Index age, y Men Women
Lifetime risk for HF (95% Cl)
40 21.0(18.7-23.2) 20.3 (18.2-22.5)
50 20.9 (18.6-23.2) 20.5 (18.3-22.6)
60 20.5 (18.1-22.9) 20.5 (18.3-22.8)
70 20.6(17.8-23.4) 20.2(17.8-22.6)
80 20.2(16.1-24.2) 19.3 (16.5-22.2)
Lifetime risk for HF without MI (95% Cl)
40 11.4 (9.6-13.2) 15.4(13.5-17.3)
50 11.6 (9.7-13.4) 15.5 (13.6-17.5)
60 11.9 (9.8-13.9) 15.8(13.7-17.8)
70 12.6(10.1-15.1) 16.2(14.0-18.5)
80 13.8 (10.0-17.6) 16.1 (13.4-18.8)
32All values are percentages. Adapted from Lloyd-Jones et al.
1.5.4 Aetiology
HF arises as a consequence of an abnormality in cardiac structure, function, rhythm,
or conduction.12 In developed countries, the commonest underlying perturbation is
ventricular dysfunction that results mainly from myocardial infarction, systemic
hypertension (HT), or in many cases both. Degenerative valve disease is becoming
more common. Other common causes include alcoholic cardiomyopathy and
“idiopathic” dilated cardiomyopathy, which may have a genetic basis. In less
developed countries, HF may result from cardiac involvement in infectious diseases
such as rheumatic valve disease, Chagas’ disease, and endomyocardial fibrosis.33'35
The relationship between diabetes mellitus and LV dysfunction is complex and
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requires further evaluation, as does the association between atrial fibrillation and HF
' i n
in patients with preserved and reduced EF. ’
1.6 BURDEN OF HEART FAILURE ON COMMUNITY RESOURCES 
1.6.1 Hospitalisations
Each year, about two individuals per thousand of the adult population are discharged 
from hospital with HF, accounting for approximately 5% of all medical and geriatric 
admissions.31, 38-43 Age at admission is increasing, which suggests that preventive 
treatments are delaying the onset of HF.31, 38-43 Patients discharged from hospital 
include those with incident HF which develops as a consequence of another cardiac 
event such as myocardial infarction; those presenting for the first time with 
decompensation of previously unidentified cardiac dysfunction; and those with 
established, chronic, HF who have suffered worsening of severity that requires in­
patient medical management. Some of these admissions reflect the incessant natural 
progression of HF, whereas others are related to avoidable factors, e.g. as a result of 
non-adherence to treatment44 After years of steady rise, age-adjusted rates of HF 
admission appear to have reached a plateau, or perhaps even decreased.
Assessment of hospital-based records in an Australian city, Perth, showed that 
medical documentation of HF is poor, particularly when the condition develops as a 
complication of acute myocardial infarction; in patients with longstanding HF who 
are prone to frequent readmission for acute HF exacerbations; and among older 
patients.45 It was concluded that data from hospital records was of questionable
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validity for HF patients, even when compared to patients with other cardiovascular 
diseases such as ischaemic heart disease. Despite these limitations, analysis of 
hospital data to monitor general trends in hospital admissions in HF or hypertensive 
heart disease (principal diagnosis only) has been reported as a measure of the 
changing burden of disease in the community.27
Over the period 1993-94 to 2000-01, rates of hospitalisation for HF or hypertensive 
heart disease have declined in adults of age >45 years (Figure 1-4). The decline is 
greatest among those aged 55-64 years, and less apparent in the very elderly (those 
aged >85 years).
Per 100,000 population 
aged 45 and over
-------------  Males
Females
93-94 94-95 95-96 96-97 97-98 98-99 00-01
Figure 1-4 Trends in hospitalisation rates where heart failure or hypertensive 
heart disease was the principal diagnosis, by sex, 1993-94 to 2000-01
Adapted from Field et al. 15
The average length of stay in hospital for HF patients has fallen from 9-10 days in 
1993-94 to 7-8 days in 2000-01. Females are hospitalized for a longer duration than 
males and, not unexpectedly, older HF patients are admitted for longer (10-11 days
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for those aged >85 years v 6 days for 45-54 year olds). Hospital deaths where HF or 
hypertensive heart disease was the principal diagnosis have also continued to decline, 
even more rapidly than the decline in hospital separation rates (Figure 1-5). In the 
period 1993-94 to 2000-01, hospital separation rates for HF fell on average by about 
2% per year, whereas deaths in hospital fell by 4-5% per year reflecting a reduction 
in the in-hospital case-fatality rate of about 2%. This reduction suggests that in- 
hospital treatment for HF is improving, although the data do not account for the 
severity of HF cases being treated in acute care hospitals. Secular changes in 
admission policies over the period studied may also be influencing the trends.
Information about HF readmissions to hospital cannot be determined using the 
National Hospital Morbidity Database because there is no individual identifier. 
However, a high readmission rate is characteristic of patients with HF and is most 
likely contributing to the high rates of hospital admission observed in the elderly. 
Because of the ageing population, falls in hospital admission rates for HF in recent 
years (Figure 1-4) may be attributable to falls in first-ever admissions rather than 
falls in the readmission rate.
1.6.2 Pharmaceutical use
In Australia, national data on the use of subsidised prescription drugs are available 
from various data sources including the Pharmaceutical Benefits Scheme and the 
Repatriation Pharmaceutical Benefits Scheme. However, these data are limited by 
their lack of specificity as they do not include information about the condition for 
which a drug is being prescribed. For instance, many of the vasoactive medications
23
used to treat HF can also be prescribed for more common conditions such as HT. 
Non-subsidised medications are not represented in these data sources.
Using data from primary care practices, it was shown that patients with HF were 
prescribed more medications than other patients of the same age.46 As anticipated 
and according to consensus guidelines, HF patients were often on a combination of 
medications including diuretics, digitalis and related drugs, potassium supplements, 
ACE inhibitors, nitrates and aspirin. Since that audit, the use of ß-blockers has 
increased with the emerging evidence for benefits in patients with HF-rEF.
Per 100,000 population 
aged 45 and over
------  Males
___Females
93-94 95-96 96-97 97-98 98-99 99-00 00-0194-95
Figure 1-5 Trends in in-hospital death rates where heart failure or hypertensive 
heart disease was the principal diagnosis, by sex, 1993-94 to 2000-01.
From Field et al.27
1.6.3 Mortality
Most reports on the trends in survival of patients with HF have shown secular 
improvement in age-adjusted death rates attributed to HF.29' 30, 47 In Australia, the 
decline in rates of HF deaths during the period 1997-2003 was accompanied by little
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change in the proportion of deaths from HF relative to competing causes (deaths 
from other cardiovascular diseases), suggesting that the decline in mortality from HF 
was likely to reflect a real change in the epidemiology of HF. HF and hypertensive 
heart disease accounted for 3,205 deaths in 2001 among people aged >45 years with 
nearly 90% of these deaths occurring in people aged >75 years. Between 1993- 2001, 
mortality rates declined for both sexes (Figure 1-6). The decline in death rates was 
lowest among 55-64 year olds, whereas this age group experienced the greatest fall 
in hospitalisation rates over a similar period of time. Death rates were similar 
between men and women (41 deaths per 100,000 v 38 deaths per 100,000, 
respectively). This contrasts with the disparity between hospitalisation rates and in- 
hospital death rates, where male death rates are much higher than those for females 
(Figures 1-4 and 1-5). The observation that women are less likely to be readmitted to 
hospital because of their role as carers in the community may be contributing to the 
gender differences.49 It may also reflect the under-diagnosis of HF in women.
Per 100,000 population 
aged 45 and over
Males
Females
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Figure 1-6 Trends in death rates where heart failure or hypertensive heart 
disease was the underlying cause, by sex, 1993 to 2001.
From Field et al. 27
1.6.4 Economic costs
National data on the cost of various diseases are limited to their “direct” costs, 
including hospital in-patient services; outpatient services; pharmaceuticals; GP and 
specialist consultations; allied health services; pathology tests; screening and 
diagnostic imaging services; and nursing homes. Disease costs that are not captured 
are related to community health services; public health programs; ambulance 
services; and medical aids and appliances. In 1993-94, the direct health care costs for 
HF were estimated to be $411 million, which equates to 10% of the total costs 
attributable to cardiovascular disease. HF costs were ranked fourth behind coronary 
heart disease (23%), HT (21%) and stroke (16%).50
1.7 CHANGING EPIDEMIOLOGY OF HEART FAILURE IN THE ERA OF 
CARDIAC IMAGING
Over the last decade, there have been a number of important observations from 
population-based echocardiographic surveys. First, it has been consistently 
documented that HF can be present without a reduction in EF, which has been widely 
used as a measure of global LV systolic function. Second, a large proportion of 
subjects with reduced EF is asymptomatic and has no clinical signs of HF. These 
observations have stimulated interest in the pathophysiology and natural history of 
HF.
26
1.7.1 Heart failure with normal ejection fraction (HF-NEF)
Comparisons of studies examining the epidemiology of HF with normal EF 
(HF-NEF) have been limited by the lack of clear consensus regarding a definition of 
the syndrome.51,52 Thus there are differences in study setting and patient populations 
(ambulatory versus hospital populations), and major differences in the methods used 
to diagnose the presence of clinical HF and to confirm preservation of LV systolic 
function. ’ Despite these limitations, studies have provided consistent results.
Most studies have reported that one third to one half of patients presenting with HF 
in a community setting have normal or near normal LV systolic function as defined 
by a EF of greater than 40-50%.20, 53 56 A review by Hogg et al.54 reported the 
prevalence rates of HF in European and North American studies according to 
preserved or impaired left ventricular systolic function (Figure 1-7). Differences in 
prevalence rates of total HF relate predominantly to differences in mean age of the 
populations, but also to the factors discussed above. Across all of these HF studies, 
the mean proportion of patients with preserved systolic function was 56%.54
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PREVALENCE OF HEART FAILURE
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Figure 1-7 Prevalence of heart failure in European and North American studies 
according to preserved or impaired left ventricular systolic function
From Hogg K et al.54
Other consistent findings are that the syndrome is relatively more common in 
women,56 and is strongly associated with HT.57 Diabetes and CAD are also relatively 
common in these patients. However, one of the most important risk factors for 
HF-NEF is advanced age, consequent to age-related structural changes that occur in 
the ventricle, principally myocardial fibrosis. In patients >65 years of age, the 
majority of HF patients will have preserved LV systolic function, a finding even 
more dominant in elderly women.58
Despite repeated confirmation that HF-NEF is more common in women than men, 
population studies assessing the prevalence of DD have found DD to be either gender 
neutral or more common in men.20,59 The reasons for this paradox are not obvious, 
but this finding suggests that gender differences may exist in the pathophysiological
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pathways that lead from DD to decompensated HF, and that mechanisms other than 
DD are involved.
1.7.1.1.1 Conceptual issues regarding the definition of HF-NEF
A fundamental concept in approaching a description of HF-NEF relates to whether 
one embraces an “inclusive” or “exclusive” definition of the syndrome. While an 
exclusive definition requires only documentation of normal EF be present in the 
setting of clinical HF, an inclusive definition further requires the demonstration of 
abnormal diastolic function, which is causally linked to the clinical HF. While an 
inclusive definition has the advantage of increasing the specificity of the diagnosis, it 
obviously requires assessment of diastolic function, which is often a very difficult 
task. Indeed, assessment of diastolic function has historically been perceived to be 
too complex for non-invasive methods, and the majority of investigators have 
therefore defined HF-NEF as a diagnosis of exclusion. When assessment of diastolic 
function is omitted, the exclusive definition assumes the clinical syndrome to be 
secondary to DD; however other possibilities also exist, including for example 
valvular dysfunction, intermittent ischaemia or intermittent atrial fibrillation.
The second fundamental concept to consider in establishing a diagnosis of HF is that
of acute versus chronic HF. Acute episodes are characterised by rapid onset ("flash")
pulmonary oedema and have unequivocal physical signs and chest X-ray evidence of
pulmonary venous congestion.60, 61 Most of the epidemiological data which follows
refers to patients who at some stage have had decompensated HF, usually requiring
hospitalisation. In contrast, patients with chronic HF-NEF are poorly characterised,
although they potentially comprise a significant proportion of the hypertensive
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population who report exertional breathlessness. These ambulatory patients are 
relatively asymptomatic at rest, but complain of exercise intolerance which is likely 
due to a combination of high filling pressures during exercise, as well as reduced 
stroke volume. Whilst the clinical presentations of these two syndromes are 
markedly different, recent evidence suggests that they likely represent two ends of 
the spectrum of the same phenomenon. Thus, the vast majority of patients who are 
admitted to hospital with acute HF-NEF report preceding chronic symptoms 
consistent with New York Heart Association (NYHA) class II-IV .  ^ It is important 
to note that as patients with chronic HF-NEF may be well-compensated and 
asymptomatic at rest, and clinical signs of HF are often absent. In this syndrome 
therefore, it is even more important to require that the diagnosis of HF-NEF includes 
confirmation of DD
1.7.1.1.2 Current definitions of HF-NEF
There are two groups who have published guidelines for diagnosing HF-NEF. Vasan 
et al have suggested that, in order to achieve a diagnosis of “definite” HF-NEF, 
patients are required to have clinical signs of decompensated HF which satisfy 
Framingham criteria; have a normal EF documented within 72 hours of the HF 
episode, and have abnormal diastology demonstrated at left heart catheterization. If 
the first two criteria are satisfied but invasive assessment is not performed, the 
patient is deemed to have only “probable” HF-NEF. As cardiac catheterization is 
generally not indicated in this condition, very few patients would receive a definite 
diagnosis of HF-NEF under these guidelines, making them clinically impractical.
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The latest criteria proposed by the European Society of Cardiology (ESC) for the 
diagnosis of HF-NEF include all of the following64: (a) the presence of signs or 
symptoms of HF, (b) the presence of normal or mildly abnormal EF, and (c) 
evidence of DD (by cardiac catheterisation, Doppler echocardiography, and the 
measurement of plasma levels of natriuretic peptides). However, these criteria do not 
take into account mechanisms, other than DD, which also cause HF in the presence 
of a normal EF. In addition, ESC guidelines do not address the lack of sensitivity in 
patients who have increased filling pressures only during exercise, but not at rest.
In contrast, the American College of Cardiology / American Heart Association 
(ACC/AHA) Heart Failure Guidelines 2001 provide no specific criteria for the 
diagnosis of HF-NEF. Instead, the taskforce states that “it is difficult to be precise 
about the diagnosis of DD”, and support a diagnosis of exclusion, based on 
symptoms and signs of HF in patients with a normal EF and no valvular 
abnormalities. Somewhat surprisingly, these recommendations were not modified in 
the recently updated guidelines.5
1.7.1.1.3 Prognosis of HF-NEF
In a community cohort from the Framingham Heart study followed for a median of 
6.2 years, patients with HF-NEF (EF >50%) had a lower mortality compared patients 
with impaired EF. However, the former group still had a fourfold mortality risk 
compared with control subjects who were free of HF.56 In one of the few studies of 
incident cases of HF, patients receiving a new diagnosis of HF over a 1 yr period had
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a mean age of 77 years.55 Forty-three percent of these patients had an EF >50%, and 
after adjusting for age, sex, functional class, and the presence of coronary disease, 
survival was not significantly different between patients with normal and those with 
reduced systolic function (Figure 1-8).55 Similar findings were reported in a 
contemporary study of Olmsted County residents.65
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Figure 1-8 Survival in heart failure patients with preserved versus impaired 
systolic function: Historical evidence.
Modified from Senni et a l 55 EF = ejection fraction.
1.7.1.1.4 Medical therapy and trends in survival for HF-NEF patients
Unfortunately, there is very little evidence on which to recommend medical therapy 
for patients with HF-NEF. The results of recent clinical trials on medical therapy for 
HF-NEF have been disappointing (Table 1-5). In general, the empirical management 
of HF-NEF has 2 objectives: (i) treatment of the presenting syndrome of HF,
32
including the therapy directed at venous congestion and precipitating factors such as 
atrial fibrillation with a poorly controlled ventricular response; (ii) treatment directed 
at risk factors for DD such as HT.5’6
Table 1-5 Randomised controlled trials for the treatment of heart failure in 
patients with normal ejection fraction
Agent Study outcomes Result
Candesartan66 CV death, HF hospitalization No effect
Nebivolol67 Death, CV hospitalization No effect*
Digoxin68 HF death, HF hospitalization No effect
Perindopril69 Death, HF hospitalization No effect
Irbesartan70 Death, CV hospitalization No effect
Spironolactone CV death, HF hospitalization Due to report 2010
inadequately powered to show separate effect in EF>35%
At present, there are ongoing clinical trials in HF-NEF that aim to test the efficacy of 
aldosterone antagonists (TOPCAT study), nesiritide, beta-blockers (Japanese 
diastolic heart failure trial) and sildenafil (RELAX trial).
The rate of morbidity and mortality of patients with HF-rEF has gradually improved 
during the past 2 decades, reflecting the impact of several evidence-based 
interventions that have been incorporated into the care of patients with HF-rEF 
(Figure 1-9).
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A Patients with Reduced Ejection Fraction
---- 1987-1991
---- 1992-1996
---- 1997-2001
P=0.005
No. at Risk
1987-1991 819 525 424 336 274 220
1992-1996 857 594 481 395 331 273
1997-2001 748 520 447 319 210 114
Figure 1-9 Trends in survival in heart failure patients with reduced ejection 
fraction: 1987-2001.
From Owan et cil.65
In contrast, the prognosis of patients with HF-NEF has remained steadfastly 
unchanged during the same time period (Figure 1-10), reflecting the dearth of 
therapeutic interventions that have been evaluated in HF-NEF, and the failure of 
these therapies to show any benefit on survival in patients with this syndrome. Thus, 
there is an urgent need to develop novel and efficacious strategies for the treatment 
of HF-NEF, particularly ones that specifically target the pathophysiologic 
mechanisms that underlie HF-NEF.
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B Patients with Preserved Ejection Fraction
No. at Risk
1987-1991
1992-1996
1997-2001
510
771
885
377
537
629
313
447
513
263
375
365
216
314
230
117
262
138
Figure 1-10 Trends in survival in heart failure patients with preserved ejection 
fraction: 1987-2001.
From Owan et al.65
1.7.2 Role of diastolic dysfunction in the aetiology of HF-NEF
In considering the aetiology of HF-NEF, the obvious question to ask is whether 
HF-NEF is actually caused by DD. As discussed, definitions of exclusion have 
assumed DD to not only be present, but to be causative. While early evidence did 
indeed support the view that the key problem in HF-NEF is an abnormal diastolic 
pressure-volume relationship, it is only quite recently that this hypothesis has been 
actively investigated.
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In 2001, Zile et al reported a study of a highly selected group of 63 patients with 
clinically defined HF and normal EF who were already scheduled for left heart 
catheterization and a detailed echo-Doppler study. All patients had LV hypertrophy 
or concentric LV remodelling. The results showed that LV end-diastolic pressure 
was elevated in 92% of patients. At least one index of diastolic function was 
abnormal in every patient, leading the authors to conclude that the diagnosis of HF- 
NEF can be reliably made clinically.72
In the same year, Gandhi et al reported a study of 38 patients who presented with 
acute pulmonary oedema and HT (mean systolic BP approximately 200 mmHg).61 
Echocardiography was performed during the acute presentation and again after 
treatment demonstrated a similar EF (approximately 50%) at both studies. No patient 
had severe mitral regurgitation during the acute episode. These authors suggested 
that the acute pulmonary oedema was therefore due to exacerbation of DD by HT 
rather than transient systolic dysfunction.
More recently, Zile et al published a second report with more detailed 
haemodynamic information on 47 patients from the original study who had 
undergone micromanometer studies at left heart catheterization.73 Compared with 
healthy controls, patients with HF-NEF had longer time constant of LV relaxation, 
higher minimal LV pressure and higher LVEDP, despite lower diastolic volumes. 
They also had increased LV chamber stiffness illustrated by an upward and leftward 
shift in pressure-volume curves (Figure 1-11). Thus patients with HF and normal EF 
were demonstrated to have impaired active LV relaxation and increased passive LV
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stiffness. Most importantly, the authors believed that these abnormalities were 
sufficient to explain the patients’ elevated diastolic pressures and clinical HF.73
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Figure 1-11 End-diastolic pressure volume curves in patients with diastolic 
heart failure versus controls.
From Zile et al. 73
Despite the careful and detailed methodology of this invasive study, the highly 
selected nature of the patient group limits extrapolation to the large clinical 
population of patients presenting with HF-NEF. Two studies of unselected patients 
with suspected HF-NEF have addressed this issue. Cahill et al evaluated the 
incidence of DD in a group of consecutive patients hospitalised with HF who had 
normal EF and no significant valvular dysfunction, and found that less than half of 
such patients had isolated DD.74 Similarly, among consecutive patients with
37
suspected HF-NEF function referred for echocardiography, Petrie et al found very 
poor concordance among different published criteria for the diagnosis of DD.7;i
Burkhoff et al compared end-diastolic pressure-volume relations in patients with 
HF-NEF and normal controls from several studies and found variable results (Figure 
1-12). The authors concluded that there is no consistent abnormality of diastolic 
properties that can explain the occurrence of HF with normal systolic function.
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Figure 1-12 End-diastolic pressure-volume relations in different populations of 
patients with heart failure and normal left ventricular ejection fraction.
Curves o f patients with HFNEF may be shifted to the left (curve 3), shifted to the
right (curves 5 and 6), or may not be significantly different (curve 4) than those o f
normal patients (curves 1 and 2). HFNEF = heart failure with normal ejection
fraction. From Burkhoff et al.76
The reasons for these discrepant results are not obvious, but likely relate to 
differences in patient selection leading to heterogeneity of patient characteristics in
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different studies of HF and preserved LV systolic function. However, this 
explanation is not the full story as the clinical syndrome of “decompensated” HF is 
associated with other pathophysiological factors. LV diastolic function is not 
necessarily the sole or even dominant factor in HF-NEF. A low cardiac output is one 
of the fundamental abnormalities of HF of any cause, whether it be predominantly 
systolic or diastolic HF.77,78 Furthermore, a strong theoretical argument can be made 
to relate low cardiac output to the known pathophysiological characteristics of 
HF-NEF.77 in addition, neurohormonal activation, which is associated with HT and 
increased venous tone is prominent in HF-NEF, and not dissimilar to that seen in 
systolic HF. As a consequence of reduced cardiac output and neuro-humoral 
activation, decompensated HF-NEF, like HF-rEF, is characterised by increased 
sodium and water retention. Finally, increased arterial stiffness is likely to be 
important in the pathophysiology of HF-NEF;80 this subject will be discussed in 
detail later in this chapter.
Despite the likely importance of all of these factors, they do not necessarily cause HF 
in patients with normal LV structure and function. When considering the totality of 
evidence, therefore, one can conclude that decompensated HF-NEF occurs through 
the interaction of the underlying substrate of DD with the exacerbating peripheral 
factors described above.
1.7.2.1.1 Ventricular-arterial interaction in HF-NEF
In addition to its direct haemodynamic load, HT is associated with increased aortic
stiffness which may contribute further to hypertrophic LV remodelling. Increased
pulsed wave velocity through stiffened arteries results in the early return of reflected
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pressure waves before systole is completed thereby increasing LV afterload, which 
of itself can directly impair LV relaxation.81 Aortic stiffening also reduces central 
diastolic pressure resulting in decreased coronary perfusion which may exacerbate 
subendocardial ischaemia in the setting of LV hypertrophy.82
Arterial stiffening is also associated with increased ventricular stiffness which in 
combination lead to markedly reduced cardiovascular reserve that is particularly 
characteristic of elderly hypertensives. ’ Patients with HF and preserved systolic 
function are also characterised by increased aortic and ventricular stiffness, resulting 
in impaired ventricular-arterial interaction which may be important to the 
pathophysiology of decompensated HF-NEF.80 In addition, increased arterial 
stiffness appears to be mechanistically related to the severe exercise intolerance in 
stable patients with HF-NEF.85
Recent studies have also shown that age-related increases in ventricular and arterial 
stiffness occur in tandem and may be more pronounced in women,8 3 ,86 which may 
explain the predilection of HF-NEF in older women. It has been proposed that these 
age-related alterations in vascular-ventricular coupling may contribute to exercise 
intolerance and could predispose to the development of DD87 and HF-NEF.80,88
Despite the emerging evidence for a key role of arterial function in HF-NEF, few 
studies have assessed the relationship of arterial stiffness to echocardiographic 
parameters of LV diastolic function.
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1.7.3 Detectable preclinical phase of disease
The confirmation of a stage of preclinical LV dysfunction in echocardiographic 
surveys has provided greater opportunity to delineate the natural history of HF. The 
information from these studies has emerged in tandem with a better understanding of 
the physiology of cardiac function and technological advances in non-invasive 
cardiac imaging.
1.8 UNDERSTANDING THE NATURAL HISTORY OF DISEASE
1.8.1 Asymptomatic left ventricular systolic dysfunction
For many years, clinicians have been aware that a reduced EF without increased LV 
filling pressures can be documented in patients without symptoms/signs of HF. Over 
the last decade, their anecdotal findings have been confirmed using population-based 
echocardiographic surveys that have consistently found that a large proportion of 
subjects with reduced EF is asymptomatic and has no clinical signs of HF.
1.8.1.1.1 Asymptomatic LV systolic dysfunction: Epidemiology
There is now a large body of evidence to support the assertion a large proportion of 
subjects with reduced EF is asymptomatic and has no clinical signs of HF (Table 1- 
6) .
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Table 1-6 Prevalence of asymptomatic left ventricular systolic dysfunction
S tu d y  (R eferen ce ) C o u n try P a rtic ip a n ts M e a n  A ge M en LVSD C riteria P rev a le n ce  
o f LVSD
P rev a le n ce  o f  LVSD 
w i th o u t  C H F t
n y % %
EF >  0 .4 0 .  o r e q u iv a le n t
S tro n g  H e a rt S tudy  (26) U n ited  S ta tes 3 1 8 4 58 37 EF -=- 0 .5 4 1 4 .0 1 2 5
H yperG EN  S tu d y  (2 7 ) U n ited  S ta tes 2 0 8 6 55 3 8 EF sc 0 .5 4 14 .0 1 2 9
D av ie s  e t  al. (28) E ngland 3 9 6 0 61 5 0 EF ss 0 .5 0 5 .3 3 3
M O N IC A  p ro je c t (A ugsburg ) (29) G e rm an y 1 5 6 6 5 0 4 8 EF <  0 .4 8 2 .7 1 .1 *
H e d b e rg  e t  al. (30) S w ed e n 4 1 2 7 5 5 0 W M I <  1 .7 6  8 3 2
N ielsen  e t  al (3 1 ) D e n m a rk 1 2 6 7 0 5 5 W M I s  1 .5  o r  F S <  0 .2 6 2 .9 1 .0
R o tte rd am  S tu d y  (3 2 ) N e th e rlan d s 2 2 6 7 6 6 4 5 FS *  0 .2 5 3 .7 2 .9 5
H elsinki A g e ing  S tu d y  (33 ) Finland 5 01 - 1 27 FS <  0  2 5 10.8 8 6
EF s  0  4 0
S tro n g  H e a rt  S tu d y  (26 ) U n ited  S ta tes 3 1 8 4 5 8 3 7 EF <: 0  4 0 2 .9 2.1
H yperC E N  S tu d y  (2 7 ) U n ited  S ta te s 2 0 8 6 5 5 3 8 EF <  0  4 0 4  0 3 4
D av ie s  e t  al (2 8 ) E ngland 3 9 6 0 61 5 0 EF <  0  4 0 1 .8 0 .9
M O N IC A  p ro jec t (G la sgow ) (34) Sco tland 14 6 7 5 0 4 8 EF *  0 0 5 7 .7 5 .9
M O N IC A  p ro jec t (G la sgow ) 0 4 ) S co tland 1467 5 0 4 8 EF sS 0 .3 0 2 .9 1.4
Q u a lita tiv e ly  " re d u c e d "  EF
C ard io v ascu la r H e a lth  S tu d y  (35) U n ited  S ta tes 5 5 3 2 73 4 2 Q u a lita tiv en 3 .5 2 .5
M o rg a n  e t  al. 0 6 ) E ngland 8 1 7 7 6 4 6 Q u a lita tiv e 7 .5 3 9
From Wang et al.89
Given the potential expense of widespread echocardiographic screening, there is 
interest in targeting subgroups at high risk for LV systolic dysfunction (LVSD) who 
could be efficiently screened.90, 91 Four studies reported the prevalence of 
asymptomatic LVSD in specific subgroups 91 94 The prevalence of asymptomatic 
LVSD was twofold to eightfold higher in men than in women and higher in elderly 
persons. Indeed, the prevalence of asymptomatic LVSD in women was low, ranging 
from 0.2% to 1.1% in community-based studies.91,93,94 When clinical features were 
considered, the prevalence was highest among individuals with known coronary 
heart disease, ranging from 4.8% to 8.5%.91, 93, 94 Only three studies enrolled an 
appreciable number of non-White participants. 92, 94, 95 The Strong Heart Study 
reported a high prevalence of LVSD in a community-based study of Native 
American participants.95In the Hypertension Genetic Epidemiology Network Study 
and the Cardiovascular Health Study, LVSD prevalence rates were slightly higher in 
black participants than in White participants.92,94
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1.8.1.1.2 Asymptomatic LV systolic dysfunction: Prognosis
In community-based observational studies, asymptomatic LVSD was associated with 
increased cardiovascular mortality94; all-cause mortality94, %; and nonfatal 
cardiovascular events, such as myocardial infarction and stroke.94,97 Little is known 
about the rate of progression from asymptomatic LVSD to overt HF in the 
community. In an earlier investigation from the Cardiovascular Health Study, 
Aurigemma and colleagues98 reported an annual HF incidence of 3% for individuals 
with LVSD, but this estimate was restricted to individuals without coronary heart 
disease.
Surv ival
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Mod/Severe A LVSD
P<0.0001
Y ears
Figure 1-13 Kaplan-Meier survival curves showing freedom from heart failure 
for subjects with asymptomatic left ventricular systolic dysfunction.
Referent group consists o f subjects with normal left ventricular systolic function (EF
=50%). Mild ALVSD indicates mild asymptomatic left ventricular systolic
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dysfunction (EF 40% to 50%); Mod/Severe ALVSD, moderate-to-severe
89asymptomatic left ventricular systolic dysfunction (EF<40%). From Wang et al.
In the placebo groups of five randomized, controlled trials that included more than 
3500 participants with asymptomatic LVSD, average annual HF rates ranged from 
4.9% to 20.0% (Figure 1-13), and average annual mortality rates ranged from 5.1% 
to 10.5% (8, 9, 42-44)." '103 These mortality rates are intermediate between those of 
persons with previous myocardial infarction and preserved systolic function and 
those of patients with systolic HF.99,104 (Figure 1-14)
Although randomized trials provide the largest source of data on prognosis of 
patients with asymptomatic LVSD, extrapolating these data to individuals in the 
community is problematic for several reasons. First, with the exception of SOLVD, 
all other trials enrolled patients in the setting of a recent myocardial infarction; even 
in SOLVD, nearly 80% of participants had previous myocardial infarction." Second, 
many participants enrolled in trials are not truly asymptomatic but may have NYHA 
class II symptoms or previous HF. Third, most trials excluded people with mild 
LVSD (EF 40-50%), even though most people identified in community-based studies 
fall into this category. Finally, trial participants were younger than typical individuals 
with LVSD in the community.
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Figure 1-14 Kaplan-Meier survival curves showing prognostic significance of 
asymptomatic left ventricular systolic dysfunction.
Referent group consists o f subjects with normal left ventricular systolic function 
(EF=50%) and no history of HF. Mild ALVSD indicates mild asymptomatic left 
ventricular systolic dysfunction (EF 40% to 50%); Mod/Severe ALVSD, moderate-to- 
severe asymptomatic left ventricular systolic dysfunction (EF<40%); Systolic HE,
89congestive heart failure with EF<50%. From Wang et al.
1.8.1.1.3 Asymptomatic LV systolic dysfunction: Treatment
Only ACE inhibitors have been shown to improve outcomes in patients with 
asymptomatic LVSD. In the SOLVD Prevention trial," treatment with enalapril was 
associated with a 37% reduction in HF and a nonsignificant reduction in mortality. 
The SAVE trial100 demonstrated reductions in both incidence of HF requiring 
hospitalization (22%) and mortality (19%) associated with captopril treatment in 
patients with asymptomatic LVSD after myocardial infarction. Accordingly, both the
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ACC/AHA and the European Society of Cardiology recommend treatment with ACE 
inhibitors in patients with HF-rEF with or without previous myocardial infarction.4, 
15 However, most individuals with LVSD in the community who would be identified 
by screening would not have been eligible for the SOLVD or SAVE trials. Thus, it 
remains unclear whether they would benefit similarly from treatment.
1.8.2 Asymptomatic left ventricular diastolic dysfunction
Since the commencement of the Canberra Heart Study, evidence has emerged that 
confirms that “isolated” DD is prognostically important, even in the absence of 
clinical HF. Redfield et al examined 2,042 randomly selected subjects of age 45 
years and over. HF, which was validated using Framingham criteria, was 
documented in 2.2% of the population. Diastolic function was comprehensively 
assessed with Doppler echocardiography, including the measurement of transmitral 
and pulmonary venous flow and mitral annular velocity using TDI. Diastolic 
function was categorised as normal or impaired to a mild, moderate or severe degree. 
Subjects were passively followed up for a median of 3.5 years. The authors found 
that moderate or severe DD in the setting of normal LV systolic function was 
common, being present in 5.6% of the population. These degrees of DD were 
associated with a hazard ratio for all-cause mortality of 10 in comparison with 
subjects who had normal diastolic function even in the absence of clinical HF, which 
was recognised in less than half of such patients. Somewhat surprisingly, even mild 
DD conferred a hazard ratio of 8 for mortality in comparison with normal diastolic 
function (Figure 1-16).20 Abnormal LV Doppler filling parameters were also 
associated with high risk of incident HF over 5 year follow-up in older patients in the
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Cardiovascular Health Study. Thus echo parameters (or patterns) of diastolic 
function have strong prognostic significance, but exactly how they relate to clinical 
HF remains unclear.
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Figure 1-15 Kaplan-Meier mortality curves for subjects with normal versus 
abnormal diastolic function as assessed by Doppler echocardiography.
From Redfield et a l20
Apart from generic advice regarding the control of risk factors, there is no evidence 
to advocate any specific therapy for patients with asymptomatic DD.
1.8.3 Stages of heart failure in the era of cardiac imaging
The insights into the natural history of HF that have been afforded by findings from 
echocardiographic surveys were acknowledged by ACC/AHA and incorporated in 
their guidelines for the evaluation and management of HF in 2001.106 The writing 
committee developed a new approach to the classification of HF that emphasizes its
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evolution and progression and defined four stages of HF. Patients with stage A HF 
are at high risk for the development of HF but have no apparent structural 
abnormality of the heart. Patients with stage B HF have a structural abnormality of 
the heart but are asymptomatic of HF. Patients with stage C HF have a structural 
heart disease and current or previous symptoms of HF. Patients with stage D HF 
have end-stage HF with symptoms that are refractory to standard medical therapy. 
This staged classification highlights the fact that established risk factors and 
structural abnormalities are necessary for the development of HF, recognises its 
progressive nature, and superimposes treatment strategies on the fundamentals of 
preventive efforts. 107
1.8.4 Screening for preclinical left ventricular dysfunction
To be appropriate for screening, a disease should be serious, and the preclinical 
phase of the disease should have a high prevalence among the population targeted for 
screening. Furthermore, screening initiated before a critical point in the natural 
history of the disease should result in treatment being initiated before the onset of 
symptoms (Fig. 1). This treatment should be more beneficial in reducing morbidity 
or mortality than treatment given after symptoms develop. Finally, the screening for 
the disease should not result in a significant incidence of “pseudodisease”. On the 
basis of these characteristics, it would appear that LV dysfunction is an appropriate 
disease for screening, although further studies are warranted to evaluate the benefits 
of treatment of preclinical LV systolic dysfunction and to determine the natural 
history of DD.
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Detectable preclinical phase of disease
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Figure 1-16 Natural history of disease: implications for screening.
The diagram can he used to evaluate appropriateness criteria for a screening test
and illustrates how lead-time bias can result in apparent increase in survival
108attributable to screening. Adapted from Herman et al.
1.9 CONCLUSIONS
Recent advances in knowledge of the pathophysiology of LV dysfunction and its 
relationship between clinical symptoms of cardiac insufficiency have direct 
implications for the diagnosis and treatment of HF. Our challenge now is to 
recognise the burden of LV dysfunction in the community and identify non-invasive 
diagnostic strategies which would be useful for the early diagnosis of LV structural 
and functional abnormalities even prior to the development of overt symptoms of 
HF. Such aims will be addressed in the research studies which follow (chapters 4-7). 
To put these concepts into perspective, however, it is first necessary to review the 
current echocardiographic techniques available for the assessment of LV function, 
with particular reference to their limitations.
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2.1 ABSTRACT
Patients with HF and “normal” LV ejection fraction are considered to have possible 
or probable HF related to LV diastolic dysfunction. A more specific diagnosis can be 
made by demonstrating abnormal LV diastolic function. While the various patterns 
of transmitral flow have been shown to have important prognostic implications, such 
assessments are complex and intrinsically dependent on LV loading conditions. More 
recent advances in echocardiographic techniques have improved our understanding 
of LV diastolic function and have provided a means of non-invasively estimating LV 
filling pressure. Because of the restricted access to echocardiography, it has been 
proposed that non-imaging methods for the detection of LV function be used as a 
filter prior to assessment. These methods may have the potential to extend their 
diagnostic application from diagnosis to screening high-risk populations, although 
further studies are required. In this chapter, I review methods for assessment of LV 
function. In particular, I outline the recent advances in the methods for assessment of 
LV diastolic function. Evidence to support the use of non-imaging methods for the 
detection of LV function (circulating biomarkers and measurement of arterial 
stiffness) is presented.
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2.2 REFERENCE STANDARD FOR ASSESSMENT OF LV FUNCTION
Echocardiography is the most practical technique for determining cardiac structure 
and function. Further, it offers a comprehensive assessment for HF patients by 
allowing the evaluation of EF, haemodynamically significant valvular heart disease 
and pericardial disease. Doppler echocardiography is widely available, non-invasive 
and less expensive than other techniques, which renders it ideally suited for 
assessment of LV diastolic function. However, a significant limitation is the 
requirement for an evaluation of a complex array of haemodynamic parameters that 
vary with loading conditions and often provide conflicting information. This chapter 
will attempt to clarify this complex area, detailing the application of 2-dimensional 
and Doppler echocardiography for the clinical assessment of LV function. The 
limitations of the currently available techniques will be outlined and non-invasive 
approaches for the detection of subjects with LV dysfunction will be discussed.
2.2.1 LV ejection fraction as a marker of cardiac function
Ejection fraction (the percentage of stroke volume divided by end-diastolic volume) 
was initially adopted as an index of LV systolic function before the introduction of 
echocardiography and other non-invasive imaging techniques, when cardiac 
catheterisation was used to assess ventricular function by contrast 
cineventriculography.109 To avoid the added effort of calibrating ventriculographic 
volumes, EF was bom as a quick and relatively reproducible way of quantifying 
function.110,111 Indeed, even after the advent of echocardiography, EF was used for 
years as the sole quantitative measure of global cardiac function.
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The assessment of LV systolic function by EF is used for the diagnosis of HF in 
patients with symptoms of cardiac insufficiency, for the prediction of morbidity and 
mortality, , and as a diagnostic criterion to enable or preclude patients from 
receiving a variety of potentially beneficial medical therapy and procedures 
including cardioverter-defibrillator implantation113 and valve replacement. 114
Despite its widespread use in the clinical setting, a number of limitations with EF as 
a marker of global systolic function have been recognised, relating principally to 
reproducibility of measurements and the sensitivity of this marker to alterations in 
LV systolic function. Although three-dimensional echocardiography and magnetic 
resonance imaging produce more reproducible measurements of EF than two- 
dimensional echocardiography or ventriculography,115, 116 no measure of EF 
sufficiently accounts for regional abnormalities unless several myocardial segments 
are involved. Recent studies have shown that longitudinal systolic function assessed 
using measures derived from tissue Doppler imaging is reduced in patients with HF- 
NEF.117, 118 Novel quantitative assessments of tissue velocity, strain and strain rate 
are now feasible on commercially available echocardiographic machines for the 
assessment of regional and global LV systolic function (in longitudinal, 
circumferentially and radial planes). However, these measures are sometimes 
cumbersome and time-consuming to measure and in most laboratories have less than 
desirable reproducibility. 119
2.2.2 Assessment of diastolic function with echocardiography
At the time that the Canberra Heart Study was conducted, there was no consensus 
regarding diagnostic echocardiographic criteria for the assessment of diastolic
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120 121function, although several recommendations had been proposed. ’ The European 
Study Group on Diastolic HF has provided comprehensive criteria which relate to 
abnormal LV relaxation, abnormal LV filling or reduced LV diastolic distensibility 
based on transmitral and pulmonary vein Doppler data.120
2.2.2.1.1 Limitations with conventional Doppler examination
Echocardiographic evaluation of diastolic function has been traditionally performed 
by measurement of transmitral flow parameters including the early (E) and late (A) 
diastolic filling velocities, the E/A ratio and the E deceleration time from an apical 4 
chamber view with conventional pulsed wave Doppler (Figure 2-la).121 The 
transmitral E wave is related to the time course of active LV relaxation which 
generates a pressure gradient from the left atrium through the LV inflow tract to the 
LV apex.122 Early diastolic LV filling is therefore largely influenced by interaction of 
left atrial (LA) compliance and the rate of ventricular relaxation. The peak E velocity 
may be increased by either elevated LA pressure (the cause of high E/A ratios in 
cardiac disease), or alternatively, by low LV minimal diastolic pressure due to rapid 
LV relaxation (which drives the high E/A ratios typical of normal young adults).123
Based upon the interpretation of the transmitral flow profile, diastolic function is 
initially classified as either normal, impaired relaxation, pseudonormal, restrictive 
(which may be reversible or non-reversible with preload reduction), or indeterminate 
(if normal or pseudonormal cannot be differentiated) (Figure 2-1). These patterns of 
LV filling represent progressively worse DD as the LV becomes increasingly 
abnormal. It is important to consider that increasing DD is usually accompanied by a 
progressive increase in LV filling pressures, which in turn have a major impact on
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the transmitral flow profile. Slow or prolonged LV relaxation therefore causes a 
decrease in E velocity but at the same time contributes to elevation of LA pressure 
which in turn tends to increase the E velocity.124 These opposing effects of LA 
pressure and LV relaxation are also operative on the E deceleration time, which tends 
to be prolonged by impaired LV relaxation and shortened by increased filling 
pressures. Thus the effects of DD on the E/A ratio and E wave deceleration time 
become progressively compensated and then over-compensated by the effects of 
loading, resulting in a non-linear (in fact “U” shaped) relationship between these 
indices and severity of DD.125 The isovolumic relaxation time bears a similar 
relationship to DD and load and does not provide additional information. In 
individual patients therefore, the filling pattern can change from mild (impaired 
relaxation) to more severe (pseudonormal or restrictive) DD with either a progression 
of the underlying pathophysiological process, or alteration of loading conditions 
(Figure 2-2). Similarly, improvement in the Doppler filling profile may occur over a 
longer period with treatments targeting the underlying cause. Thus transmitral flow 
parameters must be further interpreted in the light of LV loading. This requires either 
incorporation of alternative load-dependent parameters, or use of newer less load- 
dependent techniques (or preferably both).
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Figure 2-1 Pathophysiological characterisation of left ventricular filling 
patterns.
(a) Normal transmitral flow in a patient in sinus rhythm, (b) Impaired relaxation 
with normal filling pressures, (c) Pseudonormal filling, (d) Restrictive filling.
Figure 2-2 Load-dependence of the left ventricular filling pattern.
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A. Restrictive filling associated with increased preload in a HF patient with fluid 
overload. B. Following diuretic therapy, removal of intravascular volume has 
reduced LV filling pressure and unmasked the underlying impaired relaxation 
pattern.
2.2.2.1.2 Impaired left ventricular relaxation
Slowing and prolongation of LV relaxation becomes apparent at an early stage of LV 
dysfunction,126 perhaps because this part of the cardiac cycle is metabolically very 
demanding. Impaired LV relaxation reduces the peak transmitral pressure gradient, 
thereby reducing the E velocity and E/A ratio. Continued slow or discoordinate 
LV relaxation maintains a low transmitral pressure gradient into mid diastole 
resulting in prolongation of the E deceleration slope “ (Figure 2-lb). As LA pressure 
remains relatively normal at rest in this early stage of DD, patients may have 
symptoms only with exertion, and transmitral flow may be close to normal at rest. 
Importantly, even this mild degree of DD places patients at increased risk for adverse 
cardiovascular events.20, 127 However, the functional significance of an impaired 
relaxation pattern of LV filling is less clear, and estimation of resting LV filling 
pressures in this group is independently predictive of exercise capacity.128
2.2.2.1.3 Differentiating normal from pseudonormal LV filling
Pulmonary venous pulsed wave Doppler, tissue Doppler imaging of the mitral 
annulus, and the response of E/A to Valsalva manoeuvre can be used to distinguish
1 99normal from pseudonormal LV filling patterns.
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Pulmonary venous flow
The pulmonary venous Doppler signal comprises “forward” systolic (S) and diastolic 
(D) velocities into the left atrium, and a “backwards” late-diastolic A reversal wave 
corresponding to atrial contraction. The major factors influencing the pulmonary 
venous Doppler profile are illustrated in Figure 2-3. In older adults, systolic flow is 
dominant such that S/D is >1.129 Like the E and A velocities in the transmitral 
Doppler profile, the pulmonary venous S/D ratio exhibits a non-linear relationship to 
progressive DD. flow pattern.
P QRS
Decreased by left atrial 
dysfunction (eg. AF)
Decreased by impaired 
LV relaxation
Increased by LV contractility; 
Decreased by elevated LAP; 
Decreased by mitral regurgitation
Increased by atrial contractility; 
Increased by LV stiffness / LVEDP
Figure 2-3 Determinants of the pulmonary venous Doppler profile.
AF = atrial fibrillation, LAP = left atrial pressure, LVEDP =  left ventricular end- 
diastolic pressure, PVa =  pulmonary venous A reversal.
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The pulmonary venous A wave provides an additional tool for assessment of LV 
filling pressure and diastolic function. The peak A reversal velocity increases as 
resistance to atrial forward flow increases as a result of increased ventricular stiffness 
and/or end-diastolic pressure, such that a peak velocity >35 cm/s is suggestive of 
elevated filling pressures.121 However, LA mechanical dysfunction often 
accompanies advanced DD (particularly in association with paroxysmal atrial 
fibrillation) and may lead to low A reversal velocities. A more robust pulmonary 
venous parameter may be derived from the difference in the transmitral and 
pulmonary venous A wave durations. As LV compliance decreases and diastolic 
pressure rises, increased afterload on the left atrium tends to shorten the transmitral 
A wave, while its duration measured in the pulmonary vein may be increased. A 
difference in the respective durations of >20-30 msec accurately predicts significant 
elevation of LV end-diastolic pressure and may be an early marker of 
transformation from impaired relaxation to a pseudonormal filling pattern. The major 
advantage of this parameter is its utility in the setting of preserved LV systolic 
function,131’132 while the obvious limitation is the difficulty in acquisition of accurate 
measurements of the pulmonary venous A duration from a transthoracic window.133
Load-altering manoeuvres
The principle behind this step is to remove the effects of preload compensation and 
thereby unmask the underlying relaxation abnormality. Thus the aim is to produce a 
transient lowering of left heart filling pressures which in the clinical setting is most 
practically achieved with the Valsalva manoeuvre, although a similar effect may be 
obtained with sublingual nitroglycerin.134 During the Valsalva manoeuvre, an initial
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minor increase in systemic BP (due to increased pulmonary venous return) is 
followed by a decrease in systemic venous return and a gradual decrease in stroke 
volume, leading, after a few cardiac cycles, to a reduction in LA and LV filling 
pressures and potential “conversion” of pseudonormal filling to an impaired 
relaxation pattern. This approach remains largely qualitative, and the required 
decrease in either the E velocity or the E/A ratio to reach a diagnostic threshold 
varies with different studies and will depend upon the baseline values for E and A, 
the quality of Valsalva, degree of patient effort and other factors.133 Even in the 
research setting, ability to obtain adequate data may be particularly low,133, 136 thus 
limiting the sensitivity of the technique. A reduction of E velocity by 50% or 
complete reversal of the E/A ratio to <1 may be useful criteria,137 although other
i
investigators have been unable to determine an accurate cutoff.
Tissue Doppler imaging - long axis relaxation rate
Long-axis shortening (contraction) and lengthening (relaxation) of myocardial 
segments results in longitudinal motion of the mitral annulus toward or away from 
the (relatively fixed) LV apex during systole and diastole respectively. Although 
long-axis segmental shortening remains fairly uniform along the myocardial wall, 
a gradient of increasing velocity from apex to base has been demonstrated.139, 140 
Mitral annular velocities may therefore be regarded as an “aggregate” of segmental 
myocardial velocities and in the absence of regional LV dysfunction accurately 
reflect global long-axis LV function. The systolic velocity (Sa) corresponds to 
ventricular ejection whilst Ea and the late diastolic velocity (Aa) correspond to the 
transmitral Doppler flow. In normal subjects the Ea occurs coincident with, or just
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before, the transmitral E wave, whereas in HF there is a progressive delay in Ea with
1 1 1respect to E. Of more practical importance, the Ea velocity progressively decreases 
as the long-axis relaxation rate becomes increasingly slower in the setting of a wide 
range of cardiac disease processes including dilated, restrictive and hypertrophic 
cardiomyopathies. Invasive studies have demonstrated that the Ea velocity correlates 
strongly with the time constant of isovolumic relaxation over a wide range of filling 
pressures.141143 Specifically, the Ea velocity is much less susceptible to the effects of 
increased preload and remains low in patients with advanced DD and 
pseudonormalisation of the transmitral E velocity.143, 144 Further, Ea is typically 
lowest in patients with severe LV dysfunction and restrictive filling.
The most commonly used technique is to use pulsed wave TDI to record longitudinal 
velocities at the mitral annulus, whereby a sample volume (2-5 mm) is placed at the 
septal or lateral border of the mitral annulus in an apical 4 chamber view.12:1 If 
obtaining only a single measurement, the lateral Ea may be preferred as the septal Ea 
velocity has been demonstrated to be altered by preload in subjects with normal LV 
function,145 although this effect may decrease as LV relaxation becomes 
progressively impaired.146 In addition, the septal Ea velocity may be influenced by 
right ventricular diastolic function. Potential pitfalls to be considered when acquiring 
and interpreting pulsed wave TDI signals include ensuring that the 2-D image quality 
is optimised and that the ultrasound beam is well aligned (<30 degrees) with the 
direction of longitudinal motion (which may be more challenging at the lateral 
annulus). Finally, localised segmental hypokinesis in a given LV wall will result in
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reduced velocity of annular motion at the corresponding site, possibly leading to a 
spuriously low estimate of global LV function.
Tissue Doppler imaging - estimation of LV filling pressures
As discussed, progressive DD is associated with both impairment of LV relaxation 
and an increase in LA pressure. These concurrent events tend to have opposing 
effects on the transmitral E velocity, rendering it poorly predictive of either process. 
However, the E velocity (which increases with elevation of LA pressure) may be 
“corrected” for the degree of impairment in LV relaxation rate by relating it to the Ea 
velocity (which is a relatively load-independent measure of reduced LV relaxation) 
to provide an index, the E/Ea ratio, which has been demonstrated to correlate with 
mean LA pressure.141 This concept has been validated in various clinical conditions 
including normal and impaired systolic function, tachycardia, atrial fibrillation, and 
hypertrophic cardiomyopathy.133, 141, 147149 This application of TD1 for estimation of 
LV filling pressures has significantly advanced the ability of the echocardiographer 
to distinguish normal from pseudonormal LV filling.
As discussed for assessment of LV relaxation rate, the lateral Ea may be preferable 
for E/Ea ratio estimation of filling pressure as more defined cutoffs have been 
reported. Nagueh et al demonstrated that E/Ea>10 using the lateral mitral annular 
velocity reliably predicts a pulmonary capillary wedge pressure of >12mmHg.141 In 
comparison, using the septal Ea velocity, Ommen et al found that while pulmonary 
capillary wedge pressure is likely normal if the E/Ea ratio is <8 and likely elevated if 
>15, intermediate values were less useful. A recent report found lateral E/Ea to be 
superior to septal E/Ea for predicting wedge pressure when EF is >50%,150 although
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an average of both values is more accurate in the presence of regional 
dysfunction. 150,151
2.2.2.1.4 Restrictive filling
Restrictive filling, characterised by a marked increase in the E/A ratio and shortening 
of the E deceleration time, indicates severely reduced LV compliance and marked 
elevation of LA pressure. In the setting of preserved EF, restrictive filling usually 
indicates severe infiltrative myocardial disease such as cardiac amyloidosis rather 
than hypertensive heart disease. In clinical practice, restrictive filling is most 
commonly seen in association with LV dilatation and severe systolic dysfunction and 
is strongly predictive of mortality in this population, particularly if it is not reversible 
with treatment. 152
2.2.3 Left atrial volume as an expression of LV filling pressures
In subjects without primary atrial pathology or congenital heart or mitral valve
disease, increased LA volume usually reflects elevated ventricular filling pressures.
During ventricular diastole, the LA is exposed to the pressures of the LV. With
increased stiffness or noncompliance of the LV, LA pressure rises to maintain
adequate LV filling, and the increased atrial wall tension leads to chamber
dilatation and stretch of the atrial myocardium. Thus, LA volume increases with
severity of DD . 154,155 The structural changes of the LA may express the chronicity of
exposure to abnormal filling pressures155, 156 and provide predictive information
beyond that of diastolic function grade, 157 which is determined from evaluating
multiple load-dependent parameters and therefore reflective of the instantaneous LV
diastolic function and filling pressures. In this way, analogous to the relationship
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between hemoglobin A 1C and random glucose levels, LA volume reflects an average 
effect of LV filling pressures over time, rather than an instantaneous measurement at 
the time of study. 1 Thus, Doppler and tissue Doppler assessment of instantaneous 
filling pressure is better suited for monitoring haemodynamic status in the short term, 
whereas LA volume is useful for monitoring long-term haemodynamic control.
2.3 ALTERNATIVE IMAGING TECHNIQUES
Whilst echocardiography remains the tool of choice in the clinical arena, and is the 
only acceptable method for the comprehensive assessment of cardiac structure and 
function in surveys of the general population, other imaging modalities may be 
required in subjects with limited echocardiographic windows or poor quality 
echocardiographic data.
Cardiac catheterization
Invasive measurement of cardiac function by cardiac catheterization is often invoked 
as the gold standard method for assessment of cardiac function.63 However, this 
method is not utilized as the main method for assessment of cardiac function in the 
clinical arena because of the cost, complexity, and expertise required, as well as 
patient risk and lack of tolerability associated with this invasive procedure. Unlike 
echocardiography, cardiac catheterization does not lend itself to serial assessment for 
monitoring disease progression and response to treatment.
Magnetic resonance imaging has recently been demonstrated to be a sensitive marker 
for the detection of global DD.159 Although spatial resolution using this technique is
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excellent, diastolic function assessment with magnetic resonance is currently limited 
by its inadequate temporal resolution.
Although radionuclide techniques have been used to assess properties of diastolic 
function, these are limited by the risk of exposure to high radiation doses, low frame 
rates, background lung blood pool attenuation and cycle length variability.
2.4 THE NEED FOR A NON-IMAGING TEST FOR ASSESSMENT OF LV 
FUNCTION
Given the complexity of the echocardiographic evaluation of LV function and the 
restricted access to echocardiography, it has been proposed that non-imaging 
methods for the detection of LV function be used as a filter prior to assessment. 
These methods may have the potential to extend their diagnostic application from 
diagnosis to screening high-risk populations, although further studies are required.
2.4.1 Circulating biomarkers of LV function: Natriuretic Peptides
The clinical utility of the circulating biomarkers in HF can be judged according to 
the satisfaction of three key criteria. Firstly, the proposed biomarker must be 
accessible, reliable, and affordable. Secondly, the marker must provide incremental 
information about cardiac function and prognosis that would not otherwise be 
available. Finally, patient management with the biomarker should result in improved 
clinical outcomes. Despite many promising candidates, only the natriuretic peptides 
currently have the potential to satisfy these requirements.
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B-type natriuretic peptide (BNP) is a 32-amino acid peptide, which is derived from 
cleavage of a prohormone (pro-BNP) and is secreted primarily from the ventricular 
myocardium in response to dilatation and increased intra-cavity pressure.160, 161 
Whilst the primary role of BNP appears to be body fluid homeostasis and BP control 
through its diuretic, natriuretic, and vasodilator effects, evidence suggests that BNP 
can also modulate cellular proliferation and may act as a local regulator of 
ventricular fibrosis and remodelling.162'165
Elevation of BNP has been demonstrated in the setting of acute HF, and correlates 
with the degree of reduced EF.166, 167 Promising results from a number of relatively 
small single-centre studies166' 168 led to a large multi-center study evaluating the 
utility of a commercially available BNP test in the evaluation of acutely dyspnoeic 
patients in the emergency department. Of the 1586 study patients, 744 (47%) were 
ultimately assigned to have HF by a panel of two cardiologists who reviewed results 
of the diagnostic evaluation. A BNP of 100 pg/ml was shown to be highly accurate 
for the diagnosis of acute HF-rEF.167 The diagnostic accuracy of a clinical judgment 
was 74%, while that of BNP was 81%.1M Based on Bayesian analysis, it appears that 
BNP was most useful when the clinical diagnostic accuracy of HF is intermediate.
BNP and NT-proBNP perform similarly for the diagnosis of HF in acutely dyspnoeic 
patients. NT-proBNP may have benefits due to the “high-throughput” assay 
platform, the convenience of testing NT-proBNP levels on stored serum as a post- 
hoc assessment, the lower assay variability, and lower costs.171
In a landmark study, McDonagh et al provided the first report on the use of
natriuretic peptide levels to screen for ventricular dysfunction in the population.172
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BNP levels were higher in persons with systolic dysfunction as compared to those 
without systolic dysfunction regardless of clinical HF status. The area under the 
receiver operating characteristic curve for detection of systolic dysfunction by BNP 
was 0.88. However, as the prevalence of systolic dysfunction was low at 3% (and 
thus, the probability of not having systolic dysfunction was 97%), the probability of 
not having systolic dysfunction with a normal BNP was 97.5%. Thus, the 
incremental value of a normal BNP as a test to further “rule out’" systolic dysfunction 
was low. A post-hoc analysis of these data divided the population according to risk 
using clinical parameters and defines a “low-risk” (prevalence of systolic 
dysfunction 0.7%), “moderate-risk” (prevalence of systolic dysfunction 6.0%), and 
“high-risk” group (prevalence of systolic dysfunction 19%).173 A low BNP 
concentration with high sensitivity was used as a partition value to rule out systolic 
dysfunction. With this strategy, use of BNP coupled with echocardiography when 
BNP is abnormal was more cost-effective than echocardiography alone to screen for 
systolic dysfunction even though echocardiography was needed in 60-70% of the 
higher risk groups due to the low specificity of the most sensitive BNP value. In this 
analysis, BNP serves to “rule out” systolic dysfunction in a minority of the screened 
population, eliminating the need for echo in that segment. Others have advocated a 
“rule-in” strategy where a screening test should identify a small segment of the 
population at much higher risk of having the disease screened for, thus focusing use 
of definitive diagnostic testing on that much smaller segment of the population. 174,
175
The most comprehensive assessment of the potential value of BNP as a screening test
for pre-clinical systolic dysfunction or LV remodelling comes from the Framingham
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Heart Study.174 Investigators concluded that BNP did not appear promising as a 
screening tool for systolic dysfunction or elevated LV mass in the general population 
or in higher risk subsets of the general population.
While a number of studies had reported on the use of BNP for diagnosis of HF, there 
were relatively few data regarding normal values in persons free from cardiovascular 
disease or ventricular dysfunction. Furthermore, at the time the Canberra Heart Study 
was commenced, there was no population-based data to assess the value of 
natriuretic peptides for the diagnosis of DD. Lubien et al studied the correlation of 
BNP levels with Doppler evidence of DD in subjects referred for echocardiography 
for evaluation of ventricular function and indicated that using BNP may help identify 
DD.176 However, the potential for selection bias to adversely affect the validity of 
that clinic-based study was high.
2.4.2 Pulse wave assessment of central (aortic) arterial stiffness
As discussed in chapter 1, hypertensive heart disease is associated with abnormal 
vascular function, and increased arterial stiffness has been implicated in the 
pathogenesis of HF-NEF. Although further research is needed, newer approaches to 
HF may therefore benefit from evaluation of arterial properties. Arterial stiffness can 
be assessed noninvasively using the following methods: 1) relating change in vessel 
size (diameter or area) to distending pressure, 2) estimation of pulse wave velocity, 
3) pulse waveform analysis.
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The relation of change in vessel size to distending pressure provides a measure of 
local arterial stiffness, and is most commonly measured on superficial arteries using 
echo-tracking techniques. Local PP should be measured at the site of the distension 
measurement, such as carotid artery. The use of brachial BP in calculation of these 
indices may introduce systematic errors, particularly in younger subjects in whom 
brachial PP is significantly greater than carotid PP. Applanation tonometry can be 
used to estimate carotid BP in these circumstances. Magnetic resonance imaging 
(MRI) techniques have also been used to measure vascular distensibility and 
compliance.178 A distinct advantage of MRI is that it can be used to measure diameter 
and distension of deeper arteries such as the aorta. However, it lacks temporal 
resolution, remains expensive and the limitations relating to accurate and 
simultaneous quantitation of local arterial pressure are equally applicable to MRI.
Perhaps the simplest measure of arterial stiffness is pulse-wave velocity, the speed of 
propagation of the pressure wave along the large arteries following ventricular 
ejection. PWV has emerged as the “gold-standard” measurement of regional arterial 
stiffness.179 The theoretical basis of PWV as a measure of arterial stiffness is 
described by the Moens-Korteweg equation: PWV = E*h/2r/>; where E is the slope of 
the stress-strain relationship for a given vessel, Young’s modulus; p is the density of 
fluid; and h/2r is the wall thickness/diameter. In practice, PWV is calculated by 
measuring the time taken for the arterial waveform to pass between two points a 
measured distance apart, and involves taking readings from the two sites 
simultaneously or gating separate recordings to a fixed point in the cardiac cycle, 
usually the R wave of the electrocardiogram. Arterial pulse waves can be detected by
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using Doppler ultrasound (the pressure pulse and the flow pulse propagate at the 
same velocity), or applanation tonometry. Central PWV of large elastic arteries, such 
as the aorta, increases with age non- linearly, being more prominent in subjects of age 
greater than 50 years (Figure l) ,180 whereas peripheral PWV in the muscular arteries 
of the limbs does not increase with age.181 Accurate PWV quantitation is dependent 
on accurate measurement of the distance between recording sites. Increasing 
tortuosity of the abdominal aorta with age may lead to a systematic underestimation 
of PWV. Because PWV is also determined by distending BP, it is important to adjust 
for the effects of mean BP before estimating the independent influence of arterial 
stiffness on outcomes of interest.
Pulse wave analysis (PWA) is performed using applanation tonometry or echo 
tracking. From PWA, indexes of wave reflection such as augmentation pressure (AP; 
the difference between the first and second systolic peaks) and augmentation index 
(AIx; the quotient of AP on PP expressed as a percentage) can be derived. In healthy 
young persons, central systolic BP is significantly lower than peripheral systolic BP, 
whereas diastolic BP remains steady throughout the arterial tree. " This phenomenon 
is called PP amplification. However, in older persons, PP amplification is diminished 
as a consequence of arterial stiffening.183 Thus, central BP is often not represented by 
brachial BP. Since it is central BP that directly affects target organ function, there is 
expert consensus that PWA should be optimally obtained at the central level using 
the application of a generalized arterial transfer function to the radial artery waveform 
to reconstruct the corresponding central pressure waveform and derive an 
approximation of central BP. 184 Despite continued controversy regarding the validity
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of this approach,185,186 the estimation of central pressures has been increasingly used 
as a risk marker and surrogate outcome in epidemiological187,188 and intervention189, 
190 studies. A review of clinical studies indicating the independent value of central 
haemodynamics in these roles and as a predictor of adverse CV events has recently 
been published.191
It should be acknowledged that AIx is not a simple surrogate measure of large artery 
stiffness as it is influenced by several other factors that modulate ventricular-vascular 
coupling. AIx is inversely related to acute changes in heart rate, which result in a 
decrease in ejection duration, and a reflected wave that arrives later in the cardiac 
cycle. To account for differences in heart rate, AIx can be reported as an index that is 
normalized for a heart rate of 75 beats per minute (AIx@75). AIx is inversely 
influenced by body height, EF, peripheral vascular resistance and increases non- 
linearly with age180. Contrary to PWV, however, the positive relation between age 
and AIx is more prominent in subjects of age less than 50 years, with minimal rise in 
AIx observed after the age of 65 years (Figure l).180 181 Not surprisingly, a 
dissociation between AIx and PWV has been described,193 and the two measures 
should considered to be complementary rather than interchangeable. Further 
studies will be required to define the optimal approach to combine these measures in 
order to characterise arterial function in an individual.
2.4.2.1.1 Determinants and consequences of arterial stiffness
Traditional CV risk factors such as ageing,177, 194 HT,177 diabetes mellitus,195
dyslipidemia,196 smoking 197and sedentary lifestyle198 promote an increase in arterial
stiffness. With ageing and elevated BP, the arteries stiffen as the result of
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degeneration of the arterial media with fractures and fragmentation of elastic 
lamellae, increased collagen and calcium content, and dilation and hypertrophy of 
large arteries and the aorta.199 Such alterations are more pronounced in central 
(thoracic aorta, carotid) than in peripheral (femoral, radial) arteries.177 In addition to 
structural alterations caused by repeated cycles of arterial distension and recoil, the 
accumulation of advanced glycation end products in the arterial wall plays an 
important role in the development of arterial stiffness with ageing. AGE can also 
promote the development of arterial stiffness through impairment of endothelial 
function200 and promotion of inflammation.201
With an increase in arterial stiffness, there is less cushioning of stroke volume in the 
arterial bed during systole. Consequently, a greater proportion of stroke volume is 
forwarded to the periphery such that the amplitude of the arterial pulse wave during 
systole rises and diastolic pressure falls (Figure 2). Exposure to higher pulsatile stress 
is particularly deleterious in organs with low impedance beds, such as the brain and 
the kidney, resulting in accelerated microvascular disease ‘ and consequent 
deterioration of cognitive203 and renal204 function.
2.4.2.1.2 Arterial stiffness for the prediction of cardiovascular outcomes
Brachial PP, an index of global arterial stiffness, is an established marker of CV 
risk.205 More recently, there has been an accumulation of data confirming the 
relationship between indices of regional arterial stiffness and the development of 
adverse CV outcomes in community-based subjects and high-risk patients with overt 
CV disease.
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General Population. The prognostic value of PWV in the general population has 
been documented in recent studies. Increased PWV was independently predictive of 
CV events, including CAD, stroke and CV death in 1678 population-based 
subjects.206 For each 1-SD increment in PWV, the risk of an event increased by 16 to 
20%. In a separate study of 2835 healthy subjects, PWV was an independent 
predictor of both stroke and CAD after adjustment of various factors including 
carotid intima-media thickness, MBP and PP.“ Interestingly, in these studies, 
brachial PP (by single office measurement and 24-hour ambulatory monitoring) was 
not associated with a CV event after adjustment of PWV. It is possible that the 
superiority of PWV to brachial PP for risk stratification in the general population may 
be related to PP amplification, which differentially affects younger subjects and will 
diminish the utility of PP as a marker of CV risk in an adult population with wide age 
ranges.
Hypertension. The predictive value of arterial stiffness has been evaluated in 
preclinical subjects with classical CV risk factors such as HT. PWV was associated 
with incident CV disease including coronary events (odds ratio [OR] = 1.34 per 
3.5m/s increment in PWV )208 and stroke (OR=1.39 per 4.0m/s increment in PWV)209 
in hypertensive patients without overt CV disease. Furthermore, it was determined 
that PWV, but not brachial PP, was predictive of CV mortality, independent of age, 
prior CV disease and diabetes (OR=1.51 per 5m/s increment in PWV). There is 
scant evidence to support the incremental value of assessment of arterial stiffness to 
guide therapy in preclinical subjects with HT. Treatment-induced changes in 
surrogate outcomes such as indexed left ventricular (LV) wall mass and carotid
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intima-media thickness212 were correlated with changes in AIx, independently of 
brachial BP measurement. Further studies are required to examine whether markers 
of arterial stiffness can be utilized in strategies to identify “high-risk” patients, who 
may be more likely to benefit from intensive medical therapy in order to prevent the 
development of subsequent adverse clinical outcomes.
Elderly. An age-related increase in arterial stiffness attenuates the difference between 
central and peripheral PP. Accordingly, brachial PP represents a robust and easily 
measured marker of CV risk in elderly subjects. In contrast, because there is minimal 
increase in AIx after the age of 65 years,180 181 the value of this index of arterial 
stiffness as a marker of CV risk is diminished in older persons. 213 PWV remains an 
important prognostic marker in the elderly. In a large cohort of 2488 elderly persons, 
PWV was predictive of CV death, CAD and stroke after adjustment of age, BP, 
creatinine, prior CV disease and CV risk factors.214
Coronary artery disease. In patients undergoing coronary angiography, increased 
arterial stiffness is related to prevalent CAD.215 Moreover, assessment of arterial 
wave reflections and central BP may be more useful for prediction of CAD extent and 
severity than peripheral pressures and PWV, however, this observation varies 
according to the age of the study population. For instance, Weber et al demonstrated 
that a significant relationship between AIx and the risk of CAD was observed only in 
younger patients of age <60 years. In patients with established CAD, AIx was 
associated with the development of major adverse CV events after percutaneous 
coronary intervention, independent of clinical risk factors including lesion 
complexity, brachial systolic BP and PP (relative risk of 1.8 per AIx@75 tertile).
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Renal Disease. The majority of deaths in patients with kidney disease are attributed 
to CV events.216 In end-stage renal disease (ESRD), several abnormalities in the 
microcirculation have been reported, including rarefaction of vessels, increased ratios 
of wall to lumen of small arterioles, and decreased endothelium-mediated 
vasodilation.217 Consequently, patients with ESRD have much stiffer arteries 
compared to controls of the same age and BP. The relationship between arterial 
stiffness and CV death has been evaluated in patients with ESRD using a variety of 
methods, including arterial distensibility, PWV and PWA. 219 220 Aortic PWV is 
significantly correlated with CV death independently of BP (OR=5.9 for those with 
PWV >12m/s compared to the referent group with PWV <9.4m/s).219 Moreover, a 
reduction in PWV of 1 m/s with BP control was associated with a 21% reduction in 
the risk of CV death.220 In contrast, baseline and change in systemic BP referent 
group with PWV <9.4m/s).219 Moreover, a reduction in PWV of 1 m/s with BP 
control was associated with a 21% reduction in the risk of CV death.220 In contrast, 
baseline and change in systemic BP were not predictive of CV death. PWA has also 
been reported as a useful index for the prediction of CV outcomes in ESRD 
patients.221 There is limited information regarding the prognostic value of arterial 
stiffness in patients with mild to moderate renal disease.
Heart Failure. The relationship between arterial stiffness and CV mortality has not
o c
been evaluated in patients with HF. However, in HF patients with preserved ‘ and 
reduced EF 222, there is evidence that arterial stiffness is related to exercise capacity, 
which is an important determinant of mortality in these patients.223 There are a 
number of mechanisms whereby increased arterial stiffness can adversely affect
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exercise capacity. First, arterial input impedance is an important determinant of left 
ventricular stroke work and cardiac output,224 and increased large artery stiffness 
reduces the ability to generate adequate cardiac output during exercise. Consequently, 
patients with increased arterial stiffness have lower systolic reserve in response to 
exercise.83 Second, recent studies have documented a relationship between arterial 
stiffness and DD, which adversely affects exercise capacity through a decrease 
in stroke volume reserve ‘ and is associated with an exaggerated increase in LV 
filling pressure during exercise.128 Lastly, increased arterial stiffness, through its 
reduction of central diastolic BP and coronary perfusion pressure, may promote
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subendocardial ischemia.
2.5 CONCLUSIONS
Descriptive epidemiological data on LV dysfunction are necessary for a better 
understanding of the natural history of HF, and are important for guiding health 
policy and monitoring trends of the impact of disease over time. Echocardiography is 
the most feasible and acceptable method for the assessment of cardiac structure and 
function in surveys of the general population. The contemporary assessment of LV 
function by echocardiography includes a comprehensive assessment of diastolic 
function and filling pressures through the integration of conventional and tissue 
Doppler measurements. In chapter 4, I present the first Australian population-based 
data on the prevalence of HF and LV systolic dysfunction (EF<50%). One of the first 
estimates of the burden of DD in the community is presented in Chapter 5. Non­
imaging methods that could accurately identify subjects with LV dysfunction may be
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useful as filters prior to referral for echocardiography. In chapters 5 and 6, I evaluate 
the performances of NT-proBNP and PWV for the detection of LV dysfunction in 
the community.
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Published in part in:
Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang 
TSM. Left atrial size: physiologic determinants and clinical applications. J Am Coll 
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81
3.1 DEVELOPMENT OF STUDY PROTOCOL
The study design and methodology were developed under the supervision of 
Professors Wayne Smith and Anne-Louise Ponsonby as part of my Doctorate of 
Population Health (DrPH) coursework requirements (Research Methods II). The 
choice of a sample frame that was population-based rather than clinic-based (albeit 
“open access”229) was predicated by recognition that this approach would maximize 
the external validity of our research, and thus increase the significance and 
generalisability of the results of the various studies that emanated from the research.
3.2 SOURCES OF FUNDING
The cross-sectional study was supported by a grant from the Canberra Hospital 
Salaried Medical Officers’ Private Practice Trust Fund. Research specific to the 
assessment of vascular function (chapter 7) was supported by a Cardiovascular Lipid 
grant awarded by the Australian Physicians Independent Committee (APIC). The 
author was the principal investigator in both applications for funding. In-kind support 
was provided by Siemens Ultrasound, who loaned the 128XP echocardiography 
machine for the duration of the research; and Roche Diagnostics, who provided the 
immunoassay kits and analysis machine for the assessment of aminoterminal B-type 
natriuretic peptide.
82
3.3 SAMPLING FRAME
The sampling frame for the study population was the electoral roll of Statistical 
Divisions in the Southern Districts of the Australian Capital Territory (South 
Canberra, Woden Valley, Weston Creek and Tuggeranong). The author applied to 
the Australian Electoral Commission for permission to obtain an electronic list of 
names and postal addresses of residents of these statistical divisions who were of age 
60-85 years in January 2002. This approach was considered to be the most efficient 
in obtaining a sampling frame that was population-based.
3.4 RECRUITMENT STRATEGY
The recruitment strategy was based on a modification the Dillman approach.(22) In a 
previous study, it was noted that a telephone contact made soon after mail-out of the 
second contact letter was found to be an effective and cost-efficient way of 
recruitment of participants.230
At the time of the initial mail-out of invitations, the author was interviewed by the 
health reporter at The Canberra Times, and held live interviews on consecutive 
mornings with ABC Radio (AM Radio, Canberra) and 2CC (AM Radio, Canberra). 
This was coordinated with the assistance of Mr. Trevor Sharkie, who was the Public 
Relations Office at Canberra Hospital. The aim was to promote the study in the 
media using an approach that would be most likely to reach the demographic 
representative of the Canberra Heart Study population.
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3.5 SAMPLE SIZE CALCULATION
Sample size calculations were based on the precision of estimates of:
i. prevalence rates of HF and left ventricular dysfunction in the community;
ii. diagnostic performance of aminoterminal pro-B-type natriuretic peptide for 
the detection of systolic and diastolic dysfunction.
Data from the Framingham cohort study provided estimates of age, sex-specific 
prevalence rates of HF.(26) The rates were comparable with those of a more 
contemporary cross-sectional study that was published just prior to our study.<8) 
Based on these data, the expected rate of HF-rEF (termed at that time “systolic HF”) 
in the study population would be approximately 4%. We estimated that the 
prevalence of HF-NEF (termed at that time “diastolic HF”) would be approximately 
2%, on the basis of extrapolation from results of the Framingham cohort study and 
hospital-based studies.
At the time of our research protocol development, there were no published 
population-based studies to estimate the performance of aminoterminal pro-B-type 
natriuretic peptide as a diagnostic/screening test for HF. There was one study that 
estimated the sensitivity and specificity of the carboxy-terminal of B-type natriuretic 
peptide (BNP) in a randomly selected Glasgow population aged 25-75.<20) The 
unusually strict definition for left ventricular systolic dysfunction was an 
echocardiographic assessment of LVEF<30%. The sensitivity and specificity of BNP 
in detecting systolic was 89% and 71%, respectively. However, based on the fact that 
aminoterminal pro-B-type natriuretic peptide dysfunction has a longer circulating
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half life,231 it had been proposed that the expected performance of aminoterminal 
pro-B-type natriuretic peptide in detecting HF would be superior to BNP, although 
this had not been confirmed in clinical studies.
In contemporary population-based prevalence studies of HF, the participation rates 
have been approximately 50-65%. However, with our proposed recruitment methods 
(modified Dillman method) and the qualities of our study population (mostly retired 
from work; higher education levels; older age and more likely to benefit from 
information derived from the study assessments), we assumed that the participation 
rate for our study would be at least 60% and as high as 75%.
A sample size of 1200 participants would achieve the following levels of precision 
(point estimates and 95% Cl calculated using the exact binomial method [absolute 
numbers] are presented):-
i. prevalence of “systolic HF” - 4% (3.1-5.1) [48/1200]
ii. prevalence of “diastolic HF” - 2% (1.4-2.8) [24/1200]
iii. overall prevalence of HF- 6% (4.9-7.3) [72/1200]
iv. aminoterminal pro-B-type natriuretic peptide sensitivity for “systolic HF” - 
90% (80-96) [43/48]
v. aminoterminal pro-B-type natriuretic peptide specificity for “systolic HF” - 
72% (70-74) [829/1152]
vi. aminoterminal pro-B-type natriuretic peptide sensitivity for “diastolic HF” - 
90% (73-98) [22/24],
vii. aminoterminal pro-B-type natriuretic peptide specificity for “diastolic HF” -
72% (70-74) [847/1176]
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Based on an anticipated response rate of at least 60%, invitations to participate in the 
study were extended to 2000 people. Participants were randomly selected from the 
January 2002 electoral roll, using simple random sampling (SPSS 11.0, Chicago, 
Illinois), to constitute our study population.
3.6 CLINICAL DATA 
3.6.1 Clinical examination
A limited clinical examination was conducted by an experienced cardiology nurse. 
Height and weight were measured without shoes and in light clothing. Body mass 
index (BMI) was calculated for each participant. Brachial artery systolic and 
diastolic BP (Korotkoff phase V) were measured to the nearest 2 mmHg on the right 
arm using a standard mercury sphygmomanometer after 10 minutes of rest in a 
sedentary position; the measurement was repeated after 5 minutes and the two sets 
were averaged for each participant.
Prior to the echocardiography assessment and review of the questionnaire, subjects 
were reviewed by a cardiologist (the author). Participants were asked if they had 
symptoms of dyspnoea, orthopnea, paroxysmal nocturnal dyspnoea or dependent 
oedema; and examined for the presence of tachycardia (heart rate >100 beats per 
minute), raised jugular venous pressure, displaced apex beat, added heart sounds, 
cardiac murmurs, lung crepitations and peripheral oedema.
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3.6.2 Self-administered questionnaire
A self-administered questionnaire was compiled from a number of sources 
(Appendix A), many of which had been previously validated in an Australian 
population or were used as a standard by governmental statistical bodies such as the 
Australian Institute of Health and Welfare and the Australian Bureau of Statistics.
3.6.2.1.1 Evaluation of relevant past medical history
A self-administered questionnaire was used to document a history of myocardial 
infarction, coronary disease, diabetes and HT. A self-reported history of clinical HF 
was verified by a review of the subject’s medical records.
3.6.2.1.2 Evaluation of lifestyle factors
Questions based on the National Health Survey 2001, a triennial national health
questionnaire administered by the Australian Bureau of Statistics, were used to
assess levels of alcohol consumption and smoking status. The author sought advice
regarding the assessment of physical activity levels in older persons from the staff at
the Cardiovascular Disease and Risk Factor Monitoring Unit, Australian Institute of
Health and Welfare (contact person: Dr Tim Armstrong). On the basis of their
recommendations, physical activity levels over the last week and typical of the last
six months were evaluated using the Active Australia survey. This data will be
used as an exposure variable for incident cardiovascular events in the longitudinal
analyses, and has not been reported in studies related to this thesis.
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3.6.2.1.3 Evaluation of quality of life
A Short Form 36 Health questionnaire was used to estimate quality of life. This tool 
is widely used, and we administered a version that had been modified for Australian 
vernacular.
3.6.2.1.4 Evaluation of socioeconomic status
The author sought advice from the Australian Institute of Health and Welfare and the 
Australian Bureau of Statistics regarding the best methods for determining 
socioeconomic status in a sample of older Australian adults. Socioeconomic status 
will be used as an exposure variable for incident cardiovascular events in the 
longitudinal analyses, and has not been reported in studies related to this thesis.
3.7 CONVENTIONAL ECHOCARDIOGRAPHY
All participants underwent assessment of cardiac structure and function using 
transthoracic echocardiography (Acuson 128 XP/10, equipped with native tissue 
harmonic imaging) according to a standardised protocol and according to American 
Society of Echocardiography recommendations.234 All measurements were 
performed off-line and averaged from 3-5 consecutive cardiac cycles.
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LV ejection fraction was determined by a modified Simpson’s methods LV mass 
was assessed by the area-length method236 and indexed to height (LV mass index). 
LA diameter was obtained from the parasternal long-axis view. LA volume was 
quantitated using the prolate-ellipsoid and biplane area-length methods. Mitral and 
aortic valve function was assessed using Doppler and colour-Doppler 
echocardiography and graded according to previously published criteria.238 Valvular 
heart disease was defined as at least moderate stenosis or regurgitation of the mitral 
and aortic valves.
3.8 ASSESSMENT OF DIASTOLIC FUNCTION
In 2001, when the research presented in this thesis was being planned, contemporary 
methods for non-invasive identification of DD were based on assessment of 
transmitral flow during diastole with pulsed wave Doppler. ’ ’ In particular,
Doppler cut-offs for impaired LV relaxation were based on personal communication 
with the one of the authors of the only other large population-based study of diastolic 
function that was being proposed at the time. This study from Mayo Clinic was 
published during the period of our data collection. The consistency of Doppler 
methodology was particularly useful as it facilitated comparisons between our 
studies.
Pulmonary venous pulsed wave Doppler and tissue Doppler imaging of the mitral 
annulus was used to distinguish normal from pseudonormal LV filling patterns.123 A 
description of the data acquisition of these Doppler assessments is included in this
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section. A more detailed description of the theory that underscores these 
echocardiographic techniques is provided in chapter 2. Interpretation of these 
measures varies according to the studies published in this thesis and will be detailed 
in Chapters 4 to 9.
3.8.1 Transmitral and pulmonary venous pulsed wave Doppler
Transmitral flow was evaluated for assessment of LV filling and relaxation. The 
pulsed wave sample volume was placed at the tips of the mitral valve leaflets in the 
apical 4-chamber view. Transmitral E and A diastolic velocities, E wave deceleration 
time, A wave duration and isovolumic relaxation time were recorded. The pulmonary 
venous Doppler profile was assessed as a measure of LA pressure. Maximum 
velocities of systolic and diastolic pulmonary venous flow; and atrial reversal wave 
velocities were recorded using a pulsed wave sample volume placed at 1 cm into the 
right upper pulmonary vein in the apical 4-chamber view. The duration of the atrial 
reversal wave was also measured and the temporal difference between the durations 
of transmitral A and pulmonary venous A reversal was calculated.
3.8.2 Mitral annular tissue Doppler velocities
In order to assess mitral annular tissue Doppler velocities, the echocardiography 
machine settings were optimised to record the high amplitude, low velocity tissue 
signals. A pulse wave sample size of 2-5 mm was used with high pulse repetition 
frequency, and a sweep speed of 100 cm/second. Gains were minimized to reduce
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spectral broadening of the Doppler signals in order to increase measurement 
accuracy. Annular velocities during systole, early and late diastole (Sa, Ea and Aa, 
respectively) were measured at the medial and lateral mitral annulus in the apical 4- 
chamber view (Figure 3-1). As for all echocardiographic assessments, measurements 
were performed off-line and averaged from 3 to 5 consecutive cardiac cycles.
Figure 3-1 Lateral mitral annular pulse wave tissue Doppler velocities 
3.8.3 Left atrial size measurement
Measurement of anteroposterior LA linear dimension by M-mode 
echocardiography234,240 is simple and convenient but not reliably accurate, given that 
the LA is not a symmetrically shaped three-dimensional (3D) structure.241
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Furthermore, because LA enlargement may not occur in a uniform fashion,242 one­
dimensional assessment is likely to be an insensitive assessment of any change in LA 
size. In contrast to LA dimension, LA volume by two-dimensional (2D) or 3D 
echocardiography provides a more accurate and reproducible estimate of LA size, 
when compared with reference standards such as magnetic resonance imaging (MRI) 
and cine computerized tomography (CT),243'246 and has a stronger association with 
cardiovascular outcomes.154, 155, 237’ 247 Accordingly, the American Society of 
Echocardiography has recommended quantitation of LA size by biplane 2D 
echocardiography using either the method of discs (by Simpson’s rule) or the area- 
length method.248 Although we have routinely used the area-length method in our 
laboratory, we have found that the biplane Simpson’s method is comparable in 
accuracy and reproducibility. Critical elements and common pitfalls for accurate and 
reproducible measurement of bi-plane LA volume assessment are outlined in Table 
3-1. Echocardiographic methods systematically underestimate LA volume when 
compared with CT249 or MRI quantitation245, which in turn underestimates true LA 
size250. More recently, magnetic electroanatomic mapping has also been used for 
assessment of LA volume.251 However, because of its portability and safety, 
echocardiographic assessment of LA volume is preferable to other imaging methods 
in clinical practice.
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Table 3-1 Critical elements for accurate measurement and interpretation of
maximum left atrial volume
S te p C o m m o n  U m i ta t io n s ' L r r o n S u g g e s tio n s
A . O p tim iz e  L A A tr ia  are lo cated  in  th e  far fie ld  o f  th e  apical views. N o t  im proved  by m od ify ing  th e  gain  se ttings:
im ag e  quality R ed u c tio n  o f  lateral reso lu tion  m ay  resu lt in 
apparen tly  th ic k e r  L A  w alls.
Increase  in  gain  w ill fu rth e r  reduce I A  lum en  size 
D ecrease  in  gain  m ay  lead  to  im ag e  'd r o p  o u t’  a n d  difficulties 
in  p lan im etry  o f  L A  area
U se h ig h  reso lu tio n  sam ple  box to  increase  pixel d en sity  a n d  
fac ilitate  accu ra te  trac in g  o f  th e  en docard ial bo rd er 
C a p tu re  a t least five beats  for each  cine b o p  to  m axim ize 
lik e lih o o d  o f  o b ta in in g  adequate  im age quality
B- O b ta in  m axim al I A  size I A  is fo resh o rten ed M o d ify  tran sd u cer an g u la tio n  o r  location  (place the  tran sd u cer 
o n e  in te rco sta l space lower} u n til L A  im age is o p tim iz e d  
a n d  n o t fo resh o rten ed
I f  d iscrepancy  in  th e  tw o  len g th s  m easu red  from  th e  o rth o g o n a l 
p lan es  is > 5  m m , acquisition  sh o u ld  be  rep e a ted  u n til th e  
d iscrepancy  is red u ced
C . T im in g  o f  m ax im um  
I A  size
C o rrec t fram e fo r m easu rem en t is  n o t selected C h o o se  fram e ju s t  before  m itra l valve o p en in g
D . I A  a rea  p lan im etry l  A  bo rd er is inconsis ten tly  defined C o n s is te n tly  ad h e re  to  convention:
In fe rio r  L A  b o rd er— p lane  o f  m itra l a n n u lu s  (n o t th e  t ip  
o f  leaflets)
E x d u d e  atrial ap p en d ag e  a n d  confluences o f  p u lm onary  veins
L . L o n g -ax is  L A  len g th L A  b a g  axis is inco n sis ten tly  d e lin ea ted C o n s is te n tly  ad h ere  to  conven tion :
In fe rio r  m arg in— m id p o in t o f  m itra l a n n u lu s  p lane  
S u p erio r  (p o ste rio r) m arg in — m id p o in t  o f  p o ste r io r  L A  wall
F. In te rp re ta tio n Q u a lita tiv e  ca tegoriza tion  o f  I A  size I A  vo lum e ind ex ed  to  body’ surface area  is op tim ally
in te rp re ted  as a  co n tin u o u s  variab le (u sin g  a reference 
p o in t  o f  2 2  i  5 m l/ra 2 as 'n o rm a l”)
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3.9 12-LEAD ELECTROCARDIOGRAM
All 12-lead electrocardiograms were assessed independently by two cardiologists 
(the author and Dr Nikolic) without knowledge of the results of the clinical and 
echocardiographic assessments.
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3.10 SEROLOGICAL TESTS
3.10.1 Routine blood test
Venous blood was taken after an overnight fast of between 8-12 hours. Using 
standardised methods that are applied in the clinical setting (ACT Pathology), fasting 
glucose and lipids, full blood count and renal function were assessed.
3.10.2 Aminoterminal pro-B-type natriuretic peptide
Venous blood was collected in serum tubes, centrifuged and stored at -70()C until 
batch analysis. NT-proBNP levels were measured using a commercially available 
and fully automated electrochemiluminescence sandwich immunoassay on an 
Elecsys 1010 (proBNP®, Roche Diagnostics).
3.11 PULSE WAVE ASSESSMENT OF ARTERIAL STIFFNESS
PWV was assessed noninvasively using the Sphygmocor system (AtCor Medical, 
Sydney, Australia) on the day of the echocardiography assessment and after an 
overnight fast. Electrocardiogram-gated carotid and femoral waveforms were 
recorded using applanation tonometry. Carotid-femoral path length was estimated 
using surface measurements (Figure 3-2). Carotid-femoral transit time was estimated 
in 8-10 sequential femoral and carotid waveforms as the average time difference 
between the onset of the femoral and carotid waveforms. PWV was calculated as the 
carotid-femoral path length divided by the carotid-femoral transit time.
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Figure 3-2 Measurement of carotid-femoral pulse wave velocity by applanation 
tonometry
Left panel - Path length is calculated using the following surface measurements: 
sternal notch to carotid pulse (LI); sternal notch to umbilicus (L2); and umbilicus to 
femoral pulse (L3). Transit length (L) =  (L2+L3)-L1. Right panel - Transit time is 
calculated as the time difference (AT) between (A) the R wave on the 
electrocardiogram to the foot o f the carotid artery pulse wave; and (B) the R wave 
on the electrocardiogram to the foot o f the femoral artery pulse wave. We have used 
the intersecting tangent method to identify the foot o f respective waveforms. Carotid- 
femoral pulse wave velocity is calculated as the path length (L) divided by the transit 
time (AT).
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3.12 DATA HANDLING AND MONITORING
Data was collected on formatted sheets (questionnaires, clinical examination 
findings, and biological testing results) and later entered into computer databases. 
Multiple, linked databases were developed using Microsoft Access. The databases 
were set up with data cleaning facilities including range checks, skips and logical 
checks. A random sample of participant details (5%) required double entry to 
quantify errors in data entry. Checks on outliers also made to assess errors in data 
entry.
3.13 REPRODUCIBILITY AND RELIABILITY OF STUDY ASSESSMENTS
Echocardiographic measurements were performed off-line and averaged from 3 to 5 
consecutive cardiac cycles in order to minimize biological and intra-observer 
variations, and obtain a more representative evaluation of each individual. Intra- (the 
author) and inter-observer variability (the author and Dr Tom Marwick) were 
formally assessed using a sample of 50 subjects. The results are reported in Chapter 4 
as an inter-class variation, reflecting the fact that assessment of LV function is 
classified as ordinal categories for clinical purposes. Accordingly, this approach was 
used in the original research papers (Chapters 4 to 9, inclusively). Test-retest 
variability was assessed in 30 subjects in a separate assessment after a period of 1-36 
hours after the original study assessment.
The commercial immunoassay for NT-proBNP on the Elecsys 1010 platform has a 
within run coefficient of variability (CV) of 0.7-1.6% and a between run CV of 5.3-
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6.7%, “ and this has been verified with in-house testing in clinical laboratories 
(ACT Pathology and Mayo Clinic, Rochester).
At least three separate pulse wave assessments (with each assessment consisting of 
8-10 sequential radial, carotid and femoral waveforms) were conducted for each 
subject using the Sphygmocor system, and the average was recorded. The 
commercial software (AtCor Medical, Sydney, Australia) has internal quality checks 
based on pulse waveform variability (timing, amplitude and intensity) and the 
standard deviation of PWV measurement. Only high quality data were included in 
our analyses.
3.14 POTENTIAL SOURCES OF BIAS 
3.14.1 Sam pling b ias
Sampling bias refers to the systematic error introduced with the use of an 
inappropriate sampling frame, from which sections of the target population are over- 
or under-estimated, with extreme bias occurring if there is zero probability of being 
selected. For example, there are a number of studies have purported to be population- 
based when there sampling frame is a medical registry. Obviously, this would 
exclude subjects who were too healthy (or were unwilling) to seek medical attention 
during the period of the study. Such a bias affects the external validity of the study, 
i.e. the generalisability of the study.
The study was restricted to residents of the Southern Districts of the Australian 
Capital Territory (South Canberra, Woden Valley, Weston Creek and Tuggeranong).
97
There were a number of benefits to this approach that would potentially improve 
response rates and facilitate ascertainment of exposure/outcome status. First, the 
assessment clinic was based in Canberra Hospital, which has an established rapport 
with the communities in the Southern Districts. Second, residents in the southern 
districts of the Australian Capital Territory are generally admitted to Canberra 
Hospital for cardiovascular events, and their medical records could be accessed by 
the author and research assistants to verify self-reported comorbidities. In contrast, 
there were no identifiable disadvantages that would potentially impact on the internal 
or external validity of the study. The health and socioeconomic characteristics of the 
Southern and Northern Districts of the ACT are not considered to be different, and 
accordingly the study could be generalised to the ACT population aged over 60 
years. Indeed, one of the major benefits of conducting a population-based survey, 
particularly one that had a good participation rate, was the ability to generalise our 
results to populations of age over 60 years in Australia and most developed countries 
with similar racial/ethnic constitutions. Additionally, the characteristics of 
Canberra’s urban infrastructure and the fact that Canberra Hospital has no specific 
subspecialty services would make it highly unlikely that a patient with cardiovascular 
disease would choose to live close in proximity to the hospital. If this were the case, 
rates of cardiovascular disease would over-represent true prevalence in the 
community.
In the Canberra Heart Study, our sampling frame was the electoral roll (January 
2002). Obviously, the sampling frame would exclude those that were not eligible to 
vote because of residency status or were too incapacitated to vote due to cognitive
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deficits. Because of the known relationship between cardiovascular disease and 
cognition,202 the latter group would be expected to have a high atherosclerotic burden 
and therefore a relatively high prevalence of left ventricular dysfunction. However, 
this issue would have little effect on our results as subjects with such cognitive 
deficits would have been unable to provide informed consent to participate in our 
study had they been included in the sampling frame. A more important concern with 
the use of the electoral roll as a sampling frame was the accuracy of the electoral roll. 
To an extent, we were fortunate that our recruitment efforts commenced shortly after 
Federal and Territory elections. As a result the electoral roll had been updated by the 
voting public though the Australian Electoral Commission registry in preparation for 
the elections.
A number of factors related to our study population may limit the generalisability of 
our results to other populations. First, the vast majority of the study population of 
Canberra residents was White (97.6%) and our results may not be applicable to non- 
White populations. Second, the National Health Survey has documented that ACT 
residents have lower rates of classical risk factors for cardiovascular disease,254 
which may decrease the prevalence of HF and left ventricular dysfunction in this 
population compared to national rates. On the other hand, ready access to medical 
therapy for acute coronary syndromes and HT in this urban setting may 
paradoxically increase the prevalence of structural heart disease and HF, through a 
survivor effect.
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3.14.2 Selection bias
Selection bias refers to the systematic error introduced when access to the study 
population varies across different exposure-disease subgroups. Such a bias affects the 
internal validity of the study, which may result in an incorrect estimate of the true 
disease prevalence in the sample population and a distortion of the strength and/or 
direction of exposure-disease relationships in the study.
We extended invitations to 2000 subjects selected as a simple random sample of 
18,000 Canberra residents of age 60-85 years. A comparison of demographic 
characteristics of the sampling frame and (Chapter 4) and the study population 
confirmed that our random sampling method was successful in the selection of a 
representative sample of the population, at least with regard to age and gender. It 
would also be unlikely that our sampling process would systematically promote 
differential access to the study population for different exposure-disease subgroups
In a cross-sectional survey, the major source of selection bias is a poor participation 
rate. In general, a participation rate over 70% is required to avoid major concerns 
regarding the potential for selection bias. In the Canberra Heart Study, seventy-five 
percent (1388/1846) of the eligible subjects agreed to participate in the survey. The 
only groups with participation rates under 70% were women aged 75-79 years (68%) 
and over 80 years (49%). As older women were under-represented in our sample, 
there may be an underestimation of disease prevalence in the source population of 
community-dwelling adults aged 60-86 years.
In order to explore the possibility of a differential participation in patients with
various exposure-disease states, we assessed hospital medical records to collect
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limited clinical data on cardiovascular disease status in a random sample of 100 non­
participants. There was no significant difference between participants and non­
participants with regards to rates of exposures such as HT, diabetes mellitus; or 
disease states such as HF, atrial fibrillation, or myocardial infraction.
Despite obvious limitation of such analyses on non-participants, these findings would 
suggest that there is little evidence that non-participation in the Canberra Heart Study 
has introduced a selection bias.
3.14.3 Information bias
Information bias results from systematic differences in the manner in which exposure 
or outcome data are collected from the various study groups. Such a bias also 
adversely affects the internal validity of the study.
During the clinic assessment, the order of data gathering by the author was chosen to 
minimize potential for information (observation) bias. Specifically, a clinical 
examination was performed by a cardiologist (the author) prior to echocardiographic 
assessment or the review of either the self-administered questionnaire that detailed 
past medical history or the BP measurements performed by study nurses. This 
approach, in addition to the routine application of objective criteria for exposure and 
outcome variables, facilitated the blinding of evaluations of both exposure and 
outcome variables in order to minimise diagnostic and exposure suspicion bias.
Another source of information bias is recall bias, which occurs when individuals with
particular adverse health outcomes report their previous exposures differently from
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those without illness; or when those exposed to a potential hazard report subsequent 
events with a differing degree of accuracy or completeness. In our study, we have 
measured the majority of exposure variables biochemically and clinically, and 
checked medical records to confirm self-reported clinical exposures and outcomes. 
Thus our classification of exposure and outcome status was independent of subject 
recall and often based on objective biological measurements.
3.15 APPROVAL BY HUMAN RESEARCH ETHICS COMMITTEE
This project represents a cross-sectional observational study without a proposed 
intervention. Only individuals who volunteered to participate in the study and 
provided informed consent were recruited into the study. The project provided a low 
level of intrusion. The study was conducted according to the principles stated by the 
Helsinki declaration and complied with the recommendations of the NHMRC 1992 
Supplementary Notes 7, Guidelines for Good Clinical Research Practice, and 
Guidelines for the Protection o f Privacy in the Conduct o f Medical Research.
The two major ethical issues to be considered during this research were:
i. safety and tolerability of diagnostic procedures
ii. confidentiality
A 10-mL sample of blood was withdrawn from each study participant. As 
anticipated, the procedure caused minimal discomfort without exception. Regardless, 
each participant was offered an anaesthetic cream (EMLA) prior to venesection. All
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other diagnostic procedures included in the study were non-invasive and were 
considered to be extremely safe and indeed were well tolerated.
To ensure adequate confidentiality, individual identification details were stored in a 
locked filing cabinet in a room that was locked after hours. Research records were 
entered on a computer database with only numerical identifiers.
Each participant was provided a copy of the biological test results. At the 
participant’s request, a copy was forwarded to their nominated medical 
practitioner(s). As part of an implicit “duty of care”, any abnormal results were 
highlighted, and the participant was referred to their general practitioner for 
appropriate medical follow-up.
The research protocol was reviewed and approved by the Human Research Ethics 
Committees of ACT Health and the Australian National University. As part of the 
study protocol, approval was granted to assess hospital medical records to collect 
limited data on cardiovascular disease status on a random sample of 100 non­
participants.
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4.1 ABSTRACT
Objective. To estimate the prevalence of heart failure (HF) and left ventricular (LV) 
systolic dysfunction in older Australians.
Design, Setting, Participants. A cross-sectional survey of 1275 randomly selected 
residents of Canberra (participation rate 75%), aged 60 to 86 years (mean age 69.4; 
50% men), conducted between February 2002 and June 2003.
Main Outcome Measures. Age/gender-specific prevalence rates of clinical HF and 
LV systolic dysfunction, defined as a LV ejection fraction <50%.
Results. In the study sample, 72 subjects [5.6%; 95% confidence interval (Cl) 4.4%- 
7.1%] had clinical HF that had been previously diagnosed and confirmed by our 
assessment. A further 0.6% (95%CI 0.3%-1.2%) had evidence of structural heart 
disease and symptoms/signs of cardiac insufficiency without a previous diagnosis of 
clinical HF (i.e. undiagnosed clinical HF). Thus, overall the prevalence of clinical 
HF in the sample was 6.3% (95%CI 5.0%-7.7%). Clinical HF increased in 
prevalence with advancing age (4-fold increase in prevalence from 60-64 to 80-86 
years, pcO.0001). Of the 75 subjects (5.9%; 95%CI 4.7%-7.3%) with LV systolic 
dysfunction, 44 (59%) were in the preclinical stage of disease.
Conclusions. Diagnosed HF cases represent the “tip of the iceberg” for the national 
burden of HF and LV systolic dysfunction. Clinically identifiable HF cases can 
remain undiagnosed, and the majority of subjects with LV systolic dysfunction are 
preclinical.
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4.2 BACKGROUND
The human and economic burden of heart failure (HF) in the community is expected 
to increase with our ageing population. Even with the availability of effective 
medical therapy, the syndrome of HF is associated with substantial mortality, 
morbidity and economic cost (estimated to be over AUD$ 1,000 million in 2000).255 
Although HF, under the umbrella of ‘cardiovascular disease’, has been nominated as 
a National Health Priority Area, there are no population-based data with which to 
estimate the prevalence and incidence of HF and left ventricular (LV) dysfunction in 
Australia.27 Such information is important to guide the allocation of health resources 
for managing HF and monitoring the impact of therapeutic and preventive strategies 
over time.
The aim of this study was to determine the prevalence of HF and LV systolic 
dysfunction in a population-based sample of older Australians.
4.3 METHODS 
4.3.1 Study sample
Two thousand residents of Southern Canberra, aged 60-85 were randomly selected 
from the January 2002 electoral roll, and invited by letter to participate in a cross- 
sectional echocardiographic survey. Institutionalised subjects and those who had died 
or had moved away from the Territory were excluded from the study sample 
(n=154). Participants were enrolled between February 2002 and June 2003. The 
sample size was selected based on precision of estimates to determine a prevalence 
of LV systolic dysfunction of 4% and the assumption of a 60% participation rate.
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4.3.2 Echocardiographic assessment
Cardiac structure and function were assessed in all participants using transthoracic 
echocardiography (Acuson 128 XP/10, Siemens, Mountain View, Calif, USA) 
according to a standardised protocol.
Abnormal LV diastolic function was graded into three categories using Doppler 
evaluation of mitral and pulmonary venous inflow and tissue Doppler imaging of 
lateral mitral annulus motion (abnormal relaxation filling pattern: mild DD; 
pseudonormal filling pattern: moderate LV diastolic dysfunction; restrictive filling 
pattern: severe LV diastolic dysfunction).257
LV mass was assessed by the area-length method"' and indexed to height. Sex- 
specific reference limits (97.5th percentiles) were derived from the frequency 
distribution of indexed LV mass in a reference sample of subjects who had no history 
of ischaemic heart disease, hypertension, diabetes, atrial fibrillation or more than 
mild valvular heart disease and who were not taking cardioactive medications. 
Increased indexed LV mass was defined as > 132 g/m for women and > 157 g/m for 
men.
Mitral and aortic valvular function was assessed using Doppler and colour-Doppler 
echocardiography and graded according to previously published criteria. Valvular 
heart disease was defined as at least moderate stenosis or regurgitation of the mitral 
and/or aortic valves. Structural heart disease was defined as LV systolic dysfunction, 
moderate or severe LV DD, increased indexed LV mass and/or valvular heart 
disease.
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4.3.3 Ascertainment of heart failure clinical status
A self-reported history of clinical HF was verified by a review of the subject’s 
medical records. During a consultation with a cardiologist who was blinded to the 
echocardiography findings and past medical history, participants were asked if they 
had symptoms of dyspnoea, orthopnea, paroxysmal nocturnal dyspnoea or dependent 
oedema. They were examined for the presence of increased heart rate, raised jugular 
venous pressure, displaced apex beat, added heart sounds, cardiac murmurs, lung 
crepitations or peripheral oedema. HF clinical status was ascertained according to the 
Framingham criteria for the clinical diagnosis of HF.258 Subjects with LV systolic 
dysfunction but no past history or clinical evidence of HF were considered to be in 
the preclinical phase of disease.
4.3.4 Evaluation of clinical predictors of preclinical LV systolic 
dysfunction
A self-administered questionnaire was used to document a history of myocardial 
infarction, coronary disease, diabetes, HT and alcohol consumption levels (none; 
low-risk; high-risk [the latter defined as >140g/week for women and >280g/week for 
men]259).
Brachial artery systolic and diastolic BP (Korotkoff phase V) were measured to the 
nearest 2 mmHg on the right arm using a standard mercury sphygmomanometer after 
10 minutes of rest in a sedentary position. The measurement was repeated after 5
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minutes and the two sets were averaged for each participant. Hypertension was 
defined as systolic BP >140 mmHg, diastolic BP >90 mmHg, or the use of medical 
therapy for HT.
Diabetes was defined as a fasting serum glucose level >7mmol/L or the use of 
insulin or oral hypoglycaemic agents. Height and weight were measured without 
shoes and in light clothing.
Body mass index (BMI) was calculated for each participant and categorised using the 
World Health Organisation classification scheme (not overweight or obese <25 
kg/m2, overweight 25.0 to 29.9 kg/m2, obese >30 kg/m2).
4.3.5 Statistical analysis
Prevalence rates of LV systolic dysfunction and clinical HF were determined and 
stratified according to age and sex. The associations between clinical parameters and 
preclinical LV systolic dysfunction were examined using % tests a°d in multivariable 
analyses using logistic repression to adjust for age and gender.
4=3.6 Ethics approval
Our study was approved by the human research ethics committees of ACT Health 
and the Australian National University.
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4.4 RESULTS
4.4.1 Participation rates
Seventy-five percent (1388/1846) of the eligible subjects agreed to participate in the 
survey, including subjects of age 86 years who celebrated their birthday during the 
period between their acceptance to participate in the study and their attendance at the 
assessment clinic. All participants provided written and informed consent. The only 
groups with participation rates under 70% were women aged 75-79 years (68%) and 
over 80 years (49%). Consequently, compared to the source population, the sample 
population had a higher proportion of men (50.5% versus 47.2%, p<0.012) and were 
younger (68.9 years vs. 69.6 years, p=0.0005). Approximately 92% of participants 
(1275/1388; mean age 69.4; 50% men) completed all the investigations relevant to 
this study.
4.4.2 Prevalence rates of LV systolic dysfunction
Overall, 269 subjects (21.1%; 95%CI 18.8-24.4%) had evidence of structural heart 
disease; 75 (5.9%, 95%CI 4.7%-7.3%) with LV systolic dysfunction; 72 (5.6%) with 
moderate or severe diastolic function and EF >50%; 102 (8%) with increased LV 
mass without impaired systolic function or moderate/severe diastolic function; and 
20 (1.6%) with aortic and mitral valvular heart disease.
Age/gender-specific rates of clinical HF and LV systolic dysfunction are presented in 
Table 4-1.
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Table 4-1 Age/gender-specific prevalence of clinical heart failure and LV 
systolic dysfunction.
Subjects Affected, n ( % )
Age Group, years
60-64 65-69 70-74 75-79 80-86 All
Men 7 (3.6)
Clinical Heart Failure
12(7.3) 6(5.2) 16(17.8) 11 (15.7) 52 (8.2)
Women 5 (2.6) 3 (2.0) 7 (4.8) 8 (7.8) 5(10.4) 28 (4.4)
All 12(3.1) 15 (4.8) 13 (5.0) 24(12.4) 16(13.6) 80 (6.3)
LV Systolic Dysfunction
Anv, election fraction <50% 
Men * 1 13(7.9) 10(8.6) 9(10) 12(17.1) 55 (8.7)
Women 4(2.1) 3 (2.0) 5 (3.4) 3 (2.9) 5(10.4) 20 (3.1)
All 15 (3.9) 16(5.1) 15 (5.7) 12 (6.2) 17 (14.4) 75 (5.9)
Moderate or Severe, ejection fraction <40% 
Men 3(1.5) 6(3.7) 3 (2.6) 6 (6.7) 3 (4.3) 21 (3.3)
Women 2(1.0) 0 (0.0) 1 (0.7) 1 (1.0) 2 (4.2) 6 (0.9)
All 5(1.3) 6(1.9) 4(1.5) 7 (3.6) 5 (4.2) 27 (2.1)
Of those with any LV systolic dysfunction, 44 (59%) were preclinical. However, 
only 6 of the 27 subjects (22%) with moderate or severe LV systolic dysfunction 
were preclinical.
4.4.3 Clinical correlates of preclinical LV systolic dysfunction
Increasing age, male gender and a history of myocardial infarction were associated 
with preclinical LV systolic dysfunction (Table 4- 2).
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Table 4-2 Associations between clinical characteristics and preclinical LV 
systolic dysfunction
Unadjusted Odds 
Ratio
Adjusted Odds 
Ratio*
Men 2.3 (1.2-4.4) 2.3 (1.2-4.4)t
Age group (referent: 60-69 years)
70-79 years 1.2 (0.6-2.4) 1.3 (0.6-2.5)t
80-86 years 3.2 0.4-7.2) 3.0 (1.3-6.9)t
Hypertension 1.2 (0.6-2.1) 1.1 (0.6-2.0)
Diabetes 0.3 (0.1-1.2) 0.3 (0.1-1.1)
Myocardial infarction 3.9 (1.6-9.7) 3.0 (1.2-7.5)
Coronary disease 2.1 (1.03-4.2) 1.6 (0.8-3.3)
Body mass index (referent: <25 
kg/m2)
25-29.9 kg/m2 0.6 (0.3-1.2) 0.5 (0.3-1.1)
>30 kg/m2 0.7 (0.3-1.5) 0.8 (0.3-1.6)
High-risk alcohol intake 1.0 (0.2-4.4) 1.0 (0.2-4.4)
^adjusted for age and gender unless specified; f  adjusted for age; ^adjusted for  
gender
Although diabetes was associated with prevalent clinical systolic dysfunction (OR 
2.6; 95%CI 1.2-5.7), there was a trend toward a lower likelihood of preclinical LV 
systolic dysfunction in diabetics (OR 0.26; 95%CI 0.1-1.1). In this cross-sectional 
analysis, there were no significant associations between preclinical LV systolic 
dysfunction and hypertension, body mass index category or alcohol intake status.
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4.4.4 Clinical heart failure
Of the study sample, 72 subjects (5.6%; 95%CI 4.4%-7.1%) had clinical HF that had 
been previously diagnosed and validated by our assessment. Approximately 60% of 
subjects with diagnosed HF had preserved LV systolic function (EF>50%), a finding 
that was more frequent in women with diagnosed HF (77% vs. 52%, p=0.039). A 
further 8 participants (0.6%; 95%CI 0.3%-1.2%) without a previous diagnosis of 
clinical HF had evidence of structural heart disease and symptoms/signs of cardiac 
insufficiency (i.e. undiagnosed clinical HF). Thus overall, the prevalence of clinical 
HF in the sample was 6.3% (95%CI 5.0%-7.7%). Clinical HF was more common in 
men (8.2% vs. 4.4%, p=0.005) and increased in frequency with advancing age 
(4.4-fold increase in prevalence from 60-64 to 80-86 years, pcO.OOOl). The 
proportion of undiagnosed clinical HF cases was not related to age (p=0.34) or 
gender (p=0.54).
4.5 DISCUSSION
The Canberra Heart Study provides the first population-based estimates of HF 
prevalence in Australia. Prior estimates of HF prevalence and incidence have been 
derived from extrapolation of overseas data,260 hospital separations, or studies on 
clinic-based samples in which a minority had echocardiographic confirmation of 
underlying structural heart disease.261 Our results illustrate that diagnosed HF cases 
represent the “tip of the iceberg” for the national burden of HF and structural heart 
disease. Clinically identifiable HF cases can remain undiagnosed, and although 
21.1% of our sample of older Australians had structural heart disease, only 6.3% had
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clinical HF. Moreover, of the 5.9% of the study population with LV systolic
dysfunction, 59% were in the preclinical stage of disease.
4.5.1 Comparison with international studies
Comparison of our findings with international studies is limited by differences in 
study methodology and outcome definitions. Framingham investigators have 
reported that approximately 6% to 10% of the population aged over 65 experience 
clinical HF262. However, in such early epidemiological cardiovascular surveys, HF 
status was ascertained using clinical scores that had relatively poor sensitivity and 
specificity for structural heart disease. It has only been during the last decade that 
surveys have incorporated echocardiography to confirm structural heart disease in 
subject with non-specific symptoms and signs of cardiac insufficiency. The burden 
of LV systolic dysfunction in our sample is consistent with estimates from the 
Olmsted County20, Rotterdam21 and ECHOES93 surveys, conducted in predominantly 
Caucasian populations with similar cardiovascular risk profiles (Table 4-3). 
However, our prevalence rates of LV systolic dysfunction are lower than the 
estimates from the Strong study95, conducted exclusively in a population of Native 
Americans, and the Glasgow study , whose population has a high prevalence of 
cardiovascular disease. Like the surveys from the United States
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Table 4-3 Comparison of results from prevalence survey of LV systolic 
dysfunction
O c> O ; CO co o
W V/ v V V/
CNJ TO
116
90  91 Q l QS 961and Northern Europe,“ ’ ’ ’ ’ we have documented that most community cases 
of LV systolic dysfunction are preclinical.
4.5.2 Limitations
Although our population-based sample and good participation rate reduce selection 
bias and strengthen the validity of this study, a number of factors may limit 
generalisability of our results. First, we have identified that older women, due to their 
lower participation rate, were under-represented in our sample. This may result in an 
underestimation of disease prevalence in the source population of community­
dwelling adults aged 60-86 years. Second, the vast majority of the study population 
was Caucasian (97.6%) and our results may not be applicable to non-Caucasian 
populations. Third, the National Health Survey has documented that ACT residents 
have lower rates of classical risk factors for cardiovascular d i s ea se , wh i ch  may 
decrease the prevalence of HF in this population compared to national rates. On the 
other hand, ready access to medical therapy for acute coronary syndromes and HT in 
this urban setting may paradoxically increase the prevalence of structural heart 
disease and HF, through a survivor effect.
4.5.3 Implications
Our results have several important public health implications. Firstly, with the 
availability of efficacious medical therapy for patients with clinical HF, it is crucial
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to optimise methods of diagnosing the condition in the community. Using strict 
criteria for the clinical diagnosis of congestive HF, we found that 10% of the subjects 
with structural heart disease and clinical evidence of HF had not been previously 
diagnosed with the condition. The National Institute of Clinical Studies has recently 
evaluated barriers to the correct diagnosis of HF and the implementation of proven 
management strategies in primary care.264 Solutions based on targeted education of 
health professionals and patients, and the increased use of diagnostic tools such as 
echocardiography, have been proposed.
Secondly, since secondary preventive measures have been shown to be effective for 
patients with preclinical LV systolic dysfunction, methods for identifying affected 
patients should also be optimised. Targeted screening programs of high-risk subjects 
(as identified in this study: men, older age groups, patients with prior documented 
coronary disease or myocardial infarction) should be evaluated for their cost- 
effectiveness.
Thirdly, with the anticipated increase in the proportion of the population of age over 
60 years (among whom most HF cases arise) and escalating rates of obesity and 
diabetes in the community, there seems little hope to stem the rise in HF cases to 
epidemic proportions unless primary preventive efforts directed at the individual and 
population level are adopted.
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5.1 ABSTRACT
Objective. To determine the prevalence and predictors of left ventricular (LV) 
diastolic dysfunction in older adults.
Design, Setting, Participants. A cross-sectional survey of 1275 randomly 
selected residents of Canberra (participation rate 75%), aged 60 to 86 years (mean 
age 69.4; 50% men), conducted between February 2002 and June 2003.
Main Outcome Measures. Prevalence rates of LV diastolic dysfunction as 
characterised using comprehensive Doppler echocardiography.
Results. The prevalence of any diastolic dysfunction was 35.6% (95% confidence 
interval [Cl] 32.9%-38.3%) and moderate-severe diastolic dysfunction was 7.5% 
(95%CI 6.1 %-9.1 %). Of those with moderate-severe diastolic dysfunction, 84.7% 
had a LV ejection fraction (EF) >50% and 77.2% were preclinical. Predictors of 
diastolic dysfunction included increasing age (pcO.0001), reduced EF (pcO.0001), 
obesity (p<0.0001); history of HT (pcO.0001), diabetes (p=0.02) and myocardial 
infarction (p=0.003). Moderate-severe diastolic dysfunction with normal EF, 
although predominantly preclinical, was independently associated with increased LV 
mass (pcO.0001), LA volume (pcO.0001), circulating aminoterminal pro-B-type 
natriuretic peptide levels (pcO.0001), and decreased quality of life (p<0.005).
Conclusion. Diastolic dysfunction is common in the community and frequently 
unaccompanied by overt HF. Despite the lack of symptoms, advanced diastolic 
dysfunction with normal EF is associated with reduced quality of life and structural 
abnormalities that reflect increased cardiovascular risk.
122
5.2 BACKGROUND
Over the past decade, several important observations on the pathophysiological 
mechanisms underlying HF in the community have been documented through 
population-based echocardiographic surveys. 20, 21 ’ 58, 59, 93, 95, 263, 263 Firstly, HF 
has been reported in the presence of a normal EF. 58,265Although controversial, the
61 73presumed pathophysiology for most patients with HF and a normal EF is DD. ’ 
Secondly, subjects withHF and a normal EF have been shown to have a 
poor prognosis, even though mortality and morbidity in this group are not as high as 
in patients with a reduced EF. 94 ,265
Following these observations, interest in the epidemiology of DD has been growing, 
which has been facilitated by the availability of non-invasive Doppler methods of 
characterising diastolic function. 123 A recent study20 showed that subjects 
with normal EF can have moderate or severe DD, most often without accompanying 
clinical evidence of HF. The validity of findings from these cross-sectional surveys of 
DD has, however, been compromised by low participation rates and the failure to 
use comprehensive Doppler methods257 to distinguish subjects with normal and 
pseudonormalmitral inflow patterns, which have increased the potential for selection 
bias and misclassification of diastolic function. In addition, there is a paucity of data 
regarding echocardiographic and clinical characteristics of subjects with DDand 
normal EF (DD-NEF) and their influence on clinical status. Our objectives in this 
study were to determine the prevalence of DD in older adults and to describe 
the clinical spectrum of subjects with DD-NEF.
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5.3 METHODS
5.3.1 Study population
Using simple random sampling from a population register (Federal electoral roll, 
January 2002), 2000 Canberra residents, aged 60-85, were selected to constitute our 
study population. Subjects were invited to participate by letter. Institutionalised 
subjects and those who had died or had moved away from the Territory were 
excluded from the study sample. All study participants provided written and 
informed consent for the study investigations, and were enrolled between February 
2002 and June 2003.
5.3.2 Assessment of clinical risk factors for heart failure
A self-administered questionnaire was used to gather data on a history of myocardial 
infarction, angina, HT or diabetes. Brachial artery systolic and diastolic BP was 
measured after 10 minutes of rest in a seated position; two sets were averaged for 
each participant. Height and weight were measured without shoes and in light 
clothing. Body mass index was calculated for each participant (weight in kilograms 
divided by the square of height measured in metres) and categorised using the World 
Health Organisation classification scheme (not overweight or obese <25 kg/m2, 
overweight 25.0 to 29.9 kg/m2, obese >30 kg/m2).
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5.3.3 Echocardiography
One of two experienced sonographers assessed cardiac structure and function by 
using transthoracic echocardiography (Acusonl28 XP/10, equipped with native 
tissue harmonic imaging technology) according to a standardised protocol. 
Measurements were made online and recorded on tape with participants’ initials and 
study number as their only identification. A cardiologist, blinded to the participant’s 
clinical data, interpreted the echocardiogram after review off line. LV EF was 
quantified by the biplane disc summation method (Simpson’s rule) on the two- 
dimensional echocardiographic images from the apical four- and two-chamber 
views.266 LV systolic function was categorised according to EF (<40%, 41-50%, > 
50%) and the presence of regional LV wall motion abnormalities. LV diastolic 
function was graded into four categories by Doppler evaluation of the mitral and 
pulmonary venous inflow and by tissue Doppler imaging of the lateral mitral annulus 
motion (Table 5-1). 257 In a stratified subsample of 50 participants, interobserver 
reproducibility for grading of systolic and diastolic function was very good (Ksystoiic =  
0.88, 95% confidence interval (Cl) 0.63 to 1.0 and K^toHc = 0.89, 95% Cl 0.64 to 
1.0). Valvular heart disease was defined as at least moderate stenosis or regurgitation 
of the aortic or mitral valve on colour Doppler and quantitative Doppler 
echocardiographic evaluation. LV mass was assessed by the area-length method, by 
using the two-dimensional short-axis parasternal view at the papillary muscle level to 
measure LV muscle area and the apical four-chamber view to measure the LV 
length.235 The LV mass was indexed for each participant’s body surface area. 
Maximum LA volume was quantified by the biplane Simpson method154 and indexed 
for body surface area.
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Table 5-1 Doppler Assessment of left ventricular diastolic function
Mitral inflow Pulmonary venous inflow TDI MAM
Normal
0.75<E/A<1.5 
DT> 160ms
S>D
MV Adur> PV Adur
E/e’<10
Mild LV diastolic dysfunction
E/A<0.75
DT>240ms
S>D
MV Adur> PV Adur
E/e’<10
Moderate LV diastolic dysfunction
0.75<E/A<1.5 
DT> 160ms
S<D
MV Adur+30ms< PV E/e’>10
Adur
Severe LV diastolic dysfunction
>1.5
DT< 160ms
S<D
MV Adur+30ms< PV 
Adur
E/e’>10
At least 2 Doppler criteria consistent with moderate-severe LVDD were required to
distinguish from normal diastolic function. E, peak early mitral inflow filling 
velocity; A, peak mitral filling velocity at atrial contraction; DT, deceleration time of 
mitral E wave; MV Adur, duration o f mitral A wave; S, peak velocity o f pulmonary 
venous forward flow during systole; D, peak velocity o f pulmonary venous forward 
flow during diastole; PV Adur, duration o f pulmonary venous reversal wave at atrial 
contraction; e \ peak velocity o f lateral mitral annulus motion during early diastole. 
TDI MAM =  Tissue Doppler imaging o f mitral annular motion
5.3.4 Ascertainment of heart failure status
A self-reported history of clinical HF was verified by a review of the subject’s 
medical records. During a consultation with a cardiologist who was blinded to the 
echocardiographic findings and medical history, participants were asked if they had
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symptoms of dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea or dependent 
oedema. They were also examined for the presence of a tachycardia, raised jugular 
venous pressure, displaced apex beat, added heart sounds, cardiac murmurs, lung 
crepitations and peripheral oedema. HF clinical status was ascertained according to 
clinical scores based on the NHYA classification of functional status267 and
o
Framingham criteria for the clinical diagnosis of HF. Subjects with systolic or 
diastolic dysfunction without a history or clinical evidence of HF were considered to 
be in the preclinical phase of disease. Serum amino-terminal B-type natriuretic 
peptide (NT-proBNP) concentrations were measured with a fully automated 
electrochemiluminescence sandwich immunoassay (proBNP, R.oche Diagnostics).
5.3.5 Quality of Life
The standardised Short-Form 36-item questionnaire was administered to assess 
general health status.
5.3.6 Statistical analysis
Continuous variables are presented as mean (SD). Categorical variables are displayed 
as percentages. Differences between groups were assessed by likelihood ratio tests 
(categorical variables) or Kruskal-Wallis tests and non-parametric tests for trend 
(continuous variables), as appropriate. We calculated the point estimate and 95% Cl 
(by the exact binomial method) for DD (for any EF and for subjects with EF > 50%), 
stratified for five-year age groups and sex. Ordinal logistic regression was used to
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assess the association between the ordinal variable, diastolic function grade and 
clinical or echocardiographic predictors in univariable and multivariable analyses, 
adjusted for age and sex and relevant covariates. Least squares linear regression was 
used to assess the relationship between general health status score and diastolic 
function grade, after adjustment for age, sex and significant covariates. All 
hypothesis testing was two sided, and significance was declared if p < 0.05. The 
assumptions for regression models were checked statistically.
5.4 RESULTS
5.4.1 Study participants
Seventy-five per cent (1388 of 1846) of the eligible subjects agreed to participate in 
the survey. The only groups with participation rates < 70% were women aged 75-79 
years (68%) and > 80 years (49%). Consequently, compared with the source 
population, the sample population had a higher proportion of men (50.5% v 47.2%, p 
< 0.012) and were younger (68.9 years v 69.6 years, p = 0.0005). About 92% 
participants (1275 of 1388; mean age 69.4; 50% men) completed all the 
echocardiographic investigations necessary for assessment of LV function.
For 32 subjects, diastolic function grade could not be determined (atrial fibrillation 
with deceleration time of mitral E wave> 140 ms; mitral stenosis; mitral E:A fusion; 
and only a single criterion suggestive of moderate to severe DD). The prevalence of 
any DD was 34.7% (95% Cl 32.1% to 37.4%) and that of moderate to severe DD was 
7.3% (95% Cl 5.9% to 8.9%). Table 5-2 presents the prevalence of DD stratified by 
age group, sex and EF status.
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Table 5-2 Prevalence of diastolic dysfunction in the cohort (n = 1275) stratified 
by age group, sex and left ventricular ejection fraction status
Age groups (years)
60 -6 4 65 -6 9 7 0 -7 4 7 5 -7 9 8 0 -8 6 All
D iastolic dysfunction, any ejection fraction
M ild
M en 30 39 36 29 36 170
(15.3% ) (23.8% ) (31.0% ) (32.2% ) (51.4% ) (26.7% )
W om en 31 37 45 43 23 179
(16.1% ) (24.8% ) (30.8% ) (41.7% ) (47.9% ) (28.0% )
All 61 76 81 72 59 349
(15.7% ) (24.3% ) (30.9% ) (37.3% ) (50.0% ) (27.4% )
M oderate or severe
M en 10 13 8 8 8 47
(5.1% ) (7.9% ) (6.9% ) (8.9% ) (11.4% ) (7.4% )
W om en 4 6 13 14 9 46
(2.1% ) (4.0% ) (8.9% ) (13.6% ) (18.8% ) (7.2% )
All 14 19 21 22 17 93
(3.6% ) (6.1% ) (8.0% ) (11.4% ) (14.4% ) (7.3% )
D iastolic dysfunction w ith normal ejection fraction
M ild
M en 28 33 29 21 23 134
(14.3% ) (20.1% ) (25.0% ) (23.3% ) (32.9% ) (21.1% )
W om en 31 35 43 37 19 165
(16.1% ) (23.5% ) (29.5% ) (35.9% ) (39.6% ) (25.8% )
All 59 68 72 58 42 299
(15.2% ) (21.7% ) (27.5% ) (30.1% ) (35.6% ) (23.5% )
M oderate or severe
M en 6 9 6 4 7 32
(3.1% ) (5.5% ) (5.2% ) (4.4% ) (10.0% ) (5.0% )
W om en 2 6 12 14 6 40
(1.0% ) (4.0% ) (8.2% ) (13.6% ) (12.5% ) (6.3% )
All 8 15 18 18 13 72
(2.1% ) (4.8%) (6.9% ) (9.3% ) (11.0% ) (5.6% )
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Table 5-3 outlines the univariate associations between clinical characteristics and
diastolic function. Higher age was associated with any DD (p < 0.0001) and 
moderate to severe DD (3.6% in subjects aged 60-64 years v 14.4% in subjects aged 
> 80 years, ptrend < 0.001), but rates of any DD (p = 0.68) or moderate to severe DD 
did not differ significantly between men and women (7.4% v 7.2%, respectively, p = 
0.90).
Table 5-3 Clinical characteristics of participants according to left ventricular 
diastolic function status
D iasto lic  D ysfunction , any EF
N orm al
(n=801)
M ild
(n=349)
M oderate /S evere
(n=93)
p-value
A ge (yrs) 68±6 72+7 73+7 <0.0001
W om en, n (% ) 403 (50.3) 179 (51.3) 46 (50.0) 0 .94
Systolic blood pressure  (m m H g) 137+17 140+17 139+18 0.001
H ypertension , n (% ) 337 (42.0) 191 (54.7) 58 (63.0) <0.0001
A ngina, n (% ) 75 (9.4) 5 3 (1 5 .2 ) 22 (23.9) <0.0001
M yocard ia l Infarction , n (% ) 37 (4.6) 33 (9.5) 20 (21.7) <0.0001
D iabetes, n (% ) 73 (9.1) 37 (10.6) 18 (19.6) 0.007
O bese, n (% ) 223 (27.8) 98 (28.1) 39 (42.4) 0.01
E xcessive alcohol intake, n (% ) 30 (3.7) 1 8 (5 .2 ) 6 (6.5) 0.32
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After adjustment for age and sex, a history of hypertension (p = 0.002), diabetes (p
0.03), angina (p = 0.048), myocardial infarction (p < 0.0001), overweight (p = 0.01) 
and obesity (p < 0.0001) were associated with DD (Table 5-4).
Table 5-4 Association between clinical and echocardiographic parameters and 
left ventricular diastolic dysfunction
Adjusted OR (95% Cl)* p-value
Men 0.97 (0.76 to 1.23) t 0.78
Age group (referent: 60-69 years)
70-79 years 2.5 (1.9 to 3.2) $ <0.0001
80-86 years 5.7 (3.9 to 8.4) $ <0.0001
Hypertension 1.5 (1.2 to 2.0) 0.002
Diabetes 1.4(1.03 to 2.0) 0.029
Myocardial infarction 2.8 (1.8 to 4.4) <0.0001
Coronary disease 1.8 (1.3 to 2.4) <0.0001
Body mass index (referent: <25 kg/m2)
25-29.9 kg/m2 1.5 (1.1 to 2.0) 0.01
>30 kg/m2 1.9 (1.3 to 2.6) <0.0001
Ejection fraction <50% 5.4 (3.3 to 8.8) <0.0001
^Adjusted for age and sex unless specified; f  adjusted for age; ± adjusted for sex.
Rates of DD increased with decreasing EF (p=0.0001). Indeed, there were no 
subjects with an EF<40% with normal LV diastolic function.
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5.4.2 Diastolic dysfunction with normal ejection fraction
The prevalence of moderate to severe DD with an EF > 50% and no regional LV wall 
motion abnormalities was 5.6% (95% Cl 4.4% to 7.1%). Rates of DD-NEF increased 
with age (p < 0.0001) but did not differ between men and women (p = 0.34). Clinical 
predictors of DD-NEF were a history of FIT (p < 0.0001), angina (p = 0.04), 
myocardial infarction (p = 0.003), and obesity (p < 0.0001). Figure 5-1 presents the 
impact of cardiovascular risk factors on age-specific rates of DD-NEF. Of subjects 
aged < 70 years and without a history of HT, ischaemic heart disease, diabetes or 
obesity, advanced DD-NEF was documented in only one person.
—• — Mild DD: no risk factors 
— Mi l d DD: risk factors 
— Moderate to severe DD: no risk factors 
—A -  M oderate to severe DD: risk factorsu3 50
__
m_a> 30
60-64 65-69 70-74
A ge group (years)
75-79 80-86
Figure 5-1 Impact of cardiovascular risk factors on age-specific rates of 
DD-NEF.
Risk factor status was dichotomised according to history o f the risk factors; 
hypertension, ischaemic heart disease (angina or myocardial infarction), obesity, 
and diabetes.
132
Doppler evidence of moderate or severe DD-NEF was accompanied by 
echocardiographic and biochemical markers of impaired LV relaxation and increased 
LV filling pressure. Even after we controlled for age, sex and EF, worsening DD- 
NEF was associated with an increase in indexed LA volume (p < 0.0001) and 
NT-proBNP concentration (p < 0.0001). Indexed LA volume (p = 0.61) and NT- 
proBNP concentration (p = 0.10), however, did not differ significantly between 
subjects with normal and those with mild DD, even after stratification for age and 
sex.
In subjects with DD-NEF, there was evidence of LV remodelling and alterations in 
long axis systolic function (Table 5-5). LV mass index (pcO.0001) and mitral annular 
systolic velocity increased with advancing DD, independent of age and gender. 
However, EF did not significantly decrease in subjects with DD-NEF ( p tren d = 0 .11).
Quality of life, as assessed by general health status (Table 5-5), progressively 
deteriorated with increasing severity of DD-NEF, independent of age, gender, 
overweight/obesity status, past history of HT, diabetes or ischaemic heart disease or 
EF (p<0.0001).
133
Table 5-5 Echocardiographic and other characteristics of participants with 
normal ejection fraction by diastolic function status
D ia s to lic  d y s fu n c tio n , 
n o rm a l E F f
N o rm a l*  
(n  =  7 5 5 )
M ild  
(n  =  2 9 9 )
M o d e ra te  to  
s e v e re  
(n  =  7 2 ) p -v a lu e
A g e  (y e a rs ) 68  (6 ) 71 (7 ) 73  (6 ) < 0 .0 0 0 1
W o m e n 3 9 4
(5 2 .2 % )
165
(5 5 .2 % )
38
(5 4 .3 % )
0 .3 4
G e n e ra l  h e a lth  s ta tu s  s c o re  (/1 0 0 ) 6 9  (2 2 ) 63  (2 4 ) 5 4  (2 6 ) < 0 .0 0 0 1
E F (% ) 68  (5) 67  (5 ) 6 6  (7 ) 0 .11
M itra l  a n n u la r  sy s to lic  v e lo c ity  
(c m /s )
10 .6  (3 ) 10.8  (3 ) 8 .4  (2 ) < 0 .0 0 0 1
L V E D D  in d e x  ( c m /m 2) 2 .6 7  (0 .3 ) 2 .6 8  (0 .4 ) 2 .7 0  (0 .3 ) 0.31
L V  m a ss  in d e x  (g /m ) 100 (2 4 ) 106 (3 1 ) 121 (3 3 ) < 0 .0 0 0 1
L e f t a tr ia l v o lu m e  in d e x  (m l/m 2) 2 2 .4  (6 .6 ) 2 3 .4  (8 .3 ) 3 7 .5 ( 1 4 ) < 0 .0 0 0 1
M itra l a n n u la r  d ia s to lic  v e lo c ity  
(c m /s )
10.1 (2 ) 8 .6  (2 ) 8 .5  (2 .8 ) < 0 .0 0 0 1
A m in o - te rm in a l  p ro -B N P  
(pm ol/1)
1 4 ( 1 3 ) 1 9 ( 3 1 ) 105 (1 6 4 ) < 0 .0 0 0 1
^Ejection fraction (EF) >50%, no regional wall motion abnormalities and normal 
diastolic function; fEF >50% and no regional wall motion abnormalities.
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5.4.3 Relationship between DD-NEF and heart failure status
Of subjects with a previous diagnosis of HF, 47% (95% Cl 35% to 59%) had an 
EF > 50% and no evidence of regional wall motion abnormalities. Of subjects with 
moderate to severe DD-NEF, 86% were in the preclinical stage of disease as 
assessed by strict Framingham criteria. Even when clinical status was judged by the 
NYHA classification, 36% of subjects with moderate to severe DD-NEF were 
asymptomatic. Thus, about one in 20 subjects in the sample population 
had preclinical advanced DD-NEF (4.9%, 95% Cl 3.7% to 6.2%). In contrast, 
preclinical advanced systolic dysfunction (EF<40% )was rare (0.5%, 95% Cl 0.2% 
to 1.0%).
Markers of progression from preclinical DD-NEF to overt HFwere decreased EF 
(66% in preclinical advanced DD-NEF v 59% in clinical advanced DD-NEF, 
p = 0.003), increased NT-proBNP concentration (84 pmol/1 v 248 pmol/1, p = 0.03) 
and trends towards increased LV end diastolic size (2.67 cm/m v 2.83 cm/m, 
p = 0.13) and indexed LA volume (36.3 ml/m2v 45.1 ml/m2, p = 0.11).
5.5 DISCUSSION
In this population-based sample of older adults, DDwas common and increased in 
frequency with age. In contrast to the female preponderance documented in studies of 
HF with normal EF, we found that DD was equally common in men and women. 
Co-morbid cardiovascular conditions such as HT, ischaemic heart disease, diabetes, 
obesity and systolic dysfunction were predictors of DD, independent of age and sex. 
Advanced (moderate or severe) DD rarely equated to "diastolic" HF. Indeed, 76% of
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patients with advanced DD did not have overt symptoms or a history of HF. We 
observed that advanced DD-EF was as common as systolic dysfunction (EF < 50%) 
and more likely to be present in the preclinical phase of disease. Despite the frequent 
absence of symptoms, subjects with advanced DD-NEFhad evidence of structural 
remodelling, including increased LA size and LV mass, and raised NT-proBNP 
concentrations compared with subjects with normal or mildly impaired
diastolic function. Furthermore, DD-NEF was independently associated with a 
reduction in general health status.
Several factors enhance the validity of results from this study compared with 
previously published surveys. Our estimates of systolic and diastolic dysfunction are 
less likely to be affected by selection bias arising from a low participation 
rate20 ormisclassification error resulting from the failure to use
comprehensive Doppler methods to distinguish subjects with normal
diastolic function from those with moderate DD.59 Nonetheless, the consistency in 
prevalence and clinical predictors of DD between our study and the only other study 
that employed detailed Doppler methods of estimating LV filling pressure-provides 
reassurance as to the generalisability of our findings.
5.5.1 DD-NEF and HF status
This study extends previously published observations on the relationship between 
DD-NEF and HF status.20 In addition to surveillance of medical records, the 
incorporation of a clinical examination to detect symptoms and signs of HF has
provided a more robust classification of clinical status of subjects with DD-NEF. By
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using an array of clinical scores that offer varying degrees of sensitivity and 
specificity, we have confirmed the existence of a preclinical phase of advanced 
DDthat is detectable by comprehensive Doppler echocardiography. Indeed, the 
prevalence of preclinical advanced DD-NEF is 10-fold greater than that of advanced 
systolic dysfunction. There is scant evidence regarding the prognostic significance of 
preclinical DD. Despite their lack of symptoms, subjects with preclinical advanced 
DD-NEF have biochemical and morphological evidence supporting the presence of 
current and chronic rise of LV filling pressures as assessed by NT-proBNP 
concentration and LA size, respectively. Further, as LA size has been shown to be an 
independent risk marker for the development of atrial fibrillation,268’ 269 
stroke,270 incident HF2/1 and cardiovascular death,272 preclinical DD-NEF is likely to 
be a condition that portends a poor cardiovascular prognosis. Our conclusion 
is supported by longitudinal data from a study of Olmsted County residents, which 
has shown that people with advanced DD, most of whom were in a preclinical stage 
of disease, had a 10-fold higher risk of all cause death than subjects with normal 
diastolic function after adjustment for age, sex andEF.20
5.5.2 “Isolated” LV diastolic dysfunction
Despite evidence from convenience samples that patients withHF118,273’274 or DD- 
NEF have a subtle decrease inLV long-axis systolic dysfunction,141’274 subjects with 
DD with an EF > 50% have recently been classified as having isolated DD. Our 
results suggest that this term may be an oversimplification. We have observed that, in 
subjects with an EF > 50% and no regional wall motion abnormalities, advancing DD
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was associated with a decrease in long-axis systolic function and HF status was 
related to a reduction in radial systolic function, although EF remained within 
"normal" limits. Furthermore, there was a trend towards an increase in LV end 
diastolic size with advancing DD and in subjects with symptomatic DD-NEF. Thus, 
at least some subjects with advanced DD-NEF may have cardiac remodelling as a 
pathophysiological response to co-morbid cardiovascular conditions (HT, ischaemic 
heart disease or obesity), with increased LV filling pressure related to an increased 
ventricular capacitance rather than a shift in the end diastolic pressure- 
volume relationship caused by a pure decrease in LV compliance. Although recent 
studies have provided an insight into the mechanisms underlying such a response by 
showing that patients with advanced DD-NEF have load-dependent alterations in 
diastolic function caused by increased LV systolic and arterial stiffness,27^  more work 
is required to confirm these findings.
5.5.3 Limitations
A low participation rate from women aged >80 years may have resulted in an 
underestimation of the true prevalence of LV dysfunction in the source population. 
Although echocardiography is widely accepted as a safe and convenient method for 
the diagnosis and follow up of patients with DD,123 it is recognised that Doppler 
echocardiographic methods reflect integrative properties of diastolic function that 
lack specificity.276 In this study of survey participants, we could not justify the use of 
invasive methods for the assessment of active and passive diastolic LV properties. 
Most (97.6%) of our sample was white and our results may not be applicable to non­
white populations. As our data are cross sectional, we were unable to determine
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temporal relationships (and thus causal relationships) between clinical parameters,
cardiac remodelling and diastolic function.
5.5.4 Implications
The burden of DD-NEF in the community will probably increase with the ageing 
population and escalating rates of obesity and diabetes in the community. Whether 
this burden can be reduced by screening efforts remains to be determined. Our 
observations suggest that, as preclinical advanced DD-NEF is relatively common and 
associated with cardiac markers that portend a poor cardiovascular prognosis, 
screening efforts may be warranted. Before community-based screening programs 
for LV (systolic and diastolic) dysfunction are adopted, however, more data are 
required detailing the natural history of the disease, the efficacy of treatment for 
preclinical LV dysfunction, the screening performance of biomarkers and ultimately 
the cost effectiveness of screening strategies. As DD-NEF is rare in subjects without 
co-morbid cardiovascular conditions, the efficiency of screening programs could 
be optimised by targeting high-risk groups, defined according to age (> 70 years) or 
risk factor status (HT, ischaemic heart disease, diabetes or obesity).
5.5.5 Conclusion
DD is common in the community and is often unaccompanied by overt symptoms 
and signs of HF. Despite the absence of symptoms, subjects with advanced DD-NEF
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have accompanying structural abnormalities that reflect an increased risk for adverse
cardiovascular outcomes and have a reduced quality of life.
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C hapter 6: AMINO- 
TERMINAL PRO-B-TYPE 
NATRIURETIC PEPTIDE AS A 
MARKER OF LEFT 
VENTRICULAR SYSTOLIC 
AND DIASTOLIC 
DYSFUNCTION IN THE 
COMMUNITY
Published in part in:
Abhayaratna WP, Marwick TH, Becker NG, Jeffery IM, McGill DA, Smith WT. 
Detection of left ventricular systolic and diastolic dysfunction in the community with 
aminoterminal pro-B-Type natriuretic peptide. Am Heart J 2006;152:941-8
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6.1 ABSTRACT
Background. There is limited information regarding the clinical utility of 
aminoterminal B-type natriuretic peptide (NT-proBNP) for the detection of left 
ventricular (LV) dysfunction in the community. We evaluated predictors of 
circulating NT-proBNP levels, and determined the utility of NT-BNP to detect 
systolic and diastolic LV dysfunction in older adults.
Methods. A population-based sample of 1229 older adults underwent 
echocardiographic assessment of cardiac structure and function and measurement of 
circulating NT-proBNP levels.
R esults. Predictors of NT-proBNP included age, female gender, body mass index, 
and cardiorenal parameters (diastolic dysfunction [DD] severity; LV mass and LA 
volume; right ventricular overload; decreasing ejection fraction [EF] and creatinine 
clearance). The performance of NT-proBNP to detect any degree of LV dysfunction, 
including mild DD, was poor (AUC 0.56-0.66). In contrast, the performance of 
NT-proBNP for the detection of EF<40% and moderate-severe DD was strong with 
AUC>0.90 regardless of age and gender. The ability of NT-proBNP to detect 
EF<40% and/or moderate-severe DD was optimised by using age/gender-specific 
limits (men 60-74, 20pmol/L; women 60-74, 30pmol/L; >75 years, 45pmol/L). Of 
“false positive” tests, 88% (126/143) were explained after considering cardiorenal 
determinants of NT-proBNP levels.
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Conclusions. NT-proBNP is a suboptimal marker of mild LV dysfunction, but 
performs strongly as a marker of EF<40% and/or moderate-severe DD in the 
community.
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6.2 BACKGROUND
The natriuretic peptides are a structurally and functionally distinct group of peptides 
that play an important role in the regulation of cardiovascular and renal homeostasis. 
Recent studies have assessed the utility of natriuretic peptides in distinguishing
1 f\l 9 7 7between cardiac and non-cardiac dyspnea in the emergency department, ’ as a 
prognostic tool in patients with HF278’279 and acute coronary syndromes,280’ 281 and as 
a guide to medical therapy in patients with chronic HF.282,283 However, in a recent 
review of the diagnostic utility of natriuretic peptides for the detection of left 
ventricular (LV) dysfunction and HF, it was concluded that the body of evidence is 
“still a work in progress” .284 In particular, there are several limitations with studies 
that have sought to establish the clinical utility of natriuretic peptides for the 
diagnosis of left ventricular dysfunction. Often such studies are done using 
convenient samples in which cardiac structure and function are poorly characterised. 
Furthermore, most studies have focused on the utility of natriuretic peptides for the 
detection of systolic ventricular dysfunction, ignoring prognostically significant 
DD .20 Another important limitation of previous studies is their failure to evaluate the 
influence of the multiple determinants of circulating natriuretic peptides on the 
performance of the tests. Such information on the clinical validation of natriuretic 
peptide assays is a prerequisite for their optimal use as diagnostic tools in the
? o c
community.
The objectives of this study were to determine the clinical and echocardiographic 
determinants of circulating aminoterminal B-type natriuretic peptide (NT-proBNP) 
levels (proBNP®; Roche Diagnostics) in a population-based sample of older adults,
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establish reference ranges in subjects that have been rigorously assessed to be free of 
cardiovascular disease, and to evaluate the ability of NT-proBNP to detect subjects 
with LV systolic and diastolic dysfunction in the community. We hypothesised that a 
large proportion of apparent “false positives” could be explained after considering 
determinants of NT-proBNP levels.
6.3 METHODS
6.3.1 Subjects
Using simple random sampling from a population register (Federal electoral roll), 
2000 Canberra residents, aged 60-85, were selected to constitute our study 
population. Subjects were invited to participate by letter. Subjects provided written 
and informed consent, and 1229 participants (mean age 69.4; 50.1% women) 
completed all investigations relevant to this study between February 2002 and June 
2003.
6.3.2 Clinical assessment
Risk factors for HF were documented using a self-administered questionnaire. Body 
mass index was calculated as the weight divided by the squared height. Volume 
status was assessed clinically according to the jugular venous pressure, the presence 
of peripheral oedema and cardiorespiratory auscultation. Functional status was 
assessed using the NYHA classification. Creatinine clearance (CrCl) was 
calculated by applying relevant data to the Cockcroft-Gault formula.287
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6.3.3 Lifestyle factors
A validated, interviewer-administered physical activity questionnaire288 was used to 
assess time spent on physical activity during the preceding week, adjusting for the 
intensity of the activity. Data was collected on smoking status (non-smoker or 
current smoker), alcohol consumption (none, < 20g/day and > 20g/day) and daily 
consumption of caffeine-containing tea and coffee.
6.3.4 Cardiac structure and function
Transthoracic echocardiography was performed using the Acuson 128 XP/10 
according to a standardised protocol. Studies were recorded on tape and reviewed 
off-line by a cardiologist who was blinded to the participant’s clinical data. LV mass 
was estimated by the area-length method289 and indexed for height. EF was 
quantified by the biplane Simpson method using the 2-dimensional images from the 
apical 4- and 2-chamber views. Abnormal LV systolic function was categorised 
according to EF and the presence of regional wall motion abnormalities (regional 
wall motional abnormalities with EF>50%; EF 41-50%; EF <40%). DD was graded 
into 3 categories using Doppler evaluation of the mitral and pulmonary venous 
inflow and tissue Doppler imaging of the lateral mitral annulus motion (Table 6-1).
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Table 6-1 Doppler assessment of left ventricular diastolic function
M itra l  in f lo w P u lm o n a r y  v e n o u s  in f lo w T D I  M A M
0 .7 5 < E /A < 1 .5 S > D
N o rm a l
D T >  1 6 0 m s M V  A d u r >  P V  A d u r
E / e ’c l O
E /A < 0 .7 5 S > D
M ild  L V  d ia s to l i c  d y s f u n c t io n
D T > 2 4 0 m s M V  A d u r >  P V  A d u r
E / e ’c l O
0 .7 5 < E /A < 1 .5 S < D
M o d e r a te  L V  d ia s to l i c  d y s f u n c t io n
D T >  1 6 0 m s M V  A d u r + 3 0 m s <  P V  A d u r
E / e ’> 1 0
> 1 .5 S < D
S e v e r e  L V  d ia s to l i c  d y s f u n c t io n
D T <  1 6 0 m s M V  A d u r + 3 0 m s <  P V  A d u r
E / e ’> 1 0
At least 2 Doppler criteria consistent with moderate-severe DD were required to
distinguish from normal diastolic function. E, peak early mitral inflow filling 
velocity; A, peak mitral filling velocity at atrial contraction; DT, deceleration time of 
mitral E wave; MV Adur, duration o f mitral A wave; S, peak velocity o f pulmonary 
venous forward flow during systole; D, peak velocity o f pulmonary venous forward 
flow during diastole; PV Adur, duration o f pulmonary venous reversal wave at atrial 
contraction; e \ peak velocity o f lateral mitral annulus motion during early diastole. 
TDI MAM =  Tissue Doppler imaging of mitral annular motion
Subjects with indeterminate LV diastolic function and EF>40% were excluded for
evaluation of optimal discriminatory NT-proBNP levels. Maximum LA volume was
quantified using the area-length method and indexed for body surface area (LAVI).
Aortic and mitral valve function were quantified using Doppler methods. The
presence of right ventricular (RV) volume or pressure overload was determined using
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2-dimensional images of the right ventricle from the parasternal long and apical 4- 
chamber views and the RV systolic pressure estimated by Doppler assessment of 
tricuspid regurgitant jet.
6.3.5 NT-proBNP levels
Venous blood was collected in serum tubes, centrifuged and stored at -70°C until 
analysis. NT-proBNP levels were measured using a commercially available and fully 
automated electrochemiluminescence sandwich immunoassay on an Elecsys 1010 
(proBNP®, Roche Diagnostics). This immunoassay has a within run coefficient of 
variability (CV) of 0.7-1.6% and a between run CV of 5.3-6.7%.253
6.3.6 Statistical analysis
NT-proBNP levels were positively skewed and natural log-transformation was 
required to satisfy statistical modeling assumptions for regression analyses. For the 
entire cohort, echocardiographic and clinical variables were assessed for their 
univariate association with NT-proBNP using Spearman rho correlation. Variables 
with statistically significant associations with log NT-proBNP in the univariate 
analysis were included in the stepwise multivariable linear least-squares regression 
analysis, starting with a full model (STATA version 7.0, Texas, USA).
The reference subgroup considered for the derivation of reference ranges of 
NT-proBNP excluded subjects with atrial fibrillation, myocardial infarction, HT,
diabetes, renal impairment (creatinine>150jimol/l), echocardiographic evidence of
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abnormal cardiac structure/function (dilated cardiac chambers including 
LAVI>28mL/m , LV hypertrophy, abnormal LV systolic function, any DD, more 
than mild mitral or aortic valve disease and elevated RV systolic pressure), past or 
current clinical HF. Subjects on antihypertensive or diuretic medication were also 
excluded from the reference group. Analytical methods used on the entire cohort 
were employed to determine associations of NT-proBNP in the reference subgroup, 
and the result of the multivariable regression analysis was used to determine which 
parameters required partitioning in order to more accurately reflect NT-proBNP 
reference levels. From the least-squares regression model for log(NT-proBNP) with 
age and gender as predictor variables, 5th to 95th percentiles were estimated and 
back-transformed to the natural scale to derive gender-specific reference NT-proBNP 
ranges.
The ability of NT-proBNP to detect varying degrees of LV systolic and/or diastolic 
dysfunction in the entire cohort (n=1207) was assessed using receiver operating 
characteristic (ROC) analysis. The overall performance for the test over its entire 
range was quantified using the area under the ROC curve (AUC) curves within age- 
and gender-specific strata and compared using the method of DeLong.290 The 
diagnostic performance of NT-proBNP to detect LV dysfunction was evaluated using 
cutoff points based on:
i) age and gender-specific optimal discriminatory levels, identified as the 
NT-proBNP level that corresponded to the point on the ROC curve at 
the minimum distance to the 100% sensitivity/100% specificity point
ii) age- and gender-specific 95th percentiles from the reference subgroup
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iii) recommended decision threshold levels based on clinical data from
Roche Diagnostics291
6.4 RESULTS
6.4.1 Distribution of NT-proBNP levels
NT-proBNP levels are presented in Figure 6-1, stratified according to gender and LV 
function. There was a large overlap in NT-proBNP levels between groups with 
normal LV function and mild “isolated” DD (with EF>50%). However, NT-proBNP 
levels increased progressively with deteriorating LV function thereafter (all 
pcO.OOOl). In subjects with advanced isolated DD, NT-proBNP levels were higher 
than those with EF of 41-50% (p=0.002), but lower than subjects with EF<40%
(p=0.001).
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□  Men
□  Women
Normal Mild LVDD’ EF 41-50% Advanced LVDD* EF*40%
(n=688) (n=381) (n=43) (n=70) (n=25)
Figure 6-1 Median (bars) and interquartile range (error bars) for NT-proBNP 
levels according to gender and LV function.
NT-proBNP levels are presented in the logarithmic scale. *Mild DD and Advanced 
DD refer to diastolic dysfunction with EF>50%.
6.4.2 Associations with NT-proBNP in the entire cohort (n=1207)
In univariate analysis, age (rho=0.46), CrCl (rho=-0.41) and LAVI (rho=0.41) were 
most strongly correlated with NT-proBNP levels. All variables included in the 
multivariable model were associated (p<0.01) with NT-proBNP in univariate 
analysis. Associations between NT-proBNP and clinical and echocardiographic 
variables in the entire cohort in the multivariable analysis are reported in Table 6-2.
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Table 6-2 Multivariable associations with NT-proBNP levels in the entire cohort
Pred icto r (increm ent) ß* 95% C I p-value
A ge (per 1 year) 1.03 1.02, 1.04 <0.0001
W om en 1.39 1.27, 1.51 <0.0001
V olum e overload 1.16 1.03, 1.31 0.017
Functional C lass
N Y H A  C lass II 1.13 1.03, 1.23 0.007
N Y H A  C lass III 1.48 1.18, 1.86 0.001
N Y H A  C lass IV 4.32 1.16, 16.1 0.03
LV  systolic function
R W M A , E F>50% 1.40 1.15, 1.71 0.001
EF 41-50% 1.82 1.48, 2 .24 <0.0001
EF 31-40% 2.38 1.65, 3.42 <0.0001
EF<30% 2.98 1.86, 4 .76 <0.0001
LV  diasto lic  function
M ild DD 0.94 0.87 , 1.03 0.176
M oderate DD 2.24 1 .8 5 ,2 .7 0 <0.0001
Severe DD 4.87 2.62, 9.04 <0.0001
LV  m ass index (per 5 g/m ) 1.02 1.01, 1.03 <0.0001
L eft atrial volum e index (per m l/m 2) 1.01 1.01, 1.02 <0.0001
R V  volum e/p ressu re  overload 1.28 1.00, 1.67 0.049
C reatin ine  C learance (per m L /m in) 0.99 0.99 , 0.99 <0.0001
B ody M ass Index (per kg /m 2) 0.98 0.97, 0 .99 0.004
Pulse Pressure (per 5m m H g) 1.03 1.01, 1.04 0.001
A trial F ibrilla tion 2.69 2.02, 3.59 <0.0001
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*ß-coefficient is back-transformed to natural scale. Adjusted R~ for model=0.60. 
NYHA =  New York Heart Association; RV = right ventricular; RWMA = regional 
wall motion abnormality.
6.4.3 Associations with NT-proBNP in the reference subgroup (n=201)
In univariate analysis, increasing age (rho=0.34, pcO.OOOl) and LAVI (rho=0.15, 
p=0.03); female gender (pcO.OOOl); decreasing CrCl (rho=-0.31 pcO.OOOl); and 
coffee consumption (p=0.038) were associated with increased NT-proBNP levels. 
There was no association between NT-proBNP and heart rate (rho=-0.07, p=0.33), 
physical activity levels over the preceding week (rho=-0.03, p=0.65), tobacco 
smoking (p=0.53), or tea (p=0.79) consumption. NT-proBNP levels were not higher 
in healthy women on hormone replacement therapy (p=0.64), even after adjusting for 
age (p=0.51). Age, gender and LAVI were the only independent predictors of 
NT-proBNP levels in the reference subgroup. The addition of LAVI marginally 
improved the multivariable model for the prediction of NT-proBNP levels (R2 0.24 
to 0.25) and did not significantly alter the ß-coefficients for age and gender. Thus for 
simplicity, results of the multivariable analysis with age and gender as the only 
predictor variables were used to construct nomograms for NT-proBNP reference 
levels (Figure 6-2).
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Percentile
95th I I Recommended 
75th threshold level
50th A Str^um - 
2 5 +k specific cut-off
(45.9)4
(433 )a
(20.4)4
10 -
Age of men (years) Age of women (years)
Figure 6-2 NT-proBNP (Roche Diagnostics) reference ranges.
Reference limits are illustrated as 5th, 25th, 50th, 75th, and 95th percentile levels. 
Cutoff NT-proBNP levels based on 95th percentiles, current recommended threshold 
levels and age/gender-specific optimal discriminatory points are compared.
6.4.4 NT-proBNP utility to detect LV dysfunction in entire cohort
The results of the ROC analyses for the detection of varying degrees of LV systolic 
and diastolic dysfunction are displayed in Figure 6-3.
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1-Sp*cilci1f 1 6peci««*y
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Figure 6-3 Overall performance of NT-proBNP for the detection of EF<40% 
and/or moderate-severe DD, according to (A) age and sex ( P = 0.26); history of 
(B) hypertension ( P = 0.83); (C) diabetes ( P = 0.31); (D) coronary artery 
disease ( P = 0.90); or (E) body mass category ( P = 0.35).
157
Age and gender did not impact on the overall performance of NT-proBNP to detect 
any degree of LV dysfunction (p=0.19); EF<50% and/or advanced DD (p=0.43); or 
advanced LV dysfunction (p=0.78). The performance of NT-proBNP to detect any 
degree of LV dysfunction, including mild DD, was poor (AUC 0.56-0.66). In 
contrast, the performance of NT-proBNP for the detection of EF<40% and moderate- 
severe DD was strong with AUC levels consistently above 0.90 regardless of age and 
gender. Further analysis of NT-proBNP performance has been limited to the 
detection of EF<40% and moderate-severe DD, as this approach is more likely to 
represent the optimal use of NT-proBNP for the detection of LV dysfunction in the 
community.
Age and gender had a greater impact on 95th percentile reference limits than on 
optimal discriminatory NT-proBNP levels for the detection of EF<40% and 
moderate-severe DD (Figure 6-3). The disparity between optimal discriminatory and 
reference limits was most evident for women aged >75 years. Consequently, in this 
subgroup, identification of LV dysfunction with 95th percentile reference limits 
resulted in an almost 3-fold increase in missed advanced LV dysfunction cases 
(Table 6-3).
Compared to optimal discriminatory levels, recommended decision threshold levels 
based on data from Roche Diagnostics were lower in subjects aged 60-74 years, 
particularly for women; and much higher in subjects aged >75 years. Consequently, 
application of currently recommended cutoffs resulted in an increased false positive 
rate in subjects aged 60-74 in whom disease prevalence was low, and an increased 
false negative rate for those aged >75 years in whom disease prevalence was higher.
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C U TO FF STR ATEG Y
N T-PR O BN P
LEVEL
p m o l/L  pg /m L
SENS
( % )
SPEC
(% ) LR+
M ISSED
DISEA SE  
LR- (% )
M en 60-74 (Prevalence = 7.2%  ; A U C =0.93, 95%  C l 0.88-0.98)
S tra tu m -sp ec ific  O D P 20 .4 173 88 89 7.8 0 .1 4 12
9 5 th  P ercen tile 17.5 148 91 86 6.6 0.11 9
R eco m m en d ed  th resh o ld 14.8 125 91 84 5.6 0.11 9
M en 75-86 (Prevalence = 14.2% ; A U C =0.90, 95% C l 0.84-0.95)
S tra tu m -sp ec ific  O D P 4 5 .9 388 95 80 4 .8 0 .06 5
9 5 th  P ercen tile 37.5 317 95 76 4 .0 0 .06 5
R eco m m en d ed  th resh o ld 53 .2 4 5 0 86 85 5.5 0 .17 14
W om en 60-74 (Prevalence = 4.9%  ; A U C =0.90, 95% C l 0.82-0.98)
S tra tu m -sp ec ific  O D P 3 2 .0 270 83 91 9 .6 0 .1 9 17
9 5 th  P ercen tile 3 2 .0 27 0 83 91 9 .6 0 .19 17
R eco m m en d ed  th resh o ld 14.8 125 91 64 2.5 0 .1 4 9
W om en 75-86 (Prevalence = 16.4% ; A U C =0.91, 95% C I 0.83-0.98)
S tra tu m -sp ec ific  O D P 43 .3 366 88 85 5.7 0 .15 12
9 5 th  P ercen tile 6 6 .6 563 67 92 7.9 0 .35 33
R eco m m en d ed  th resh o ld 53 .2 4 5 0 75 89 5.9 0 .2 9 25
AUC = area under receiver operating characteristic curve; LR+ =positive likelihood 
ratio; LR- =negative likelihood ratio; Missed disease = proportion o f subjects with 
LV dysfunction who would have been missed with NT-proBNP test; ODP = optimal 
discriminatory point based on receiver operating characteristic curve analysis; Sens 
=sensitivity; Spec =specificity; Recommended threshold 291
Table 6-3 Performance of NT-proBNP in detecting EF <40% and/or moderate- 
severe DD
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Using NT-proBNP cutoffs of 20pmol/L for men aged 60-74, 30pmol/L for women 
aged 60-74 and 40pmol/L for subjects aged >75; one subject with an LVEF<40% 
(male, aged 67, EF=40%) and 10 subjects with moderate-severe DD (60% female, 
mean age 72 years) were missed with NT-proBNP testing. Of the 143 subjects with 
false positive tests, 70 subjects had milder degrees of LV dysfunction (20 with 
EF = 41-50%, 21 with LV regional wall motion abnormalities and EF>50%; and 29 
with impaired relaxation and evidence of increased LV filling pressure [as defined by
'y
Doppler-echo or an otherwise unexplained LAVI>28mL/m ]); 21 with increased LV 
mass (>132g/m for women and >157g/m for men); 16 with LAVI>28mL/m2 and no 
evidence of DD or mitral valve disease; 4 with dilated RV; and 15 with 
CrCl<60ml/min. Only 17 individuals did not have an identifiable cardiorenal cause 
for an elevated NT-proBNP level.
6.5 DISCUSSION
In this large population-based cohort of older adults, some of the complexities of 
using NT-proBNP as a tool for the detection of LV dysfunction have been identified 
and explored.
6.5.1 Determinants of NT-proBNP
An understanding of the determinants of NT-proBNP in the community is a
prerequisite for its optimal use as a diagnostic tool for LV dysfunction. Results of our
multivariable analysis could serve as a guide to determine the extent to which each
factor influences NT-proBNP and identify potential sources of elevated NT-proBNP
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levels other than parameters of LV function, which may be the cause of apparent 
“false positive” tests.
Our observations provide a valuable insight into the relationship between natriuretic 
peptides and mild isolated diastolic function, a topic of recent dispute. Lubien et al176 
assessed the relationship between BNP levels and diastolic function in clinic-based 
patients with preserved systolic function. These investigators observed that BNP 
levels increased with progressive stages of DD and found that patients with mild DD 
had significantly higher BNP levels than those with normal diastolic function.176 
Indeed, they found that the performance of BNP for the detection of mild isolated 
DD was good (AUC 0.87). However, since then, several studies with differing study 
populations have provided conflicting results.292"294 We have confirmed that 
NT-proBNP levels were increased in subjects with advanced isolated DD, in whom 
LV filling pressures were raised. In a proportion of such cases, preload-dependent 
mitral inflow Doppler patterns were only mildly impaired. Such subjects are more 
likely to be symptomatic and to constitute cases of “mild” isolated DD in studies 
with samples referred to a clinic for LV assessment. However, in this population- 
based sample, we have shown that NT-proBNP was a poor marker of mild isolated 
DD.
6.5.2 Reference limits
Prior efforts to define NT-proBNP reference limits have been on clinic-based294,295
or convenience samples291. For instance, reference ranges cited by the manufacturer
of the NT-proBNP assay used in this study were derived from a population that was
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incompletely characterised by an assessment of cardiac function and structure and
291included subjects with diabetes, HT, pulmonary disease and renal insufficiency.
As expected, reference limits from such a heterogeneous population were higher than 
those derived in our population-based sample.
In this study, we have extended efforts by previous investigators to restrict the 
reference subgroup to subjects free of any identifiable cardiovascular disease. 
Comprehensive Doppler-echo methods were employed to exclude subjects with any 
DD from the reference subgroup. In addition, subjects with a dilated left atrium or 
significant renal dysfunction were excluded for the derivation of reference limits 
since these conditions have been recognised as subclinical markers of increased 
cardiovascular risk2 0 ,296 and were independently associated with increasing levels of 
NT-proBNP in our cohort. Despite our efforts to rigorously define the reference 
subgroup, the association between age, gender and NT-proBNP levels was 
reconfirmed in this study. Accordingly, we have presented reference limits that are 
stratified according to age and gender. Data from longitudinal studies are required to 
determine if the increase in NT-proBNP levels with advancing age is related to 
occult pathophysiological rather than physiological influences, in which case 
age-specific reference limits may be unwarranted.
A novel and important aspect of this study was the evaluation of impact of lifestyle 
factors on the relationship between age, gender and NT-proBNP levels. Experimental 
animal studies have demonstrated that chronic moderate ethanol exposure results in a 
lowering of circulating BNP levels297 that may be related to an inhibition of 
natriuretic peptide gene expression.298 In our study, lifestyle factors did not alter the
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impact of age or gender on NT-proBNP levels. Interestingly, despite excluding 
subjects with any DD, more than mild valvular heart disease and LA enlargement 
(>28mL/m2) from the reference subgroup, there was an independent positive 
association between LAVI and NT-proBNP levels. Since LA size is a marker of 
chronic diastolic burden,155 this finding may reflect increases in NT-proBNP levels 
associated with a chronic exposure to DD that is undetectable by Doppler-echo 
assessment of resting instantaneous diastolic function grade.
6.5.3 NT-proBNP detection of LV dysfunction in the community
This is the first study to assess the value of NT-proBNP for the detection of LV 
dysfunction, including isolated DD as evaluated using comprehensive Doppler 
echocardiography, in a population-based sample. Previous studies have determined 
the performance of the assay to detect either systolic299'302 or isolated DD294 in clinic- 
based populations. The evaluation of the performance of NT-proBNP to detect 
both systolic and predominantly diastolic LV dysfunction is important for a number 
of reasons. In recent years, it has been recognised that almost half of HF cases have 
an EF>50%,54 and that DD in the community confers an adverse prognosis.20 
Consequently, a contemporary assessment of LV function should routinely 
incorporate an assessment of both systolic and diastolic function. Furthermore, given 
the large overlap in NT-proBNP levels between subjects with systolic dysfunction 
and predominantly DD, the specificity of NT-proBNP will appear to be reduced if its 
diagnostic role is limited to the detection of those with systolic dysfunction, due to 
“false negative” results in subjects with predominantly DD. Indeed, we have
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confirmed that a large proportion of the “false positive” tests occurred in subjects 
with elevated NT-proBNP levels related to prognostically significant cardiorenal 
diseases. Since the impact of age and gender on reference limits was greater than 
their effect on optimal discriminatory levels, we would advise against a common 
practice of using reference limits as thresholds for the detection of LV dysfunction in 
the community. Such a strategy is likely to result in reduced NT-proBNP 
performance as a “rule out” test, particularly in older women.
Our results should not be extrapolated to patients presenting acutely with dyspnea for 
investigation. Since natriuretic peptide levels are also raised by non-cardiac causes of 
acute dyspnea, NT-proBNP cutoff levels have been set higher to optimise the 
diagnosis of acute HF in the emergency department.277 Moreover, the overall 
performance of the test is also likely to vary depending on the setting in which it is 
employed, although a recent study has shown that even in the emergency department, 
the performance of NT-proBNP for the diagnosis of acute HF was very good (AUC 
0 .94).277
6.5.4 Limitations
Echocardiographic methods are imperfect “gold” standards for the classification of 
systolic and diastolic function. However, these methods are currently accepted as the 
reference standard for the assessment of LV function in clinical practice, and we 
could not justify the evaluation of diastolic function in survey participants with
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invasive tests. While our sample of older adults represents a suitable population for 
which natriuretic peptides would have potential use in the diagnosis or screening of 
HF, study findings may not be valid in younger subjects. As the vast majority of the 
sample was Caucasian, our results may not be applicable to non-Caucasian 
populations.
6.5.5 Conclusions
NT-proBNP is a suboptimal marker of mild LV dysfunction but performs strongly as 
a marker of EF<40% and/or moderate-severe DD in the community.
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C hapter 7: PULSE PRESSURE 
AND PULSE WAVE VELOCITY 
FOR THE DETECTION OF 
PRECLINICAL LEFT 
VENTRICULAR 
DYSFUNCTION IN THE 
COMMUNITY
Published in part in:
Abhayaratna WP, Srikusalanukul W, Budge MM. Aortic Stiffness for the Detection 
of Preclinical Left Ventricular Diastolic Dysfunction: Pulse Wave Velocity versus 
Pulse Pressure. J Hypertension 2008;26:758-64.
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7.1 ABSTRACT
Objective: An age-dependent relationship between aortic and left ventricular (LV) 
stiffening has been observed in community-based adults. Our aim was to compare 
the performances of wave reflection-dependent (pulse pressure) and independent 
[carotid-femoral pulse wave velocity (PWV)] indexes of aortic stiffness to detect 
preclinical LV diastolic dysfunction.
Methods. In this case-control study, a stratified subsample of participants of a 
population-based echocardiographic survey with LV ejection fraction higher than 
45% and without overt HF was randomly selected to undergo assessment of brachial 
BP, LV diastolic function by Doppler echocardiography, and estimation of central 
aortic pressures and PWV by applanation tonometry.
Results. Of the 233 subjects (mean age 73 ± 6 years, 54% men), 84 had normal 
diastolic function, 99 had mild diastolic dysfunction, and 50 had moderate or severe 
diastolic dysfunction. Brachial pulse pressure, central pulse pressure, and PWV 
progressively increased according to the severity of diastolic dysfunction, 
independent of age and sex. The overall performance of PWV was superior to 
brachial pulse pressure [area under receiver operating characteristic curve (AUC): 
0.70 versus 0.59, respectively; P = 0.005] and central pulse pressure (AUC: 0.70 
versus 0.56, respectively; P = 0.001) for the detection of any diastolic dysfunction.
Conclusion. PWV appeared to be superior to central and brachial pulse pressure 
for the detection of diastolic dysfunction in older adults with ‘preserved’ LV ejection 
fraction.
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7.2 BACKGROUND
Recently, the prognostic value of two integrative markers of cardiovascular disease 
has been demonstrated in the general population. First, noninvasive indices of aortic 
stiffness such as pulse pressure and carotid-femoral pulse wave velocity (PWV) have 
been shown to predict cardiovascular outcomes in the community, independent of 
traditional risk factors.2 06 ,207 Second, left ventricular (LV) diastolic dysfunction has 
been shown to be increasingly prevalent with advancing age and, although most 
frequently found in the preclinical phase of disease, is a predictor of all-cause 
mortality.20
Although the mechanisms underlying the prognostic value of aortic stiffness and DD 
have not been fully determined, a common causal path way may be present whereby 
increased aortic stiffness promotes ventricular remodelling and the development of 
DD. Indeed, recent cross-sectional studies85, 86, 226, 275, 304' 307 have observed age- 
related coupling of ventricular-vascular function and reported a positive association 
between aortic stiffness and DD. Whether measurement of aortic stiffness can be 
utilized to screen for DD in the community is not known.
In this population-based study, we evaluated the association between pulse pressure, 
PWV and diastolic function in subjects with ‘preserved’ EF. Furthermore, we 
compared the utility of PWV and pulse pressure to detect preclinical DD. We 
hypothesised that PWV would be superior to pulse pressure for screening DD, as the 
latter index of aortic stiffness, despite being easy to measure, is also influenced by 
other determinants of aortic wave reflection such as height and heart rate.
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7.3 METHODS
7.3.1 Study population
In March 2002, 2000 Canberra residents of age 60-85 years were randomly selected 
from a general population list (Federal electoral roll) and invited to participate in an 
echocardiographic survey that was conducted in 2002-2003. The participation rate 
for the survey was 75%. In this nested case-control study, a subsample of 
participants with preserved systolic dysfunction (EF > 45%) and without more than 
mild mitral or aortic valve disease was selected using stratified random sampling 
according to the diastolic function grade determined in the parent study, age (62-74 
and > 75 years) and sex. The participation rate for this study was 96% and subjects 
underwent assessment between February 2004 and June 2004. All participants 
provided informed consent.
7.3.2 Echocardiographic assessment of cardiac structure and function
Cardiac structure and function was assessed by one of two experienced sonographers 
using transthoracic echocardiography (Acuson Sequoia, Mountain View, California, 
USA) according to a standardised protocol. Measurements were made on-line and 
recorded digitally with participants' initials and study number as their only 
identification. A cardiologist, blinded to the participant's clinical data, interpreted the 
echocardiogram after review off-line. LV diastolic function was graded into four 
categories using Doppler evaluation of the mitral and pulmonary venous inflow and 
tissue Doppler imaging of the lateral mitral annulus motion as previously detailed 
[normal diastolic function; Grade 1 DD (impaired relaxation mitral inflow pattem);
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Grade 2 DD (pseudonormal mitral inflow pattern); and Grade 3/4 DD (restrictive 
mitral inflow pattem)].309 Interoperator (k = 0.98), intraobserver (k = 0.98) and 
interobserver (k = 0.9) reproducibility for diastolic function grading was very good. 
LV mass was quantified using the area-length method248 and indexed for body 
surface area. EF was quantified by the biplane disc summation method (Simpson's 
rule) using the two-dimensional echocardiography images from the apical four- and 
two-chamber views.248
7.3.3 Assessment of cardiovascular risk factors
A self-administered questionnaire was used to gather data on a history of CAD, HT, 
hyperlipidemia, diabetes and smoking status. Brachial artery systolic and diastolic 
BP was measured using a mercury sphygmomanometer after 10 min of rest in a 
seated position; three sets were averaged for each participant. Height and weight 
were measured without shoes and in light clothing. BMI was calculated for each 
participant as weight in kilograms divided by the square of height measured in 
metres.
7.3.4 Assessment of aortic pulse wave velocity
PWV was assessed noninvasively using the Sphygmocor system (AtCor Medical, 
Sydney, Australia) on the day of the echocardiography assessment and after an 
overnight fast. Electrocardiogram-gated carotid and femoral waveforms were 
recorded using applanation tonometry. Carotid-femoral path length was measured as
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the difference between the surface distances joining the suprasternal notch, the 
umbilicus and the femoral pulse and the suprasternal notch and the carotid pulse. 
Carotid-femoral transit time was estimated in 8-10 sequential femoral and carotid 
waveforms as the average time difference between the onset of the femoral and 
carotid waveforms. PWV was calculated as the carotid-femoral path length divided 
by the carotid-femoral transit time.
7.3.5 Statistical analysis
Data are summarized as mean values ± 1 SD for continuous variables or as frequency 
percents for categorical variables. Baseline characteristics of the sample were 
compared according to diastolic function status using Kruskal-Wallis tests for 
continuous variables and ordinal logistic regression for categorical variables.
The effects of age on pulse pressure, aortic stiffness, LV relative wall thickness, LV 
mass, LV filling pressure [as determined by the ratio of mitral inflow early diastolic 
velocity (E) and the early diastolic annular velocity (Ea); E/Ea) and LV relaxation 
(Ea) were assessed separately in men and women using Spearman [rho] correlation. 
Age-adjusted associations between sex and log-transformed indices of arterial 
stiffness, LV mass, LV filling pressure and LV relaxation were evaluated using least- 
squares linear regression, and an interaction term with age and sex was assessed to 
determine whether the effect of age on the individual indices parameters varied 
according to sex.
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Univariate associations between pulse pressure, PWV and clinical or 
echocardiographic parameters were assessed using Spearman [rho] correlation. 
Age/sex-adjusted associations between pulse pressure or PWV and selected 
echocardiographic parameters (dependent variable) were examined with least- 
squares linear regression. The association between diastolic function grade and 
clinical parameters, echocardiographic variables and pulse pressure or PWV was 
examined using multivariable ordinal logistic regression (STATA Version 8.0; 
STATA Corp., College Station, Texas, USA). The base model consisted of age, sex 
and pulse pressure or PWV and stepwise models were constructed by the addition of 
univariate clinical correlates (p <0.10) of diastolic function grade, echocardiographic 
correlates of diastolic function grade and lastly BP parameters. First-order 
interactions between age, sex and echo-clinical predictors of diastolic function grade 
were also assessed in the model.
The utility of PWV to detect any level of DD or advanced (moderate or severe) DD 
was compared with that of pulse pressure using receiver-operating analyses. Areas 
under the receiver-operating characteristic curves (AUC) were compared using the 
method of DeLong et al.290 All hypothesis testing was two sided and statistical 
significance was declared if p< 0.05.
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7.4 RESULTS
7.4.1 Clinical characteristics
Baseline characteristics of the 233 study participants (mean age 73 ± 6 years, 54% 
men) are outlined in Table 7-1, stratified by diastolic function status. Clinical 
correlates of DD included advancing age and a history of HT, diabetes mellitus and 
CAD.
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Table 7-1 Baseline characteristics according to diastolic function grade*
N orm al D FG  
(n=84)
G rade 1 DD 
(n=99)
G rades 2-4 DD 
(n=50)
p-value
A ge, y (SD) 71.2 (5.7) 73.8 (6.1) 76.2  (6.1) <0.0001
M en, n ( % ) 45 (54) 58 (59) 23 (46) 0.58
H ypertension , n ( % ) 35 (42) 54 (55) 36 (72) 0.001
D iabetes, n (% ) 4 ( 5 ) 11 (11) 7 (1 4 ) 0.06
C oronary  artery  d isease, n (% ) 9 (1 1 ) 1 2 (1 2 ) 1 2 (2 4 ) 0.05
H yperlip idem ia, n (% ) 30 (36) 50 (51) 18 (36) 0.58
H istory  o f sm oking, n (% ) 48 (57) 62 (63) 20 (40) 0 .14
V asoactive  m edications, n (% ) 29 (34) 59 (60) 35 (70) <0.001
LV  relative w all th ickness 0 .40 (0.07) 0 .44 (0.09) 0 .47 (0.17) 0.001
Indexed LV m ass, g /m 2 (SD ) 8 9 .6 (1 5 .0 ) 105.8 (19.9) 117.3 (29.9) <0.001
LV ejection  fraction , % (SD ) 65.8 (6.6) 63.6 (9.0) 6 6 (1 0 ) 0.71
B rachial systo lic  BP, m m H g (SD) 135 (17) 139 (19) 1 4 8 (2 0 ) <0.0001
C entral systo lic  BP, m m H g (SD ) 128 (17) 130 (20) 140 (21) <0.001
B rachial d iasto lic  BP, m m H g (SD ) 80 (7) 83 (10) 81 (10) 0.29
C entral d iasto lic  BP, m m H g (SD) 81 (7) 8 4 (1 0 ) 8 2 (1 0 ) 0.37
B rachial pu lse  pressure, m m H g (SD ) 5 5 (1 6 ) 5 7 (1 5 ) 67 (17) <0.001
C entral pulse pressure, m m H g (SD ) 47 (16) 4 7 (1 5 ) 58 (17) <0.001
M ean arterial pressure, m m H g (SD) 99 (9) 103 (12) 1 0 4 (1 3 ) 0.02
*Preserved systolic function (LV ejection fraction >45%), no more than mild mitral 
or aortic valve disease. BP = blood pressure; DD =  diastolic dysfunction
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A graded association existed between increasing severity of DD and increased PWV 
(Table 7-2), indexed LV mass, systolic and pulse pressure (all p < 0.0001), LV 
relative wall thickness (p = 0.001) and mean arterial pressure (p = 0.02).
Table 7-2 Median aortic PWV (interquartile range) according to age, gender 
and diastolic function grade
Aortic PWV (m/s)
Normal diastolic function Grade I DD Grade II-IV DD p-value
Women; 62-74 years 9.2 (8.2-10.1) 10.3 (8.9-12.1) 10.7 (8.4-13) 0.01
Women: 75+ years 9.6(8.8-11.6) 10.7 (9.9-13.1) 12.6(11.6-14.1) 0.002
Men: 62-74 years 9.6 (7.9-10.5) 10(8.4-11.7) 12.3 (10.7-12.7) 0.005
Men: 75+ years 10.2 (9.3-10.9) 11.4(10-13.7) 12.1 (9.7-12.9) 0.13
7.4.2 Association between age, gender and indices of arterial stiffness
The effects of age and sex on indices of aortic stiffness and selected parameters of 
LV structure and diastolic function are detailed in Table 7-3. There was a trend to 
suggest that age-associated differences in indices of arterial stiffness and LV 
remodelling and diastolic function were steeper in women than in men; PWV; 
ß = 0.19 versus 0.11 m/s for each year, respectively; LV mass index: ß = 0.83 versus 
0.40 g/m2 for each year, respectively; E/Ea: ß = 0.20 versus 0.05 for each year, 
respectively; Ea: ß = -0.08 versus -0.07 cm/s for each year, respectively.
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Table 7-3 Association between of age, gender and indices of aortic stiffness, and 
selected parameters of LV structure and diastolic
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7.4.3 Association between arterial stiffness and diastolic function
Univariate associations between PWV and history of HT and diabetes mellitus, body 
mass index, LV mass index, Ea, E/Ea and diastolic function grade were stronger in 
women than in men (Table 7-4).
T able 7-4 U nivariate associations betw een aortic  
param eters, stratified by gender
PW V and clin ical/echo
A ortic  PW V
W om en M en
rho p-value rho p-value
H ypertension 0.33 <0.001 0.20 0 .026
D iabetes 0.17 0.08 0.05 0.57
C oronary  artery  d isease 0.12 0.23 0.13 0.13
H eart rate 0 .14 0.16 0.07 0.41
B rachial systo lic B P 0.47 <0.001 0.42 <0.001
C entral systo lic BP 0.46 <0.001 0.42 <0.001
B rach ial d iasto lic  BP 0.15 0 .14 0.14 0.13
C entral d iasto lic  B P 0.16 0.10 0.16 0.08
B rachial pulse pressure 0.47 <0.001 0 .40 <0.001
C entral pulse pressure 0.48 <0.001 0.36 <0.001
M ean arterial pressure 0.38 <0.001 0.36 <0.001
B ody m ass index 0.31 0.001 0.03 0.77
Ea -0.31 0.001 -0.16 0.07
E /E a ratio 0.27 0.005 0.19 0.039
Indexed LV  m ass 0.25 0.009 0.07 0.46
LV  ejection  fraction 0.09 0.34 0.01 0.91
D iasto lic  function  grade 0.44 <0.001 0.31 <0.001
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The independent associations between PWV, diastolic function grade and significant 
covariates did not differ according to sex, and sex-pooled estimates are presented in 
(Table 7-5). After adjusting for age, sex, clinical risk factors, LV mass index and 
mean arterial pressure, the odds of DD were 22% higher with every 1 m/s increase in 
PWV. In contrast, neither brachial nor central pulse pressure was significantly 
associated with diastolic function grade in the multivariable models (Table 7-5).
Table 7-5 Association between indexed aortic PWV and diastolic dysfunction
Odds Ratio p-value
A ortic PW V  (per 1 m /s) 1.22 0.001
A ge (per 5 years) 1.39 0.005
Fem ale gender 1.64 0.07
H ypertension 1.60 0.09
D iabetes 3.01 0.02
Indexed LV  m ass (per 5 g/m 2) 1.25 <0.0001
P>0.20: history o f coronary artery disease, hyperlipidemia or smoking; body mass 
index; mean brachial artery pressure; brachial pulse pressure.
7.4.4 PWV and pulse pressure for the detection of diastolic dysfunction
PWV and pulse pressure performance did not vary according to sex for the detection 
of any DD (p = 0.38 and p = 0.06, respectively) or advanced DD (p = 0.44 and
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p = 0.33, respectively). Sex-specific optimal discriminatory cut-offs were also similar 
for both sexes (Table 7-6). Accordingly, sex-pooled receiver-operator analyses were 
performed to compare the utility of PWV and pulse pressure for the detection of DD 
(Figure 7-1).
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7.5 DISCUSSION
Our findings support the concept that increased aortic stiffness is associated with
on oc T/V7
load-dependent alterations in diastolic function. Previously, most studies ’ ’ have 
investigated the relationship between arterial stiffness and diastolic function in 
clinic-based populations. More recently, Redfield et al. demonstrated a positive 
association between advancing age, female sex and echocardiographic indices of 
vascular and ventricular stiffness in a community-based study. In this population- 
based study, a similar effect of female sex on the relationship between age, aortic 
stiffness and diastolic function was found. We have extended previous findings by 
confirming a direct association between PWV and diastolic function grade, which is 
independent of clinical-echocardiographic predictors of DD and distending arterial 
pressure. Additionally, we have shown that the overall performance of PWV to 
detect the presence of DD was superior to pulse pressure, a widely accepted 
surrogate measure of arterial stiffness.
7.5.1 Relationship between arterial stiffness and diastolic dysfunction
Since our data are cross-sectional, we are unable to determine the causal relationship 
between PWV and DD. Such a relationship, however, is biologically plausible and 
temporally feasible. Numerous potential pathways exist whereby increased aortic 
stiffness may result in DD. Stiffening of the aorta increases PWV, resulting in the 
earlier return of wave reflection from the periphery to the proximal aorta, an 
augmentation of aortic systolic pressure and a decrease in aortic pressure during 
diastole.81 The resultant increase in afterload during LV systole and relative
reduction in coronary perfusion during LV diastole may promote LV concentric
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remodelling and hypertrophy ’ and retard LV relaxation . In addition,
T 1 o
development of subendocardial ischemia may lead to further impairment of 
myocardial relaxation and promotion of interstitial fibrosis with a subsequent 
reduction in LV compliance 314 and global LV long axis systolic function82. Further, 
age-related increases in PWV appear to precede Doppler abnormalities in diastolic 
function. Numerous population-based studies in adults have shown that PWV rises at 
a constant rate up to the age of 40 years and then rises exponentially thereafter even 
in the absence of identifiable cardiovascular risk factors.180, 315 In contrast, the 
prevalence of any DD by echocardiography is rare prior to the age of 60 years in the 
absence of cardiovascular risk factors.20,309 Longitudinal studies will be required to 
describe the natural history of diastolic function and determine whether individuals 
with increased PWV (or a greater rise in PWV over time) during middle age are 
more likely to develop DD and perhaps HF thereafter.
7.5.2 PWV versus pulse pressure as a marker of arterial stiffness
Although there is consensus that widened pulse pressure and increased PWV are 
both manifestations of aortic stiffness, the indices do not represent the same 
components of arterial function . Pulse pressure is dependent on the timing and 
amplitude of arterial wave reflection, and is therefore significantly influenced by 
characteristics such as heart rate and height as well as properties relating to arterial 
function. Furthermore, due to the phenomenon of pulse pressure amplification in 
peripheral arteries, brachial and aortic pressures may differ vastly, particularly in the 
younger adult, and the central BPs are proposed to be a more reliable measure of 
target organ load.316 In contrast, PWV represents a measure of aortic stiffness that is
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Table 7-6 Utility of aortic pulse wave velocity and brachial pulse pressure to 
detect diastolic dysfunction
AUC
(95%CI)
Optimal
cut-off
Sens
(%)
Spec
(%) LR+ LR-
Men: Any diastolic dysfunction (n=81)
Aortic pulse wave velocity (m/s) 0.67 (0.58-0.77) 11.1 51 80 2.5 0.62
Brachial pulse pressure (mmHg) 0.52 (0.42-0.63) 64 31 78 1.4 0.89
Central pulse pressure (mmHg) 0.50 (0.41-0.59)
Women: Any diastolic dysfunction (n=68)
Aortic pulse wave velocity (m/s) 0.73 (0.64-0.83) 11.1 54 82 3.0 0.56
Brachial pulse pressure (mmHg) 0.67 (0.56-0.77) 65 51 79 2.5 0.61
Central pulse pressure (mmHg) 0.66 (0.56-0.74) 57 49 74 1.9 0.69
Men: Moderate or severe diastolic dysfunction (n=23)
Aortic pulse wave velocity (m/s) 0.67 (0.54-0.80) 12.0 61 77 2.6 0.51
Brachial pulse pressure (mmHg) 0.64 (0.50-0.78) 66 48 82 2.6 0.64
Central pulse pressure (mmHg)
Women: Moderate or severe diastolic dysfunction (n=27)
Aortic pulse wave velocity (m/s) 0.74 (0.62-0.85) 11.9 67 78 3.0 0.43
Brachial pulse pressure (mmHg) 0.73 (0.62-0.84) 69 63 75 2.6 0.56
Central pulse pressure (mmHg)
AUC  =  area under receiver operating characteristic curve; Cl =  confidence 
interval; LR+ = positive likelihood ratio; LR- =  negative likelihood ratio; Sens 
=sensitivity; Spec =specificity
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The overall performance of PWV was superior to brachial pulse pressure (AUC: 0.70 
versus 0.59, respectively; p = 0.005) and central pulse pressure (AUC: 0.70 versus 
0.56, respectively; p = 0.001) for the detection of any DD. The poor performances of 
pulse pressures were due to the large overlap in subjects with normal diastolic 
function and those with mild diastolic function (Grade 1). No difference, however, 
existed in the utility of these indices of aortic stiffness for the detection of advanced 
DD (p = 0.85).
P = 0,002
0.50
1 - S p e c i f i c i t y
Figure 7-1 Comparison of overall performances of pulse wave velocity and pulse 
pressure for the detection of diastolic dysfunction.
Pulse wave velocity: area under receiver-operating characteristic curve
(AUC) = 0.70. Brachial pulse pressure: AUC  =  0.59. Central pulse pressure: AUC
=  0.56.
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independent of wave reflection.310 To the best of our knowledge, this is the first 
study to compare the utility of pulse pressure and PWV for screening of LV 
dysfunction. We found that the value of PWV as a screening tool in this study was 
modest but superior to pulse pressure for the detection of preclinical DD, including 
‘mild’ DD. Although early alterations in myocardial relaxation and LV filling have 
been clinically regarded as a part of the normal ‘ageing’ process, recent findings 
have highlighted the importance of LV diastolic function as a robust and independent 
marker of increased risk of death in community-based adults. Consistent with 
previous studies181 showing an age-related loss of peripheral pressure amplification, 
we found that there was low pulse pressure amplification between central and 
brachial BPs in this sample of older adults. Accordingly, estimation of central 
pressures using applanation tonometry did not improve the performance of pulse 
pressure for the identification of subjects with DD.
7.5.3 Implications
Our results have important clinical and methodological implications. First, since 
PWV is modifiable with medical therapy, ’ its value as an intermediate outcome 
for future therapeutic studies on patients with DD or HF should be determined. 
Perhaps more importantly, strategies incorporating PWV as a tool for the 
identification of subjects with increased aortic stiffness should be considered in 
primary prevention studies of DD, a condition associated with adverse prognosis in 
the community. Second, the association between female sex and age-associated 
increases in aortic stiffness, concentric LV remodelling and Doppler parameters of
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LV relaxation and filling pressure may at least partly account for the consistent 
observation of preponderance of women in community-based studies54, 308 of HF 
with preserved EF. Finally, future studies assessing the incremental value of PWV as 
a risk marker for the development of adverse cardiovascular outcomes such as 
congestive HF, atrial fibrillation and cardiovascular death should adjust for the 
potential intermediary effects of DD.
7.5.4 Limitations
Several potential limitations should be considered when interpreting our results. The 
study population was not ethnically diverse (97% white) and the association between 
PWV and diastolic function was determined using cross-sectional data. Thus, further 
work is required to confirm our results in other population groups and to delineate 
the temporal relationship between PWV and diastolic function. The majority of our 
sample was treated chronically with antihypertensive medications that may 
differentially modify indices of aortic stiffness and DD and alter the true relationship 
between these physiological risk markers. Given that a decrease in PWV to BP 
reduction is, however, more likely to be related to change in distending pressure than 
to the effects on aortic stiffness, one could argue that the relationship between PWV 
and DD could be attenuated in patients on vasoactive medication. Further, with the 
widespread prescription of antihypertensive medications in older adults, such a 
limitation is unavoidable in population-based studies.
7.5.5 Conclusion
Our results suggest that age-related deterioration in DD is independently associated 
with increasing aortic stiffness and appears to be more prominent in women than in
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men. PWV, but not pulse pressure, was related to diastolic function grade, 
independent of clinical-echocardiographic predictors of DD and distending arterial 
pressure. The overall utility of PWV to identify preclinical DD was superior to pulse 
pressure. Studies are required to evaluate whether modification of PWV with 
medical therapy is associated with attenuation of risk for the development of DD and 
adverse cardiovascular events such as congestive HF and atrial fibrillation.
188

190
Chapter 8: CONCLUSIONS 
AND FUTURE DIRECTIONS
Published in abstract form in part in:
Abhayaratna WP, Hayes K, O’Reilly C, Sakuragi S, Becker NG. Asymptomatic left 
ventricular diastolic dysfunction and risk of death in the community. J Am Coll 
Cardiol 2006;47:1018-23
Submitted for publication in part in:
Abhayaratna WP, Marwick TH, Becker NG. Asymptomatic left ventricular diastolic 
dysfunction and risk of death in the community. Under review at: Eur Heart J 2009
191
8.1 CONCLUSION
Results of this thesis have advanced the knowledge of cardiovascular epidemiology 
on a number of fronts, specifically in the fields of HF and left ventricular 
dysfunction.
On the national front, the Canberra Heart Study is the first Australian study to 
carefully evaluate the prevalence of HF and left ventricular systolic dysfunction in 
the community. Our results show that HF rates and the proportion of the population 
are similar to estimates in the United States and Western Europe. Personal 
communication with HF researchers and health policy advisors would indicate that 
this information is being used as it was anticipated; to guide health policy with 
regards to service delivery and illness care interventions at the individual level; and 
to plan illness care primary preventative interventions at the population level in order 
to reduce the burden of HF in our community.
On the international front, the Canberra Heart Study has provided important data on
the epidemiology of DD in the community, and our results are being used to inform
expert opinions319 and taskforce guidelines.64 In particular, our robust
echocardiographic methods and high response rates are likely to increase internal
validity of results when compared to previous international efforts that either had
inadequate echocardiographic assessment for the assessment of diastolic function
(with the increased potential for “non-systematic” misclassification) or suffered from
poor response rates that increase the potential for selection bias. Our study shows
that DD is common in the community and is frequently unaccompanied by overt
symptoms and signs of HF. Despite the absence of symptoms, individuals with
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advanced DD-NEF have accompanying structural abnormalities that reflect an 
increased risk for adverse cardiovascular outcomes and have a reduced quality of 
life.
We have used cross-sectional data to assess the clinical characteristics of subjects 
with left ventricular dysfunction. Obviously, these data will not be able to be used to 
establish causality, as the temporal relationship between “risk” exposure and left 
ventricular dysfunction cannot be evaluated in a “snap-shot” observation. 
Nonetheless, identification of the clinical characteristics of subjects with prevalent 
left ventricular dysfunction has provided an epidemiological insight into disease 
causality. This information will be used in future research efforts such as the 
assessment of a screening program. In general, the cost-effectiveness of screening is 
likely to be optimised when high-risk subgroups are targeted. Our results would 
indicate that members of the general population who are at higher risk of preclinical 
left-ventricular systolic dysfunction include older persons, men, patients with a 
history of myocardial infarction, and probably patients with diabetes mellitus. 
Clinical predictors of DD, which was mostly present without overt HF, include 
ischaemic heart disease and risk factors for cardiovascular disease such as older age; 
increased systemic BP and a history of HT; diabetes mellitus; and obesity. It is likely 
that the burden of DD-NEF in the community will increase with our ageing 
population and increasing rates of obesity and diabetes in the community. Whether 
this burden can be reduced by screening efforts remains to be determined. Our 
observations suggest that, since preclinical advanced DD-NEF is relatively common 
and associated with cardiac markers that portend a poor cardiovascular prognosis,
193
screening efforts may be warranted. Furthermore, since DD-NEF is rare in subjects 
without comorbid cardiovascular conditions, the efficiency of screening programs 
should be optimised by targeting high-risk groups, defined according to age (>70 
years) and/or risk factor status (HT, ischaemic heart disease, diabetes or obesity).
At present, access to an assessment with transthoracic echocardiographic is very 
limited, largely due to workforce issues (undersupply of cardiac sonographers) and to 
a lesser extent related to supplier-related economic considerations (high recurrent 
costs relating to sonographer wages; considerable cost of echocardiography machines 
and reporting systems which need to be updated every 3-5 years) relative to income 
(largely predicated by the Medicare rebate for each study). Accordingly, the ability 
to provide an echocardiographic service for patients who have few, if any, symptoms 
or signs of overt cardiovascular disease would not be feasible even in a world that is 
not confronted with the realities of economic scarcity from the perspective of the 
government and taxpayer. The availability of a cheaper, more accessible, and well- 
tolerated non-invasive test that could serve as a filter prior to referral for 
echocardiography may be able to identify individuals with early myocardial 
dysfunction. We have assessed the diagnostic performances of 2 such investigations; 
the NT-pro-BNP levels, and pulse wave analysis.
NT-proBNP levels are clearly related to both systolic and diastolic LV function in 
the general community, but are also influenced by other important factors that are 
known risk markers of adverse cardiovascular outcomes, such as renal disease and 
left ventricular hypertrophy without measurable myocardial dysfunction. Indeed, 
NT-proBNP may be a good integrative marker of cardiac stessors rather than simply
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a measure of left ventricular dysfunction, and therefore may provide incremental 
information beyond echocardiographic assessment. This needs to be assessed in 
future studies.
Our results suggest that age-related deterioration in DD is independently associated 
with increasing PWV, an index of aortic stiffness. However, the overall utility of 
PWV to identify preclinical DD was marginal. Because of the relatively low 
specificity of PWV to detect even advanced DD, one could not recommend this test 
as a filter prior to referral for echocardiography unless further studies show that such 
an approach could assist with the provision of “personalised medicine”, in which 
patient management is guided by their own physiological measures rather than 
generic recommendations based on secular trends. This topic needs to be addressed 
by future clinical studies.
8.2 FUTURE DIRECTIONS
To establish whether Stage B HF (preclinical left ventricular dysfunction) is a 
condition that would be suitable for screening:
i. The disease represents a serious condition. Clearly HF is a serious condition 
that is worthy of screening (see review in Chapter 1);
ii. The condition is detectable in the preclinical phase of the disease. We and 
others have now shown that LV diastolic and systolic dysfunction is 
detectable in persons who have no overt symptoms of HF;
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iii. There is a critical phase during the detectable preclinical stage during which 
treatment is beneficial; there is only very limited evidence, which is restricted 
to persons with reduced EF, to support this assertion (Chapter 1).
Several important questions have been raised by our results and need to be addressed 
by future studies in order to support a screening program for LV dysfunction. These 
include:
i. What is the relationship between preclinical left ventricular dysfunction and 
the risk of death and incident cardiovascular events such as HF and atrial 
fibrillation? With the ability to detect preclinical left ventricular dysfunction 
with echocardiography, more work is required to establish the clinical risk 
associated with early myocardial dysfunction, and whether this risk can be 
ameliorated by early intervention strategies such as the lowering of BP.
ii. What is the optimal method of screening for preclinical left ventricular 
dysfunction? We have avoided the obvious temptation to address this 
question using our cross-sectional study in which prevalent cases of 
preclinical left ventricular dysfunction have been identified using 
echocardiography. Rather, it would be preferable to assess a screening 
program that identifies incident disease in subsequent assessments of this 
cohort in order to avoid overestimation of the performance of the screening 
test.
Even if the pre-conditions for an efficacious screening program are established for 
left ventricular dysfunction, scarcity of resources will necessitate the need for a
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formal economic evaluation of such a screening program prior to its widespread 
adoption in order to address the fundamental issue of “at what cost?”.320
We have received funding from the National Heart Foundation of Australia to 
continue the Canberra Heart Study as a prospective cohort study. Response rates are 
over 90%, and data collection will be completed by 2010. At present, we only have 
preliminary data to report. In 2008, we assessed mortality rates of subjects with DD 
without a history or clinical evidence of HF. During a mean follow-up of 4.8 years, 
there were 61 deaths in preclinical subjects with EF>50%. Death rates among 
individuals with normal LV diastolic function and mild DD were similar (0.8 v 1.1 
per 100 person-yrs, respectively; p=0.24). However, the rate of death among those 
with advanced DD (3.0 per 100 person-yrs) was higher when compared to subjects 
with normal diastolic function and mild DD (pcO.Ol for both) (Figure 8-1).
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Figure 8-1 Survival in preclinical subjects with EF>50%, according to baseline 
diastolic function.
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After adjustment for age, sex, EF and cardiovascular risk factors, preclinical
advanced DD was associated with an increased mortality risk (adjusted Hazards 
Ratio 2.2, Cl 1.1 to 4.2).
We anticipate that our ongoing Canberra Heart Study will continue to provide novel 
data to address the highlighted gaps in knowledge in this field of cardiovascular 
epidemiology. Such information is essential if we are to evolve from the current 
paradigm of healthcare that is focused on the treatment of individuals with disease to 
a paradigm directed at disease prevention at the population-level in order to maintain 
the health and well-being of individuals (Figure 8-2).
Figure 8-2 The Superior Doctor: extract from 1st Chinese Medical Text.
“The superior doctor prevents sickness; the mediocre doctor attends to impending 
sickness; the inferior doctor treats actual sickness”: Attributed to Huang Dee Nai- 
Chan, circa 2600BC.
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APPENDIX A: SELF ADMINISTERED 
QUESTIONNAIRE
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Questionnaire A
Dear Title Surname,
To help us understand more about the relationship between certain personal 
characteristics and heart failure, we would like to ask you some questions about your 
general health, past medical history, education and occupation history.
All questions should be answered unless indicated otherwise. Please return the 
questionnaire when you attend the ‘assessment clinic’ at the Canberra hospital.
You may be assured of complete confidentiality.
If you have any queries please do not hesitate to call one of our research nurses 
(phone: 62443762).
Thank you for your assistance,
Dr Walter Abhayaratna 
Cardiology Fellow 
Chief Investigator
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Put a tick 0  in the most appropriate box
Years
mm  Aboriginal or 
Torres Strait 
Islander origin
Neither
Aboriginal
Torres Strait Islander
Both
Country of birth
Australia
UK and Ireland 
Italy 
Greece 
Germany
-h>Go to Q5 Netherlands
New Zealand 
Vietnam 
Poland
Year of arrival in Australia
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The following questions relate to your health.
In general, 
would you say
Excellent
Very good
Good
Fair
Poor
Compared to one year ago, how would you rate your health
in nonoral nnxA/9
Much better now than one year ago
Somewhat better now than one year ago
About the same as one year ago
Somewhat worse now than one year ago
Much worse now than one year ago
I The following questions are about activities you might do during a 
typical day. Does vour health now limit you in these activities? If so,
(Circle one number on each
AC TIV IT IES
Yes, 
L im ited  
a Lot
Yes, 
L im ited  
a L ittle
N o, N ot 
L im ited  
At All
a. V ig o r o u s  a c t iv i t ie s ,  s u c h  a s  ru n n in g , l if t in g  
o b je c ts , p a r t ic ip a t in g  in s t re n u o u s  s p o r ts 1 2 3
b. M o d e ra te  a c tiv itie s , such as moving a table, 
pushing a vacuum  cleaner, bow ling, or playing golf 1 2 3
c. L if t in g  o r  c a r ry in g  g ro c e r ie s 1 2 3
d . C lim b in g  s e v e r a l  f l ig h ts  o f s ta irs 1 2 3
e. C lim b in g  o n e  f l ig h t  o f s ta irs 1 2 3
f. B e n d in g , k n e e lin g ,  o r  s to o p in g 1 2 3
g W a lk in g  m o re  th a n  o n e  k i lo m e tr e 1 2 3
h. W a lk in g  h a lf  a  k i lo m e tr e 1 2 3
i. W a lk in g  1 0 0  m e tr e s 1 2 3
j. B a th in g  o r  d re s s in g  y o u rs e lf 1 2 3
8 During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of your 
physical health? . , . . . .----------------- (Circle one number on each line)
Yes No
a. Cut dow n on the am ount of tim e you spent on w ork or 
o ther activ ities
1 2
b. A ccom plished  less than you w ould  like
1 2
c. W ere  lim ited in the kind of w ork or o ther activ ities
1 2
d. Had d ifficu lty  perfo rm ing  the  w ork or o ther activ ities 
(for exam ple , it took extra  effort) 1 2
During the past 4 weeks, have you had any of the following 
problems with your work or other regular daily activities as a result 
of any emotional problems (such as feeling depressed or anxious)?
(Circle one number on each line)
Y e s N o
a. Cut dow n on the  am ount of tim e you spent 
on w ork  or o ther activ ities 1 2
b. A ccom plished  less than you w ould like
1 2
c. D idn ’t do w ork o r o ther activ ities as
carefu lly  as usual 1 2
m
W  During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbours, or groups?
Not at all
Slightly
Moderately
Quite a bit
Extremely
How much bodilv pain have vou had in the past 4 weeks?
No bodily pain
Very mild
Mild
Moderate
Severe
Very severe
^ 3  During the past 4 weeks, how much did pain interfere with vour normal 
work (including both work outside the home and housework)?
Not at all
A little bit
Moderately
Quite a bit
Extremely
I These questions are about how you feel and how things have been 
with you during the past 4 weeks. For each question, please give the 
one answer that comes closest to the way you have been feeling. 
How much of the time during the past 4 weeks -
(Circle one number on each
All o f 
the  
tim e
M o st of 
th e  tim e
A  G ood  
Bit o f th e  
T im e
S om e  
of th e  
tim e
N o n e  of 
th e  tim e
a. Do you feel full of 
life? 1 2 3 4 5
b. Have you been a 
very nervous person? 1 2 3 4 5
c. Have you felt so 
down in the dumps 
that nothing could 
cheer you up?
1 2 3 4 5
d. Have you felt calm 
and peaceful? 1 2 3 4 5
e. Did you have a lot of 
energy? 1 2 3 4 5
f. Have you felt down?
1 2 3 4 5
g. Did you feel worn 
out? 1 2 3 4 5
h. Have you been a 
happy person? 1 2 3 4 5
i. Did you feel tired?
1 2 3 4 Fi
During the past 4 weeks, how much of the time has your physical health 
or emotional problems interfered with your social activities (like visiting 
friends, relatives, etc.)?
All of the time
Most of the time
Some of the tim e
A little of the time
None of the time
How TRUE or FALSE is each of the following statements for you?
(Circle one number on each
Definitely
true
Mostly
true
Don’t
know
Mostly
false
Definite! 
y false
a. 1 seem  to get s ick a 
little eas ie r than o ther 
people
1 2 3 4 5
b. 1 am as hea lthy as 
anybody 1 know
1 2 3 4 5
c. 1 expect m y health  to 
get w orse
1 2 3 4 5
d. My health  is exce llen t 1 2 3 4 5
El Do you consider yourself to be-
Acceptable weight
Underweight
Overweight
Don’t know
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The following questions relate to the physical activity you did IN THE LAST WEEK.
H I  IN THE LAST WEEK how many times have yc 
at least 10 minutes, for recreation, exercise or
)u walked continuously, for 
to get to or from places?
(If ‘none’ go to Q19)Number
What do you estimate was the total time that you spent walking in this 
way IN THE LAST WEEK?
In Hours and /  or minutes
Hours
Minutes
IN THE LAST WEEK how many times did you do any vigorous 
gardening or heavy work around the yard that made you breathe 
harder or puff or pant?
Number (If ‘none’ go to Q21)
What do you estimate was the total time that you spent doing 
vigorous gardening or heavy work around the yard IN THE LAST 
WEEK? '
Hours
Minutes
The following questions EXCLUDE household chores or gardening or yardwork.
K j£ |  IN THE LAST WEEK, how many times did you do any vigorous
physical activity that made you breathe harder or puff and pant? (e.g. 
jogging, cycling, aerobics, competitive tennis, etc.)
Number (If ‘none’ go to Q23)
^ £ 1  What do you estimate was the total time that you spent doing this 
vigorous physical activity IN THE LAST WEEK?
Hours
Minutes
The following questions EXCLUDE household chores or gardening or yardwork.
E j ]  IN THE LAST WEEK, how many times did you do any other more
MODERATE physical activity that you haven’t already mentioned? (e.g.
Number (If ‘none’ go to Q25)
K 3  What do you estimate was the total time that you spent doing these 
activities IN THE LAST WEEK?
Hours
Minutes
The following questions are about your average WEEKLY level of activity IN
THE LAST SIX MONTHS.
On average, IN THE LAST SIX MONTHS how much time did you spend 
each week walking for recreation/exercise or to get to or from places?
(THIS IS WALKING CONTINUOUSLY FOR AT LEAST 10 MINUTES)
Hours
Minutes
The following questions EXCLUDE household chores or gardening or yardwork.
On average, IN THE LAST SIX MONTHS how much time did you spend 
each week doing vigorous physical activity which made you breathe 
harder or puff and pant? (e.g. jogging, cycling, aerobics, competitive 
tennis, etc.)
Hours
Minutes
m cOn average, IN THE LAST SIX MONTHS how much time did you spend 
each week doing any other more moderate physical activity that you 
haven’t already mentioned (e.g. gentle swimming, social tennis, golf,
etc) _________  ^
Hours
Minutes
The next few questions relate to smoking and alcohol habits.
Have you ever smoked cigarettes, cigars or a pipe regularly, that is, 
every day?
Yes
No
->At what age did you start smoking regularly? 
-^Go to Question 32
years
Have you given up smoking?
Yes ->When did vou last aive up smokina? years ago
No ->Go to Question 31
Prior to giving up smoking, how much did you smoke?
Manufactured cigarettes per day 
Grams “hand-rolled” per week 
Cigars per week 
Grams pipe tobacco per week
—>Go to 
Question 32
If currently smoking: How much do you usually smoke?
Manufactured cigarettes per day
Grams “hand-rolled” per week
Cigars per week
Grams pipe tobacco per week
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m  How many days a week would you usually have an alcoholic drink 
NOW?
Never
Less than once a week
1-2 days a week
3-4 days a week
5-6 days a week
Every day
->Go to Question 35
What do you mostly drink?
Light beer
Beer
Wine
Spirit
Other
On the days when you have a drink, how many drinks do you usually 
have?
13 or more drinks
9-12 drinks
5-8 drinks
3-4 drinks
1-2 drinks
Has there been a period in your life when you drank quite a bit more 
than you do now?
Yes -^How many years ago? years
No
Don’t know
—
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The next few questions relate to your caffeine intake.
S 3  Do you drink tea?
Yes -^H ow many cups per day? cups
No -^G o to Question 39
How do you usually make your tea?
Teabags 
Tealeaves
Both
S 3  Do you drink coffee?
Yes
~NÖ~
-^H ow  many cups per day? 
-^G o to Question 40
cups
(excluding DECAFFEINATED)
How do you usually make your coffee?
Instant
Percolated
Both
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The following questions are about specific health conditions.
Has a doctor ever told you that you have heart failure (a weak heart)?
Yes
No
Don’t know
-» Go to Question 45
Q  How old were you when you were first diagnosed with heart failure?
Years
^ 9  Do you currently have heart failure?
Don’t know
Are you currently on any treatment for heart failure?
Yes
No
Don’t know
Have you ever been admitted to a hospital for treatment of heart 
failure?
Yes
No
Don’t know
->How many times?
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Has a doctor ever said that you have any of the following conditions?
C O N D IT IO N No
D o n ’t
kn ow Y e s -»
A ge w h en  
firs t to ld
Y ears  o f 
tre a tm e n t
Anaemia □ □ □
Angina □ □ □
Osteoarthritis / Rheumatoid arthritis □ □ □
Coronary artery disease (narrowing in 
the heart artery / arteries) □ □ □
Asthma n n n
Chronic bronchitis □ □ □
Cancer: which type(s)? □ □ □
Diabetes
Emphysema n
Heart attack(s) n □ □
High blood pressure n □
High Cholesterol n
Gout
Rheumatic fever □ □
Peripheral vascular disease 
(narrowings in the leg or arm artery / 
arteries) □ □ □
Sleep apnoea
’Mini-stroke’ □ □
Stroke □ □
Thyroid condition
The following section asks about your education and employment status.
What is the highest level you reached at school? If educated overseas 
record equivalent.
No schooling
Some primary
Completed primary
Some secondary
Completed intermediate/school certificate (Year 10)
Completed leaving / higher school certificate (Year 12)
Don’t know
Have you completed a trade certificate or any other educational 
qualification since leaving school?
Go to Q 49 
Go to Q 49 
-> Go to Q 48
No
Still studying for first qualification
Yes
48 Which of these categories best describes the highest qualification you 
have completed since leaving school?
Trade Certificate/Apprenticeship Associate Diploma
Technician’s Certificate/ Advanced Undergraduate Diploma
Nursing Certificate (Enrolled Nurse) Bachelor Degree
Nursing Certificate (Registered Nurse) Postgraduate Diploma
Teaching Certificate Masters Degree/ Doctorate
Other Certificate Other (specify)
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K 3  What is your employment status?
->Go to Q 50 
-*Go to Q 50 
—>Go to Q 53 
->Go to Q 54 
->Go to Q 52 
-^Go to Q 52
Employed
Unpaid work for family business
Home-maker/housewife
Never worked
Retired
Social security/disability pension
How many hours a week do you usually work in (all) your job(s)?
Hours
Don’t know
Main
occupation? ->Go to Q 53
Prior to retirement, what was your main occupation? 
Occupation (specify)
Could you list other jobs that you have held for a period of over 5 
years, and state the approximate age at which you commenced 
each job.
Position
Age at
commencement
The next section asks about members of your household.
What is vour marital status
-> Go to Q 55 
-> Go to Q 55 
^  Go to Q 55 
-> Go to ‘Q 63’
Go to Q 55 
-> Go to ‘Q 63’
Married 
De facto 
Separated 
Divorced 
Widowed 
Never married
What is the highest level that your spouse/partner reached at school?
No schooling
Some primary
Completed primary
Some secondary
Completed intermediate/school certificate (Year 10)
Completed leaving / higher school certificate (Year 12)
Don’t know
Has your spouse/partner completed a trade certificate or any other 
educational qualification since leaving school?
-> Go to Q 58 
-> Go to Q 58 
-» Go to Q 57
No
Still studying for first qualification
Yes
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1 9  Which of these categories best describes the highest qualification 
that your spouse/partner has completed since leaving school?
Trade Certificate/Apprenticeship Associate Diploma
Technician’s Certificate/ Advanced Undergraduate Diploma
Nursing Certificate (Enrolled Nurse) Bachelor Degree
Nursing Certificate (Registered Nurse) Postgraduate Diploma
Teaching Certificate Masters Degree/
Other Certificate Other (specify)
What is your spouse’s/partner’s employment status?
Employed
Unpaid work for family business
Home-maker/housewife
Never worked
Retired
Social security/disability pension
->Go to Q 59
-^Go to Q 59 
—>Go to Q 62 
-*Go to Q ‘63’ 
—>Go to Q 61 
-^Go to Q 61
How many hours a week does your spouse/partner usually work in (all) 
his/her job(s)?
Hours
Don’t know
What is your partner’s main occupation?
Occupation (specify) -^Go to Q 62
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K j f l  Prior to retirement, what was your partner’s main occupation?
Occupation (specify)
Could you list other jobs that your spouse/partner has held for a 
period of over 5 years, and state the approximate age at which 
he/she commenced each job.
Position
Age at
commencement
Would you like to make any comments?
Thank you for your participation.
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